UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

FORM 10-K/A

Amendment No. 1

 þ

xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the Fiscal Year Ended fiscal year ended December 31, 20152022

OR

 o

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to ___________

Commission File Number: 000-53862file number 001-41346

IGAMBIT

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)

Delaware11-3363609
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

Delaware6030 S. Rice Ave, Suite C,
Houston, Texas77081
Telephone Number (
713) 660-0557

11-3363609

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

1050 W. Jericho Turnpike, Suite A

Smithtown, New York 11787

(Address of principal executive offices)

(631) 670-6777

(Registrant’s telephone number)

(Registrant’s former telephone number)

Securities registered underpursuant to Section 12(b) of the Exchange Act:

Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 par valueNUTXNASDAQ Capital Market

Title of Each Class: NONE

Name of Each Exchange on Which Registered:

Securities registered pursuant to Section 12(g) of the Act: Common StockNone

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the

Securities Act. Yes o¨Noþx

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section

15(d) of the Exchange Act. Yes o¨Noþx

Indicate by check mark whether the registrant:registrant (1) has filed all reports required to be filed by Section 13 or

15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period

that the registrant was required to file such reports), and (2) has been subject to such filing requirements for

the past 90 days. Yesþx No o¨



Indicate by check mark whether the registrant has submitted electronically and  posted  on  its  corporate

website,  if  any,  every Interactive DateData File required to be submitted and  posted  pursuant to Rule 405 of

Regulation S-T (Section 232.405 of thethis chapter) during the preceding 12 months (or for such shorter period

that the registrant was required to submit and post such files). Yesþx No o¨

Indicate  by  check  mark  if  disclosure  of  delinquent  filers  pursuant  to  Item 405  of  Regulation S-K  is  not

contained  herein,  and  will  not  be  contained,  to  the  best  of  registrant’s  knowledge,  in  definitive  proxy  or

information  statements  incorporated  by  reference  in  Part III  of  this  Form  10-K  or  any  amendment  to  this

Form 10-K. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-

acceleratednon-accelerated filer, or   a   smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”

“accelerated filer” “accelerated filer,” “smaller reporting company,” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filerxAccelerated filer¨
Non-accelerated filer¨Smaller reporting company¨
Emerging growth company¨

AcceleratedIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Non-accelerated filer o

SmallerIndicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x

filer o

filer oIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨

reporting

company þIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 126-212b-2 of the act):Act). Yes ¨Nox

Yes o     No þ

There is not currently aThe aggregate market for the Registrant’svalue of voting common stock.

As  of  April  14,  2016stock held by non-affiliates at June 30, 2022 was approximately $1.034 billion. At March 2, 2023, there were 39,683,990650,926,125 shares of the  Registrant’s  $0.001  par  value  common stock outstanding.

outstanding.

DOCUMENTS INCORPORATED BY REFERENCE: NoneREFERENCE

Not applicable.

Auditor NameMarcum LLP
Auditor LocationHouston, Texas
Auditor Firm ID688



iGambit

EXPLANATORY NOTE

Nutex Health Inc. (the “Company,” “Nutex,” “we,” “us” or “our”) is filing this Amendment No. 1 on Form-10-K/A (this “Amendment No. 1”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, originally filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2023 (the “Original Filing”), to include the information required by Items 10 through 14 of Part III of Form 10-K. This information was previously omitted from the Original Filing in reliance on General Instruction G(3) of Form 10-K, which permits such information to be incorporated by reference in the Form 10-K from the Company’s definitive proxy statement if such proxy statement is filed no later than 120 days after the end of the Company’s fiscal year. The Company is filing this Amendment No. 1 to include the information required by Part III of the Original Filing to publicly disclose such information prior to the date on which the Company intends to file such proxy statement.

In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Items 10 through 14 of Part III and Item 15 of Part IV of the Original Filing have been amended and restated in their entirety. This Amendment No. 1 does not amend or otherwise update any other information in the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing and with the Company’s other filings with the SEC subsequent to the Original Filing. In addition, this Amendment No. 1 does not reflect events that may have occurred subsequent to the Original Filing date.

Pursuant to Rule 12b-15 under the Exchange Act, this Amendment No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements are included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. In addition, because no financial statements are included in this Amendment No. 1, new certifications of the Company’s Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with Amendment No. 1.


NUTEX HEALTH INC.

AMENDMENT NO. 1 TO FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 20152022

TABLE OF CONTENTS

PART III4
Item 10. Directors, Executive Officers and Corporate Governance4
Item 11. Executive Compensation and Other Information11
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters22
Item 13. Certain Relationships and Related Persons Transactions23
Item 14. Principal Accountant Fees and Services26
Item 15. Exhibits and Financial Statement Schedules27
SIGNATURES30


Page No.

PART I

Item 1

Business

1

Item 1A

Risk Factors

10

Item 1B

Unresolved Staff Comments

10

Item 2

Properties

10

Item 3

Legal Proceedings

10

Item 4

(Removed and Reserved)

11

PART II

Item 5

Market for Registrant’s Common Equity, Related Stockholder Matters

and Issuer Purchases of Equity Securities

11

Item 6

Selected Financial Data

12

Item 7

Management’s Discussion and Analysis of Financial Condition and

Results of Operations

12

Item 7A

Quantitative and Qualitative Disclosure About Market Risk

23

Item 8

Financial Statements and Supplementary Data

23

Item 9

Changes in and Disagreements with Accountants on Accounting and

Financial Disclosure

23

Item 9A

Controls and Procedures

24

Item 9B

Other Information

25

PART III

Item 10

10. Directors, Executive Officers and Corporate Governance

25

The following table shows information for the executive officers, directors and director nominees as of December ‎‎31, 2022. Directors hold office until their successors have been elected or qualified or until the earlier of their death, ‎resignation, removal or disqualification. Executive officers serve at the discretion of the board of directors (the “Board”).‎

Item 11

NameAgePosition
Executive Officers and Directors
Thomas T. Vo, M.D., MBA50Chief Executive Officer and Chairman of the Board
Warren Hosseinion M.D.51President and Director
Jon C. Bates53Chief Financial Officer
Michael Chang, M.D.52Chief Medical Officer
Elisa Luqman, ESQ., MBA58Chief Legal Officer (SEC)
Pamela Montgomery, R.N., J.D.57Chief Legal Officer (Healthcare & Secretary)
Mitchell Creem, MHA63Independent Director
Cheryl Grenas, R.N., M.S.N61Independent Director
Michael L. Reed, MPH64Independent Director
John Waters, CPA77Independent Director
Danniel Stites, M.D.42Director

Executive CompensationDirectors

29

Our Board manages our business and affairs. Under our Amended and Restated Certificate of Incorporation and ‎Second Amended and Restated Bylaws, the Board must consist of one or more members and those members hold ‎office until the expiration of the term for which elected and until such director’s successor is elected and qualified or ‎until such director’s earlier death, resignation or removal. Currently, our Board consists of seven directors.‎

Thomas T. Vo, M.D., MBA, Chief Executive Officer, Director and Chairman of the Board

Dr. Vo was appointed as the Company’s Chief Executive Officer on April 1, 2022 and elected, effective April 1, ‎‎2022, as the Chairman of the Board. Since 2010, Dr. Vo has served as the founder and executive officer of ‎affiliates of the Company. Although no longer practicing, Dr. Vo worked as an emergency medicine physician in ‎Houston, Texas, for over twenty years. Between 2008 and 2011, Dr. Vo served as a founder and original partner at ‎the free-standing emergency health company, Neighbors Emergency Center. Since then, Dr. Vo has been involved ‎with the opening of over 40 freestanding emergency departments and micro hospitals. Dr. Vo holds a Bachelor of ‎Science in Life Sciences from Kent State University and received his Doctor of Medicine from North East Ohio ‎Universities College of Medicine. In 2004, Dr. Vo also received his Master of Business Administration from Rice ‎University. The Company believes that Dr. Vo’s unique background in the emergency hospital field and proven ‎management experience make him well qualified to serve as a director.‎

Warren Hosseinion, M.D., President and Director

Warren Hosseinion, M.D., is the President and a director of the Company, positions he has held since April 2022. ‎From February 26, 2021 to April 1, 2022, Dr. Hosseinion was Chief Executive Officer of Clinigence Holdings, Inc. ‎‎(n/k/a Nutex Health Inc.). From April 2019 to April 2022, Dr. Hosseinion served as Chief Executive Officer and ‎Chairman of the board of directors of Clinigence Holdings, Inc. In addition, Dr. Hosseinion has served as the Non-‎Executive Chairman of the board of directors of Cardio Diagnostic Holdings, Inc. (“Cardio”) (NASDAQ: CDIO) ‎since the consummation of its business combination with Mana Capital Acquisition Corp. in October 2022. Cardio ‎was formed to further develop and commercialize a series of products for major types of cardiovascular disease ‎and associated co-morbidities including coronary heart disease, stroke, heart failure and diabetes, by leveraging our ‎proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine™. Dr. Hosseinion is a Co-Founder of ‎Apollo Medical Holdings, Inc. (Nasdaq: AMEH) (“ApolloMed”) and served as a member of the board of directors ‎of ApolloMed from July 2008 to March 2019, as the Chief Executive Officer of ApolloMed from July 2008 to December ‎‎2017, and as the Co-Chief Executive Officer of ApolloMed from December 2017 to March 2019. ApolloMed is a ‎physician-centric, technology-powered, risk-bearing healthcare company with an integrated healthcare delivery ‎platform that enables providers to successfully participate in value-based care arrangements. Dr. Hosseinion ‎received his Bachelor of Science in Biology from the University of San Francisco, his Master of Science in Physiology and ‎Biophysics from the Georgetown University Graduate School of Arts and Sciences, his Doctor of Medicine from the ‎Georgetown University School of Medicine and completed his residency in internal medicine from the Los Angeles ‎County-University of Southern California Medical Center. Dr. Hosseinion’s qualifications to serve on our Board ‎include his position as our current President. In addition, Dr. Hosseinion’s experience as a physician, along with his ‎background at ApolloMed and Cardio, brings our Board and our Company a depth of understanding of physician ‎culture and the healthcare market, as well as a strong knowledge of the public markets.‎


Non-Management Directors

Mitchell Creem, MHA, Director, Compensation Committee Chairman

Mitchell Creem, MHA has been a director of the Company since April 1, 2022. Mr. Creem has spent over 30 years as a “C-level” executive of healthcare organizations, and he brings strong business evaluation and operational experience to the Company. Since July 2017, Mr. Creem has served as President of The Bridgewater Healthcare Group, which provides hospital and health network management services and performance consulting. From October 2015 to July 2017, Mr. Creem served as the Chief Executive Officer of Verity Health System, a six-hospital system in California. Prior to this, he served as the Chief Financial Officer and Board Member of ApolloMed from October 2012 to October 2015. Prior to ApolloMed, he served as the Chief Executive Officer of the Keck Hospital of University of Southern California (“USC”) and USC Norris Cancer Center. Prior to his tenure at USC, he served as the Chief Financial Officer and Associate Vice Chancellor of University of California, Los Angeles (“UCLA”) Health Sciences, including UCLA Medical Center, the Geffen School of Medicine at UCLA, and UCLA Faculty Practice. Prior to UCLA, he served as Chief Financial Officer of Beth Israel Deaconess Medical Center, a Harvard University teaching hospital, and Chief Financial Officer of Tufts University Medical Center. Prior to this, he worked for several years in a senior management position at the healthcare practice group of PricewaterhouseCoopers, where he was responsible for numerous consulting engagements, financial statement audits and financial feasibility studies. He has been a guest lecturer at USC, UCLA and Harvard University. Mr. Creem holds a Bachelor of Science in Accounting and Business Administration from Boston University and a Master of Health Administration from Duke University. The Company believes that Mr. Creem’s background and experience in healthcare management roles make him well qualified to serve as a director.

Cheryl Grenas, R.N. M.S.N., Director ‎

Cheryl Grenas, R.N., M.S.N. has been a director of the Company since April 1, 2022. Since March 2018, Ms. ‎Grenas has served as the Chief Nursing Officer at Behavioral Hospital of Bellaire. From July 2017 to March 2018, ‎she was a consultant to start-up and existing freestanding emergency departments in the Houston metropolitan ‎area. From August 2015 to July 2017, she was the Regional Facility Director at Neighbors Emergency Center (Free Standing ‎Emergency Departments). Ms. Grenas served in the United States Navy for 20 years, achieved the rank of Lieutenant ‎Commander, and is a veteran of two deployments in support of Operation Iraqi Freedom (2005) and Operation ‎Enduring Freedom (2011). She was awarded two Navy Commendation Medals and four Navy Achievement ‎Medals during her service. Ms. Grenas, holds a Bachelor of Science in Nursing and a Master of Science in nursing ‎from Prairie View A&M University. The Company believes that Ms. Grenas’ background and experience in ‎healthcare management roles make her well qualified to serve as a director.‎

Michael L. Reed, MPH. Director, Governance Committee Chairman

Michael L. Reed, MPH has been a director of the Company since April 1, 2022. Mr. Reed has been an independent ‎consultant providing advisory services in the areas of emergency medicine, hospitalist medicine, hospital ‎operations, risk-based payor contracts, value-based care, and physician practice operations and development since ‎January of 2018. From January 2019 to January 2020, Mr. Reed was Senior Vice President of Business ‎Development and Strategic Partnerships of the Oncology Institute, a value-based oncology care company. From ‎April 2018 to December 2018, Mr. Reed served as the Chief Executive Officer of Turtle Peak Customer Service, ‎LLC, a Las Vegas, Nevada-based privately-held customer service company. Since August 2017, Mr. Reed has ‎served as Senior Advisor to NueHealth, LLC, based in Leawood, Kansas, a privately-held developer and investor in ‎lower-cost healthcare centers. ‎ From July 2009 to October 2013, Mr. Reed was President and Chief Executive ‎Officer of Team Health Hospital Medicine, a division of TeamHealth, a once publicly-traded company that was ‎acquired by Blackstone in 2017. In addition, from December 2001 to November 2004, he served as the Chief ‎Operating Officer of Pinnacle Health System, a health care solutions company providing outpatient, inpatient, ‎claims, billing, and medical management. Mr. Reed holds a Bachelor of Science in Health Services Management ‎from California State University and received his Master of Public Health from UCLA. The Company believes that ‎Mr. Reed's long-standing career as a professional healthcare executive within the emergency medicine system and ‎value-based care make him well qualified to serve as a director.‎


John Waters, CPA, Director, Audit Committee Chairman

John Waters, CPA has been a director of the Company and Chairman of our Audit Committee since April 1, 2022. ‎Prior thereto, Mr. Waters served as a director and the Chairman of the Audit Committee of Clinigence Holdings, ‎Inc. starting October 29, 2019, the date of the closing of the reverse merger of Clinigence Holdings, Inc. with iGambit, Inc. From ‎‎2016 until October 29, 2019, Mr. Waters served as an Advisor to the board of directors of iGambit Inc.‎‎ Mr. Waters was a Senior Partner at Arthur Andersen from 1967 to 2001 with a focus on ‎mergers and acquisitions, particularly reverse mergers, and Securities Act (as defined below) filings with the SEC. For the past five years, he ‎has also worked as a consultant to various public companies. Mr. Waters is a Certified Public Accountant ‎‎(“CPA”), a member of American Institute of Certified Public Accountants (“AICPA”) and the New York State ‎Society of CPAs. He has a Bachelor of Business Administration from Iona College.‎

Danniel Stites, M.D.

Danniel Stites, M.D. was elected as a director of the Company effective April 1, 2023. Dr. Stites is board certified in Emergency Medicine by the American Board of Emergency Medicine and is a Fellow of the American College of Emergency Physicians. Dr. Stites has been a practicing emergency medicine physician in Arizona for over 10 years. He has been the Managing Partner at Phoenix ER & Medical Hospital since March 2019 and the Chief Medical Officer since March 2020. He has also served as the Managing Partner and Chief Medical Officer of East Valley ER & Hospital since February 2022. Both hospital facilities are affiliates of the Company. Dr. Stites is one of only a few state certified EMS physicians and serves as Medical Director for several EMS and Law Enforcement agencies statewide. Dr. Stites has been the EMS and Prehospital Medical Director for a large, urban Level 1 trauma center since 2013. Additionally, Dr. Stites has worked as a Supervising Physician for hyperbaric oxygen therapy since 2020, Laboratory Clinical Consultant and Laboratory Director since 2020. Dr. Stites completed his emergency medicine residency at New York Hospital Queens/Weill Cornell Medical College, followed by a fellowship in Emergency Medical Services and Disaster Medicine from the University of New Mexico. Prior to his residency, he first earned his Doctor of Medicine from Ponce School of Medicine. Prior to this, he received a Bachelor of Science in Physiological Sciences from the University of Arizona. Dr. Stites’ passion for excellence in clinical care, along with his diverse clinical background and wealth of experience, make him well qualified to serve as a director.

Executive Officers

Jon C. Bates

Jon Bates was appointed as the Company’s Chief Financial Officer effective June 30, 2022. From 2006 until June ‎‎2022, Mr. Bates served as Vice President of Accounting/Corporate Controller at U.S. Physical Therapy, Inc., ‎‎(NYSE: USPH), one of the largest publicly traded, pure-play national operators of outpatient physical ‎therapy clinics and provider of industrial injury prevention services.‎ Before joining USPH, Mr. Bates served as Chief Financial Officer and Chief Accounting Officer at Commerciant, ‎L.P., Chief Accounting Officer/Corporate Controller at National Alarm Technologies LLC, Assistant Corporate ‎Controller at American Residential Services, Inc., and a Senior Auditor at Arthur Andersen LLP. His areas of ‎expertise include strategic financial planning, risk assessment & evaluation, Internal Audit/SOX reporting, valuation ‎and deal acquisition, and many more. Mr. Bates is a Certified Public Accountant, holds a Bachelor of Business ‎Administration from University of Texas at Austin and also received his Master of Business Administration from ‎University of Houston. The Company believes that Mr. Bates extensive knowledge of Finance and Accounting, in ‎combination with his experience with public financial reporting with the SEC, makes him a valuable Chief Financial ‎Officer.‎


Michael Chang, M.D.‎

Michael Chang, M.D. ‎was appointed Chief Medical Officer of the Company effective April 1, 2022. ‎Since founding ‎Tyvan LLC, a medical billing company in 2012, he has served as principal of Tyvan LLC, which became a wholly ‎owned subsidiary of the Company in connection with the Merger (as defined below). Jointly with Dr. Vo, in 2008, he ‎also founded Neighbors ‎Emergency Center, a licensed and accredited full-service emergency room with several ‎location in the greater Houston area, and served as Executive Director of practice management as well as ‎Chairman of the Board. Further, Dr. Chang is founder and medical director for Hope ‎Restored Treatment Center, a ‎medical detox and rehab program as part of Nutex and Southeast Texas Hospital, a ‎subsidiary of the Company. In ‎addition, in 2018, he founded Synergy Wellness as a separate business focusing on ‎wellness practices and mental ‎health.‎

Elisa Luqman, ESQ., MBA

Ms. Luqman has served as the Chief Legal Officer (SEC) of our Company since April 1, 2022. She served as ‎the ‎Chief ‎Financial Officer, Executive Vice President Finance and General Counsel of Clinigence Holdings, Inc. from ‎October ‎‎2019 until the ‎Merger. She also served as a director of Clinigence Holdings, Inc. from October 2019 to ‎February 2021. At ‎Clinigence Holdings, Inc., Ms. ‎Luqman was responsible for maintaining the corporation’s ‎accounting records and statements, ‎preparing its SEC ‎filings and overseeing compliance requirements. She was an ‎integral member of the Clinigence Holdings, Inc. ‎team responsible for ‎obtaining its NASDAQ Stock Market LLC‎ ‎‎(“NASDAQ”) listing and completing the reverse merger with the Company. At ‎the Company, Ms. Luqman ‎‎continues to be responsible for preparing its SEC filings and overseeing compliance ‎requirements. Ms. Luqman ‎has ‎served as Chief Financial Officer of Cardio since March 2021. In addition, Ms. ‎Luqman co-founded bigVault ‎‎Storage Technologies, a cloud- based file hosting company acquired by Digi-Data ‎Corporation in February 2006. ‎‎From March 2006 through February 2009, Ms. Luqman was employed as Chief ‎Operating Officer of the Vault ‎‎Services Division of Digi-Data Corporation, and subsequently during her tenure with ‎Digi-Data Corporation she ‎‎became General Counsel for the entire corporation. In that capacity she was responsible ‎for acquisitions, mergers, ‎‎patents, customer, supplier, and employee contracts, and worked very closely with Digi-‎Data’s outside counsel ‎‎firms. In March 2009, Ms. Luqman rejoined iGambit Inc. (“IGMB”) as Chief Financial ‎Officer and General ‎‎Counsel. Ms. Luqman has overseen and been responsible for IGMB’s SEC filings, FINRA ‎filings and public ‎‎company compliance requirements from its initial Form 10 filing with the SEC in 2010 through its ‎reverse merger ‎‎with Clinigence Holdings, Inc. in October 2019. Ms. Luqman received a Bachelor of Arts, a Juris Doctor, and ‎a ‎‎Master of Business Administration with a specialization in Finance from Hofstra University. Ms. Luqman is a ‎‎member of the bar in New York and New ‎Jersey..‎

General

Our Board has adopted a Code of Business Ethics Policy, and charters for our Audit Committee, Compensation Committee and Nominating and Governance Committee to assist the Board in the exercise of its responsibilities and to serve as a framework for the effective governance of the Company. You can access our current committee charters, our Code of Business Conduct and Ethics in the “Governance” section of the “Investor Relations” page of our web site located at https://www.nutexhealth.com/governance-documents/.

Audit Committee

The Audit Committee is responsible for monitoring and reviewing our financial statements and internal controls ‎‎over financial reporting. In addition, they recommend the selection of the independent auditors and consult with ‎both ‎management and the independent auditors prior to the presentation of financial statements to stockholders ‎and the ‎filing of our forms 10-Q and 10-K. The Audit Committee has adopted a charter and it is posted on our web ‎site at ‎https://www.nutexhealth.com/governance-documents/.‎


The Audit Committee consists of Messrs. Mitchell Creem, Michael Reed, MPH, and John Waters, CPA with Mr. ‎Waters serving ‎as Chairman. The Board has determined that Mr. Waters is an “audit committee financial ‎expert” ‎‎(as that term is defined under SEC rules implementing Section 407 of the Sarbanes-Oxley Act) and, each of ‎the ‎three audit committee members are “independent” directors that satisfy the heightened audit committee ‎‎independence requirements under the NASDAQ Listing Rules and Rule 10A-3 of the Exchange Act.‎

Compensation Committee

The Compensation Committee consists of Messrs. Mitchell Creem, MHA, and Ms. Cheryl Grenas, R.N., M.S.N. and ‎‎Michael Reed, MPH, with Mitchell Creem, MHA serving as Chairman and is responsible for reviewing and ‎recommending to the Board the compensation and ‎over-all benefits of our executive officers. The Compensation ‎Committee may, but is not required to, consult with ‎outside compensation consultants. The Compensation ‎Committee has adopted a charter and the charter is posted ‎on our web site ‎https://www.nutexhealth.com/governance-documents/.‎ ‎

Nominating and Governance Committee

The ‎Nominating and Governance Committee is responsible for assisting the Board in fulfilling its fiduciary ‎responsibilities with respect to the oversight of the Company’s affairs in the areas of corporate governance matters.‎

Additionally, the Nominating and Governance Committee is responsible for overseeing the selection of persons to be nominated to serve on our Board. The Nominating and Governance Committee considers persons identified by its members, management, shareholders, investment bankers and others.

The guidelines for selecting nominees, which are specified in a charter adopted by us, generally provide that persons to be nominated:

should have demonstrated notable or significant achievements in business, education or public service;

should possess the requisite intelligence, education and experience to make a significant contribution to the Board and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and

should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders.

The Nominating and Governance Committee considers a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s candidacy for membership on the Board. The Nominating and Governance Committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The Nominating and Governance Committee does not distinguish among nominees recommended by shareholders and other persons. The Nominating and Governance Committee consists of Messrs. Mitchell Creem, MHA, Michael Reed, MPH, and Ms. Cheryl Grenas, R.N., M.S.N., with Michael Reed, MPH ‎serving as chairman‎. The Nominating and Governance Committee has adopted a charter and the charter is posted ‎on our web site https://www.nutexhealth.com/governance-documents/.

Board Composition

Our Board currently consists of seven members: Messrs. Thomas T. Vo M.D. MBA, Jon C. Bates, Warren ‎Hosseinion M.D., Danniel Stites, M.D., John Waters CPA, Michael Reed MPH, Mitchell Creem, MHA, and Ms. ‎Cheryl Grenas R.N., M.S.N. As set forth in our Certificate of Incorporation, the Board is currently divided into three ‎classes with staggered, three-year term. At each annual meeting of stockholders, the successors to directors whose ‎terms then expire will be elected to serve from the time of election and qualification until the third annual meeting ‎following election. Our Amended and Restated Certificate of Incorporation and Second Amended and Restated ‎Bylaws provide that the authorized number of directors may be changed only by resolution adopted by a majority ‎of the entire Board. Any additional directorships resulting from an increase in the number of directors will be ‎distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. ‎The division of our Board into three classes with staggered three-year terms may delay or prevent a change of our ‎management or a change in control of our Company. Our directors may be removed only for cause by the ‎affirmative vote of the holders of a majority in voting power of the outstanding shares of our capital stock entitled ‎to vote in the election of directors.‎


Director Independence

Ms. Grenas, R.N., M.S.N. and Messrs. Mitchell Creem, MHA, Michael Reed MPH, and John Waters, CPA each qualify as “independent” in accordance with the listing requirements of NASDAQ. The ‎NASDAQ independence definition includes a series of objective tests, including that the director is not, and has not ‎been for at least three years, one of our employees and that neither the director nor any of his family members has ‎engaged in various types of business dealings with us. ‎

In addition, as required by NASDAQ rules, our Board has made an affirmative determination as to each ‎independent director that no relationships exist, which, in the opinion of our Board, would interfere with the exercise ‎of independent judgment in carrying out the responsibilities of a director. In making these determinations, our ‎Board reviewed and discussed information provided by the directors and us with regard to each director’s business ‎and personal activities and relationships as they may relate to us and our management, including the beneficial ‎ownership of our capital stock by each director.

Messrs. Thomas T. Vo, M.D., MBA and Warren Hosseinion, M.D. are not considered independent because they are ‎officers of the Company. Danniel Stites, M.D. is not considered independent because he is the Chief Medical Officer and Managing Partner of both East Valley ER & Hospital and Phoenix ER & Medical Hospital, affiliates of the Company. Our Board also determined that each non-employee director who serves as a member of ‎the Audit, Compensation, and Nominating Committees satisfies the independence standards for such committee ‎established by the SEC and NASDAQ, as applicable.

Executive Sessions

Our independent directors meet in executive sessions without non-independent directors or management present on a regularly scheduled basis, but no less than twice per year. Each executive session of the independent directors is presided over by the Chair of the Nominating and Governance Committee.

Director Candidates

The Nominating and Governance Committee is primarily responsible for searching for qualified director candidates for election to the Board and filling vacancies on the Board. To facilitate the search process, the Nominating and Governance Committee may solicit current directors and executives of the Company for the names of potentially qualified candidates or ask directors and executives to pursue their own business contacts for the names of potentially qualified candidates. The Nominating and Governance Committee may also consult with outside advisors or retain search firms to assist in the search for qualified candidates, or consider director candidates recommended by our stockholders. Once potential candidates are identified, the Nominating and Governance Committee reviews the backgrounds of those candidates, evaluates candidates’ independence from the Company and potential conflicts of interest and determines if candidates meet the qualifications desired by the Nominating and Governance Committee for candidates for election as a director. In evaluating the suitability of individual candidates (both new candidates and current Board members), the Nominating and Governance Committee, in recommending candidates for election, and the Board, in approving (and, in the case of vacancies, appointing) such candidates, may take into account many factors as set forth in our Corporate Governance Guidelines, including: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly held company; strong finance experience; relevant social policy concerns; experience relevant to the Company’s industry; experience as a board member or executive officer of another publicly held company; relevant academic expertise or other proficiency in an area of the Company’s operations; diversity of expertise and experience in substantive matters pertaining to the Company’s business relative to other board members; diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience; practical and mature business judgment, including, but not limited to, the ability to make independent analytical inquiries; and any other relevant qualifications, attributes or skills. The Board evaluates each individual in the context of the Board as a whole, with the objective of assembling a group that can best perpetuate the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. Stockholders may recommend individuals to the Nominating and Governance Committee for consideration as potential director candidates by submitting the names of the recommended individuals, together with appropriate biographical information and background materials, to the Nominating Committee, c/o Secretary, Nutex Health Inc., 6030 S. Rice Ave, Suite C, Houston, TX 77081. In the event there is a vacancy, and assuming that appropriate biographical and background material has been provided on a timely basis, the Nominating and Governance Committee will evaluate stockholder-recommended candidates by following substantially the same process, and applying substantially the same criteria, as it follows for candidates submitted by others.


Communications from Stockholders

The Board will give appropriate attention to written communications that are submitted by stockholders, and will respond if and as appropriate. Our Secretary is primarily responsible for monitoring communications from stockholders and for providing copies or summaries to the directors as he considers appropriate.

Communications are forwarded to all directors if they relate to important substantive matters and include suggestions or comments that our Secretary and Chairman of the Board consider to be important for the directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters as to which we tend to receive repetitive or duplicative communications. Stockholders who wish to send communications on any topic to the Board should address such communications to the Board in writing: Nutex Health Inc., 6030 S. Rice Ave, Suite C, Houston, TX 77081.

Board Leadership Structure

Our Second Amended and Restated Bylaws and Corporate Governance Guidelines provide our Board with flexibility to combine or separate the positions of Chairman of the Board and Chief Executive Officer in accordance with its determination that utilizing one or the other structure would be in the best interests of our Company. Currently, Dr. Vo serves as the Company’s Chairman and Chief Executive Officer. The Board may, however, make changes to its leadership structure in the future as it deems appropriate.

In addition, the Board may appoint a lead independent director. The lead independent director, if appointed, will preside over periodic meetings of independent directors, serve as a liaison between the Chairman and the independent directors and perform such additional duties as the Board may otherwise determine and delegate.

Role of the Board in Risk Oversight

Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management meetings and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the Board at regular Board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. Our Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various standing committees of the Board that address risks inherent in their respective areas of oversight. While our Board is responsible for monitoring and assessing strategic risk exposure, our Audit Committee is responsible for discussing the Company’s policies with respect to risk assessment and risk management, including guidelines and policies to govern the process by which the Company’s exposure to risk is handled. The Audit Committee also oversees management of financial and cybersecurity risks and potential conflicts of interest. Our Nominating and Governance Committee is responsible for overseeing the management of risks relating to the Company’s compensation plans, equity incentive plans and other compensatory arrangements as well as risks associated with the Company’s corporate governance framework. The Board does not believe that its role in the oversight of our risks affects the Board’s leadership structure.


Code of Business Ethics

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Our code of business conduct and ethics is available under the Corporate Governance section of our web site at https://www.nutexhealth.com/governance-documents/. In addition, we intend to post on our web site all disclosures that are required by law or the NASDAQ rules concerning any amendments to, or waivers from, any provision of the code. The reference to our web site address does not constitute incorporation by reference of the information contained at or available through our web site, and you should not consider it to be a part of this proxy statement.

Anti-Hedging Policy

Our Board has adopted a Securities Trading Policy, which applies to all of our directors, officers and employees. The policy prohibits our directors, officers and employees and any entities they control from purchasing financial instruments such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company’s equity securities, or that may cause an officer, director, or employee to no longer have the same objectives as the Company’s other stockholders.Our Securities Trading Policy can be found under the Corporate Governance section of our web site at https://www.nutexhealth.com/governance-documents.

Compensation Committee Interlocks and Insider Information

During 2022, the members of our Compensation Committee were Mitchell Creem, MHA, Cheryl Grenas, R.N., M.S.N. and Michael Reed, MPH‎, none of whom was during fiscal year 2022 an officer or employee of the Company or was formerly an officer of the Company. Related person transactions pursuant to Item 12

Security Ownership404(a) of Regulation S-K involving those who served on the Nominating and Governance Committee during 2022 are described in “Certain Beneficial Owners and Management

Relationships and Related Stockholder MattersPerson Transactions.” During 2022, none of our executive officers served as a member of the Board or Compensation Committee (or other committee performing equivalent functions) of any entity that had one or more executive officers serving on our Board or Nominating and Governance Committee.

32

Item 13Attendance by Members of the Board at Meetings

Certain Relationships, Related Transactions and Director

Independence

33

Item 14

Principal Accountant  Fees and Services

33

PART IV

Item 15

Exhibits and Financial Statement Schedules

34

EX-31.1

EX-31.2

EX-32.1

EX-32.2

i



This  annual  report  on  Form  10-K  is  forThere were 12 Board meetings during the fiscal year ended December 31, 2015.  The2022.

Securities

Under our Corporate Governance Guidelines, which are available on our web site at https://www.nutexhealth.com/governance-documents, a director is expected to spend the time and Exchange  Commission  (“SEC”)  allows  useffort necessary to “incorporate  by  reference”

information  that  we  fileproperly discharge his or her responsibilities. Accordingly, a director is expected to regularly prepare for and attend meetings of the Board and all committees on which the director sits (including separate meetings of the independent directors), with the SEC,  which  meansunderstanding that, we  can  disclose  important

information   to   you   by   referring    you   directly   to   those   documents.    Information

incorporated  by  reference  is  considered  to  be  part  of  this  annual  report.  In  addition,

information   that   we  file  with   the   SEC   in   the   future   will  automatically  update   and

supersede  information  contained  in  this  annual  report.  In  this  annual  report,  “Company,”

“we,” “us” and “our” refer to iGambit Inc. and its subsidiaries.

ii



PART I

This Annual Report on Form 10-K includes forward-looking statements within the

meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the

SecuritiesExchangeActof1934,asamended.TheCompanyhasbasedtheseforward-

lookingstatementsontheCompany’scurrentexpectationsandprojectionsaboutfuture

events.Theseforward-lookingstatementsaresubjecttoknownandunknownrisks,

uncertaintiesandassumptionsaboutusandtheCompany’ssubsidiariesthatmaycause

the  Company’s  actual  results,  levels  of  activity,  performance  or  achievements  to  be

materially   different   from   any   future   results,   levels   of   activity,   performance   or

achievementsexpressedorimpliedbysuchforward-lookingstatements.Inmanycases,

youcanidentifyforward-lookingstatementsbyterminologysuchas“anticipate,”

“estimate,”“believe,”“continue,”“could,”“intend,”“may,”“plan,”“potential,”

“predict,”“should,”“will,”“expect,”“objective,”“projection,”“forecast,”“goal,”

“guidance,”“outlook,”“effort,”“target”andothersimilarwords.However,the

absence  of  these  words  does  not  mean  that  the  statements  are  not  forward-looking.

Factors  that  might  cause  or  contribute  tooccasion, a material  difference  include,  but  are  not

limitedto, thosediscussedelsewhereinthisAnnualReport, includingthe sectionentitled

“RiskFactors”andtherisksdiscussedintheCompany’sotherSecuritiesandExchange

Commission  filings.The  following  discussionshouldbereadin  conjunctionwiththe

Company’s   audited   Consolidated   Financial   Statements   and   related   Notes   thereto

included elsewhere in this report.

ITEM 1.BUSINESS

HISTORY

We were incorporated in the State of Delaware under the name BigVault.com Inc.

on  April 13,  2000.  On  April 18,  2000,  we  merged  with  BigVault.com,  Inc.,  a  New  York

corporation with which we were affiliated. We survived the merger, and on December 19,

2000  changed  our  name  to  bigVAULT  Storage  Technologies,  Inc.  At  that  time  we  were

in  the  business  of  providing  remote,  internet-based  storage  vaulting  services  and  related

ancillary services to end users and resellers (the “Vault Business”).

On   February 28,   2006   we   sold   all   of   our   assets   to   Digi-Data   Corporation

(“DDC”), an unrelated third party, pursuant to the  terms of an Asset  Purchase Agreement

dated  December 21,  2005  (the  “APA”),  a  copy  of  which  is  filed  herewith  as  an  exhibit.

As  consideration  for  our  transfer  of  assets  under  the  APA,  DDC  paid  certain  of  our

liabilities  and  agreed  to  make  certain  quarterly  and  annual  revenue  sharing  payments  to

us,  as  is  further  described  below.  Mr. Salerno  and  Ms.  Luqman  accepted  employment

with  DDC  in  senior  management  positions  post  closing,  and  continued  to  work  for  DDC

until  February 2009.  As  of  March 1,  2009  Mr. Salerno  and  Ms. Luqman  returned  to  their

full time management roles with the Company.

On April 5, 2006, we changed our name to iGambit Inc.

1



On October 1, 2009, we  acquired the  assets  of Jekyll  Island Ventures, Inc., a New

York  corporation  doing  business  as  Gotham  Photo  Company  (“Jekyll”)  through  our

wholly   owned   subsidiary   Gotham   Innovation   Lab,   Inc.,   a   New   York   corporation

(“Gotham”).

On December 28, 2012,  we entered  into an  Asset  and Stock   Purchase  Agreement

(the “Purchase Agreement”) to acquire substantially all of the assets of IGX Global  Inc. a

Connecticut  corporation  (“IGXUS”),  and  all  of  the  issued  and  outstanding  shares  of  IGX

Global  UK  Limited  a  UK  Private  Limited  company  (“IGXUK”)  through  our  wholly

owned  subsidiary  IGXGLOBAL  CORP.,  a  Delaware  corporation  (“IGXGLOBAL”),  and

thereby acquired the business operated by IGSUS and IGSUK (the “Acquired Business”).

Thomas  Duffy  is  the  sole  shareholder  of  both  IGXUK  and  IGXUS  (the  “Shareholder”).

The  Purchase  Agreement  was  disclosed  on  the  Company’s  current  report  on  Form  8-K

filed on January 7, 2013.

On  April  8,  2013,  iGambit  Inc.  (“iGambit”)  and  its’  wholly  owned  subsidiary,

IGXGLOBAL,  CORP.    (“IGXGLOBAL”,  and  collectively,  the  "Company"),  entered

into,  and  became  obligated  under,  a  transaction  to  rescind  the  Company’s  Purchase

Agreement  dated  December  28,  2012   with   IGX  Global  Inc.  (“IGXUS”),  IGX  Global

UK Limited (“IGXUK”, and collectively,  “IGXNJ”) and Tomas  Duffy (“Duffy”) the sole

shareholder of both IGXUK and IGXUS (the “Shareholder”).   The Rescission Agreement

was disclosed on the Company’s current report on Form 8-K filed on April 12, 2013.

On  April  25,  2013  the  conditions  to  closing  the  Rescission  Agreement  were

completed.

On  November  4,  2015,  we  consummated  the  acquisition  of  Wala,  Inc.  doing

business   as   ArcMail   Technology   (ArcMail)   in   accordance   with   a   Stock   Purchase

Agreement   (the   “ArcMail   Purchase   Agreement”)   by   and   among   Wala,   Inc.   doing

business  as  ArcMail  Technologies  (“ArcMail”),  Rory  T.  Welch  (the  “Seller”)  and  the

Company.  PursuanttotheStockPurchase,thetotalconsiderationtobepaidfortheoutstanding

capital  stock  of  ArcMail  is  11,500,000  shares  of  the  Company’s  Common  stock.  10,500,000

shares  of  iGambit’s  Commonstock  to  the  Seller,  and/or  Seller’s  designees  at  Closing  and

the  Holdback  Amount  of  1,000,000  shares  of  the  iGambit’s  Commonstock  to  be  held  in

Escrow and paid to the Seller on later of (i) the first (1st) anniversary of completion of the

first  audit  of  Purchaser  after  the  Closing,  or  (ii)  that  date  which  is  twelve  (12)  months

from  the  Closing,  provided  that  in  the  event  iGambit  or  the  Purchaser  has  any  claims  for

indemnification   against   the   Seller   under   the   Purchase   Agreement,   Purchaser   shall

continue to withhold the portion of the Holdback Amount subject  to such  claims until the

parties fully and finally resolve such claims.

The ArcMail Purchase Agreement  was  disclosed  on the Company’s  current report

on Form 8-K filed on November 10, 2015.

On  November  5,  2015,  through  our  wholly  owned  subsidiary  Gotham  Innovation

Lab,  Inc.  (“Gotham”),  we  completed  the  sale  of  certain  assets  of  Gotham  to  VHT  Inc.

(“VHT”)   in   accordance   with   an   Asset   Purchase   Agreement   (the   “VHT   Purchase

2



Agreement”)  by  and  between  Gotham  and  VHT.      Pursuant  to  the  Purchase  Agreement

the  Company  received  $600,000  in  consideration,  $400,000  of  the  consideration  was

received  at  closing  and  the  remaining  $200,000  portion  of  the  consideration  is  subject  to

twelve  (12)  equal  monthly  payments  beginning  January  2016.  The  sale  included  certain

of  the  assets  of  the  Gotham,  including  the  Elliman  customer  agreement,  all  customer

accounts, all vendor agreements and all the intellectual property.

The VHT  Purchase Agreement  was  disclosed on  the Company’s  current  report  on

Form 8-K filed on November 11, 2015.

OUR COMPANY

Introduction

We  are  a  company  focused  on  the  technology  markets.  Presently  we  have  one

operating  subsidiary,  of  Wala,  Inc.  doing  business  as  ArcMail  Technology  (ArcMail)

which  was  purchased  on  November  4,  2015.  .  ArcMail  is  in  the  business  of  providing

simple,   secure   and   cost-effective   email   and   enterprise   archiving   and   management

solutions  to  businesses  of  all  sizes  across  a  wide  range  of  vertical  markets     Revenues

consist  entirely  of  revenues  from  the  operation  of  our  ArcMail  subsidiary  ($474,679

during   the  period  November  4,  2015  through  the  year  ended  December  31,  2015).   In

addition   to   ArcMail’s   operations,   we   had   income   from   discontinued   operations   of

$627,384.

Our  primary  focus  is  the  acquisition  of  additional  technology  companies.  We

believe  that  the  background  of  our  management  and  of  our  Board  of  Directors  in  the

technology  markets  is  a  valuable  resource  that  makes  us  a  desirable  business  partner  to

the  companies  that  we  are  seeking  to  acquire.  When  we  acquire  a  company,  we  work  to

assume  an  active  role  in  the  development  and  growth  of  the  company,  providing  both

strategic  guidance  and  operational  support.  We  provide  strategic  guidance  to  our  partner

companies   relating  to,   among  other   things,   market   positioning,  business   model   and

product  development,  strategic  capital  expenditures,  mergers  and  acquisitions  and  exit

opportunities. Additionally, we provide operational support to help our partner companies

manage  day-to-day  business  and  operational  issues  and  implement  best  practices  in  the

areas  of  finance,  sales  and  marketing,  business  development,  human  resources  and  legal

services.  Once  a  company  joins  our  partner  company  network,  our  collective  expertise  is

leveraged   to   help   position   that   company   to   produce   high-margin,   recurring   and

predictable earnings and generate long-term value for our stockholders.

Our  current  intention  is  to  fund  the  purchase  price  of  acquisitions  through  a

combination of the issuance of our common stock at  closing and the issuance of common

stock  purchase  or  common-stock  warrants  that  would  become  exercisable  only  in  the

event  certain  earn-out  conditions  are  satisfied  by  the  acquired  company.  In  addition  to

acquiring  entire  companies,  we  would  also  consider  entering  into  joint  ventures  and

acquiring less than 100 percent of a target company.

3



Our Strategy to Grow the Company

General

We  have  an overall  corporate business  plan  as  a  holding company to seek out  and

acquire  operating companies.   Phase  one  of our strategy is  complete.  We  established new

corporate   headquarters   and   a   website,   expanded   our   board   to   include   3   outside

independent   directors,   set   up   periodic   board   meetings,   engaged   a   sophisticated   full

service law firm, engaged a new PCAOB registered auditing firm, engaged an investment

banking  firm  as  advisors  to  assist  in  the  analysis  of  target  acquisitions,  and  become  an

SEC  reporting  company.    In  addition,  we  are  working  on  a  daily  basis  towards  our

strategy, identifying further  acquisitions  that  will expand  and  or  complement  our existing

subsidiary.

Sources of Target Businesses

We  anticipate that target business candidates will  be brought to our attention from

various  sources,  including  our  management  team,  investment  bankers,  venture  capital

funds,   private   equity   funds,   leveraged   buyout   funds,   management   buyout   funds,

consulting  firms  and  other  members  of  the  financial  community  who  will  become  aware

that  we  are  seeking  business  partners  via  public  relations  and  marketing  efforts,  direct

contact  by  management  or  other  similar  efforts,  who  may present  solicited  or  unsolicited

proposals.  Any  finder  or  broker  would  only  be  paid  a  fee  upon  the  completion  of  a

business  combination.  While  we  do  not  presently  anticipate  engaging  the  services  of

professional  firms  that  specialize  in  acquisitions  on  any  formal  basis,  we  may  decide  to

engage  such  firms  in  the  future  or  wedirector may be approached  on  an  unsolicited  basis.  Our

officers  and  directors,  as  well  as  their  affiliates,  may  also  bringunable to our  attention  target

business candidates that  they become aware of through their business contacts.  While  our

officers  and  directors  make  no  commitment  asattend a meeting. A director who is unable to the  amount  of  time  they  will  spend

trying  to  identify  or  investigate  potential  target  businesses,  they  believe  that  the  various

relationships  they  have  developed  over  their  careers  together  with  their  direct  inquiry,

will   generate   a   number   of   potential   target   businesses   that   will   warrant   further

investigation.  In  no  event  will  we  pay  any  of  our  existing  officers,  directors,  special

advisors  or  stockholders  or  any  entity  with  which  they  are  affiliated  any  finder’s  fee  or

other   compensation   for   services   rendered   to   us   prior   to   or   in   connection   with   the

completion of a  business  combination.  In  addition, none of our  officers, directors, special

advisors  or  existing  stockholders  will  receive  any  finder’s  fee,  consulting  fees  or  any

similar  fees  from  any  person  or  entity  in  connection  with  any  business  combination

involving  us  other  than  any  compensation  or  fees  that  may  be  received  for  any  services

provided following such business combination.

Selecting Acquisition Targets

Our  management  has  virtually  unrestricted  flexibility  in  identifying  prospective

target business and diligently reviews all of the proposals we receive.

4



The  criteria  we  look  for  in  a  potential  acquisition  include,  but  are  not  limited  to,

the following:

Company Characteristics

§     Established Company with proven track record

o    Company with history of strong operating and financial performance, or

o    Companyundergoingaturnaroundthatdemonstratesstrongprospectsfor

future growth

§     Strong Cash Flow Characteristics.

o    Cash flow neutral or positive,

o    Predictable recurring revenue stream,

o    High gross margins and

o    Low working capital and capital expenditure needs

§     Strong Competitive Industry Position

o    Leading or niche market position, and/or

o    Strong channel relationships that promote barriers to entry

§     Strong Management Team

o    Experienced,  proven  track  record  in  delivering    revenue  and  abilityto

execute, or

o    Amanagementteamthatcanbecomplementedwithourcontactsand

team

§     Diversified Customer and Supplier base

§     Proprietary products or marketing position

Industry Characteristics

§     Non-cyclical

§     Services Consumer or niche market

§     Fragmented with potential for consolidation or growth

§     Emerging markets

Industries of Interest

§     Real Estate Services

§     Managed Security Services Providers (MSSP)

§     ITSolutionsProvidersspecializinginsecurityandnetworktechnology

products, services, and support

§     Internet

o    Cloud Computing

o     Security focused applications

5



Investment Criteria

§     Sales Volumes: $500 thousand to $30 million

§     Cash Flow: Neutral or positive

§     Structure: Controlled ownership. Closely held private company

§     Geography: North America  Investment size: $1 million to $5 Million

§     Involvement: Board oversight

§     Controlling Interest: Acquire 100% of controlling interest in target

§     Marketing:

o    Target captures a particular segment of the market

o    Target has a focused strategic marketing plan.

These  criteria  are  not  intended  to  be  exhaustive.  Any  evaluation  relating  to  the

merits  of  a  particular  business  combination  will  be  based,  to  the  extent  relevant,  on  the

above  factors  as  well  as  other  considerations  deemed  relevant  by  our  management  in

effecting a business combination consistent with our business objective.

Diligence Process

Upon  receipt  of  a  business  plan,  the  procedure  is  for  management  to  review  the

business plan and determine if it satisfies the Company’s acquisition criteria, and whether

the   business   plan   should   be   rejected   or   pursued   further.   If   the   plan   satisfies   the

requirements, then Management meets with the target’s management to determine if there

is  a  synergy  that  can  work  and  to  explore  the  business  plan  in  greater  detail.  Generally

this occurs over several meetings and can take some time. Depending on the nature of the

business,  management  may  enlist  certain  technical  or  industry  consultants  to  meet  with

the  target  and  provide  feedback  and  analysis.  Management  will  also  review  the  target’s

financials.  If the analysis suggests the target should be explored further Management will

present the opportunity to the BOD for approval to pursue the opportunity further. One or

two outside directors  may meet  with the target to  make an independent  assessment.  If the

opportunity   is   approved   for   further   exploration   management   will   discuss   potential

purchase structure with target’s  management to be sure thatattend a meeting of the minds exists

forBoard or a potential  deal.    At  this  point  management  will  request  that  our  investment  banking

advisors  give  their  opinioncommittee of the industry,Board is expected to notify the market  and  potential  financing  options  of

the   deal.   Often,   the   investment   bankers   will   meet   with   target’s   management.     The

investment   banker’s   feedback  is   presented   to   the  board   and,   if   positive,   the   Board

analyzes   the   proposed   financing  structure,   discusses   effects   of   a   transaction   on   the

Company  as  they  relate  to  taxes,  capitalization,  stock  value  etc.,  engaging  the  necessary

outside  consultants.  If  all  appears  positive  a  letter  of  intent  is  negotiated  and  executed,

additional  diligence  is  conducted,  and  definitive  transaction  documents  are  negotiated

and executed.

6



EvaluationChairman of the Target’s Management

We  would  condition  any  acquisition  onBoard or the commitment  of  managementChairman of the

target  business  to  remain appropriate committee in place  post-closing.  Followingadvance of such meeting, and, whenever possible, participate in such meeting via teleconference in the case of an in-person meeting. We do not maintain a business  combination,  we

may seek to recruit  additional managers to supplementformal policy regarding director attendance at the incumbent  management ofAnnual Meeting; however, it is expected that absent compelling circumstances directors will attend. Given the

target  business.  We  cannot  assure  you  that  we  will  have  the  ability  to  recruit  additional

managers,  or  that  any  such  additional  managers  will  have  the  requisite  skills,  knowledge

or  experience  necessary  to  enhance  the  incumbent  management.  Although  we  intend  to

closely  scrutinize  the  management  of  a  prospective  target  business  when  evaluating  the

desirability   of   effecting   a   business   combination,   we   cannot   assure   you   that   our

assessment timing of the target business’s management will prove to be correct.

Competition

In  identifying,  evaluating  and  selecting  a  target  business,  we  may  encounter

intense  competition  from  other  entities  having a  business  objective  similar  to  ours.  Many

of  these  entities  are  well  established  and  have  extensive  experience  identifying  and

effecting  business  combinations  directly  or  through  affiliates.  Many  of  these  competitors

possess  greater  technical,  human  and  other  resources  than  us  and  our  financial  resources

will be relatively limited when contrasted with those of many of these competitors, which

may  limit  our  ability  to  compete  in  acquiring  certain  target  businesses.  This  inherent

competitive  limitation  gives  others  an  advantage  in  pursuing  the  acquisition  of  a  target

business.

Companies Currently Under Review

We   are   constantly   in   the   process   of   reviewing   potential   target   companies.

Currently, we are not under contract to acquire any companies.

Our Partner Company

Wala Inc. dba ArcMail Technology

Products and Services

ArcMail  is  a  provider of  enterprise  information  archiving solutions  for businesses

of  all  sizes  across  a  wide  range  of  vertical  markets.   ArcMail  offers  a  full  array  of  email

and  data  archiving  solutions  with  broad  deployment  options  that  support  a  wide  range  of

content types from various sources.

ArcMail’s  products  and  services  are  offered  in  a  variety  of  deployment  options

that  include  a  turnkey  appliance,  a  virtual  machine  (VM)  software  (VMware  or  MS

Hyper-V), a cloud/premise-based hybrid gateway (which can store information to a SAN,

NAS,  or  any  cloud-based  storage  provider),  and  fully-hosted  services  in  the  cloud.   Each

deployment  option  can  support  multiple  data  types  from:  most  commercially  available

mail  servers,  including  all  versions  of  MS  Exchange,  Linux  variants,  IBM  Lotus  Notes,

IBM   Domino,   and   GroupWise   among   others;   most   cloud-based   systems,   including

7



Google   Gmail,   MS   Office365,   Google   Apps,   and   Google   Docs   among   others;   and

Microsoft   SharePoint,   enterprise   social   media   such   as   your   corporate   Twitter;   and

Microsoft and Linux-based file systems.

Whether  a  customer  wants  their  archive  to  reside  behind  the  firewall,  in  the

cloud,  or  anywhere  else,  ArcMail  offers  products  and  services  to  fit  that  deployment

strategy.  Whatever  deployment  option  ArcMail’s  customers  elect,  their  data  is  properly

organized  and  maintained, for e-Discovery,  compliance, disaster recovery and for finding

that  file  that  a  CEO  needs  immediately.  Customers  discoverable  information  is  being

archived  using  a  compliant  and  secure  solution  that  is  scalable,  dependable,  and  easy  to

install, deploy, use, and maintain.

In  addition  to  being  an  archiving  solutions  provider,  ArcMail  has  created  a  sales

and  support  organization  to  help  companies  in  search  of  expertise,  information,  and

supporting  resources  as  they  investigate  their  need  and  develop  strategies  for  enterprise

information  archiving.   ArcMail  recognizes  that  customers'  needs  are  not  met  through  a

"cookie  cutter/one  size  fits  all"  approach.  As  an  expert  in  the  enterprise  information

archiving  market,  ArcMail  works  in  partnership  with  customers  to  ensure  their  archiving

solution is tailored to meet their unique situation and environment.

Competitive Comparison

ArcMail’s  archiving  solution  is  built  on  a  simple  and  flexible  design  that  gives

customers  ownership  and  control  over  their  data  and  offers  a  single  comprehensive

solution  for  regulatory  compliance,  data  retention  and  eDiscovery.  ArcMail’s  primary

competitors   include   Barracuda   Networks,   Inc.,   MS   Office365,   and   Google   Vault.

ArcMail  rarely  encounters  other  competitors  such  as  EMC,  Symantec  and  Smarsh,  as

they primarily focus on Fortune 500 and SME markets.

ArcMail  competes  effectively  against  its  primary  competitors  by  providing  a  simple  and

scalable  architecture,  and  world-class  customer  support.   ArcMail’s  primary  competitive

differentiation includes:

§     Simplest User Interface

MS Outlook client or a simple Web-based UI

§     Fastest Search and Retrieval

Proprietary algorithms with granular indexing

§     Most  Data Source Types

We  archive  email,  hosted  email,  SharePoint,  system  files,  social  media,

Google Drive, and other data sources

§     Most Deployment Options

We    offer    appliances,    VM    software,    a    cloud/premise-based    hybrid

gateway, and a fully-hosted solution

8



§     Leading Storage-Saving Performance

Single-instance  storage,  granular  retention  rules  and  oneClosing of the highest

Data compression rates

§     Best  Customer Service

Support  is  provided  at  our  U.S.  headquarters  by  an  experienced  technical

team

Future Products and Services

ArcMail’s product strategy is to provide architectures and deployment capabilities

that  address  the  widest  possible  segment  of  the  archiving  market.  While  ArcMail  is  not

attempting to  be  “all  things  to  all  people”  per  se,  ArcMail,  as  a  result  of  its  differentiated

capabilities,   is   able   to   address   a   majority   segment.   We   see   the   ArcMail   platform

including  appliance,  hosted  and  virtual  products  and  services  as  viable  in  both  the  near

and  long  term.  Enterprise  class  customers  will  continue  to  see  the  appliance  model  as

preferential  to  a  hosted  platform  in  most  cases.  The  SMB  market,  which  is  transitioning

to   the   cloud   in   significant   numbers,   will   help   our   virtualized   and   hosted   solutions

continue to gain ground.

Customers

ArcMail currently has approximately 1,500 client accounts ranging from 50 active

email  accounts  to  5,000  active  email  accounts.   Most  of  ArcMail’s  customers  are  in  the

Northeast, South, and Central  region of the  country.   The typical  profile of our customers

are  100-5,000  email  mailboxes/employees.   ArcMail’s  customers  are  usually in  regulated

industries  or  have  e-discovery  legal  requests,  H.R.  audits,  and/or  regulatory  compliance

issues.  Their  pain  points  will  vary depending  on  the  prospect  you  are  speaking  with.   No

one  Customer  constitutes  more  than  5%  of  ArcMail’s  sales  and  the  loss  of  any  customer

will not have a material adverse effect on the Company’s financial condition.

Expansion Summary

ArcMail’s   objective   is   to   be   a   market   leader   in   the   Enterprise   Information

archiving  industry.  ArcMail  currently  has  significant  market  share  in  the  education  and

local/County/State  government  industry  sector.   ArcMail  is  currently  expanding  its  sales

and marketing initiatives to further penetrate the health care, financial services, insurance,

manufacturing,  and  transportation  industry  sectors.     ArcMail  has   expanded  its  sales

channel  overseas  to  such  areas  as  New  Zealand,  Australia,  Canada,  Mexico  and  other

Latin  American  countries.    ArcMail  is  also  actively  working  to  expand  by  providing

services to larger accounts in the SME enterprises with 5,000+ end users.  ArcMail is also

planning  to  expand  its  products  and  services  portfolio  and  customer  channels  through

acquisition.

Employees

We presently have 14 total employees all of which are full-time.

9



OUR CORPORATE INFORMATION

Our   principal   offices   are   located   at   1050   W.   Jericho   Turnpike,   Suite   A,

Smithtown,  New  York,  11787.  Our  telephone  number  is  (631) 670-6777  and  our  fax

number  is  (631) 670-6780.  We  currently  operate  two  corporate  websites  that  can  be

found  at  www.igambit.com,  and  www.arcmail.com  (the  information  on  the  foregoing

websites does not form a part of this report).

ITEM 1A.RISK FACTORS

Not Required.

ITEM 1B.UNRESOLVED STAFF COMMENTS

None.

ITEM 2.PROPERTIES

Our  corporate  executive  office  is  located  in  Smithtown,  New  York,  where  we

lease   approximately  1000   square   feet   of   office   space.   Monthly   lease   payments   are

approximately $1,620.  The  lease  is  for  a  term  of  five  (5)  years  commencing on  March  1,

2012  and  ending  on  February  28,  2017.   The  lease  contains  annual  escalations  of  2%  of

the annual rent.

Our  ArcMail  operations  are  located  in  Shreveport,  Louisiana,  where  we  lease

approximately 2,989  rentable  square  feet  to  used  as  office  space  and  178  rentable  square

feet  to used  as  storage  space, for a  total  of 3,167  rentable square  feet.  space.   The  lease  is

for  a  term  of  forty  five  (35)  months  beginning  February  1,  2015  and  ending  October  31,

2018 payable monthly in the following manner:

02-01-15 through 04-30-15

$    0.00/mth.

05-01-15 through 04-30-16

$ 3,404.19/mth. ($13.25/s.f/yr.-office; $7.00/s.f.Iyr.-storage)

05-01-16 through 04-30-17

$ 3,528.73/mth. ($13.75/s.f/yr.--office; $7.00/s.f./yr.-storage)

05-01-17 through 10-31-18

$ 3,653.27/mth. ($14.25/s.f/yr.--office; $7.00/s.f./yr.-storage)

Our  leased  properties  are  suitable  for  their  respective  uses  and  are,  in  general,

adequate  for  our  present  needs.  Our  properties  are  subject  to  various  federal,  state,  and

local  statutes  and  ordinances  regulating  their  operations.  Management  does  not  believe

that  compliance  with  such  statutes  and  ordinances  will  materially  affect  our  business,

financial condition, or results of operations.

ITEM 3.LEGAL PROCEEDINGS

Digi-Data Corporation

On  October  1,  2012,  we  filed  a  lawsuit  in  the  United  States  District  Court  for  the

District   of   Maryland,   Baltimore   Division,   asserting   claims   against   DigiData   Corp.

10



("Defendant")  for  monetary  damages  arising  from  the  Defendant's  breach  of  contract

regarding  that  certain  Asset  Purchase  Agreement  dated  February  26,  2006  among  the

parties,   and   to   enforce   payment   of   outstanding   contingency   payments   due   to   the

Company pursuant to said agreement.

On December 13, 2013 the  Court Granted Summary Judgment in iGambit’s favor

against  Digi-Data  in  the  amount  of  $570,590,  plus  interest  at  the  Maryland  legal  rate  of

6% per annum from August 31, 2012, and post judgment interest at the Federal statutory

Rate.   Furthermore, Digi-Data’s Counterclaim was dismissed.

On  February  24,  2014  we  entered  into  a  Forbearance  Agreement  with  Digi-Data

pursuant  to  which  Digi-Data  shall  pay  to  iGambit  Six  Hundred  Forty-Six  Thousand,  Six

Hundred   Sixty-Eight   Dollars   and   Sixty-Seven   Cents   ($646,668.67)   (the   “Settlement

Amount”) in  full  satisfaction  of the  Judgment  based  upon   certain   terms,  which  included

the following:

Digi-Data  Sale:    In  the  event  of  a  Digi-Data  Sale,  iGambit  shall  be  paid  the

Remaining   Balance   at   closing   of   any   such   Digi-Data   Sale   as   provided   in

paragraph 2, below.   iGambit  acknowledges that,  if the Digi-Data  Sale is  a ��sale or

sales  of  the  Digi-Data  Assets,  there  may  be  insufficient  proceeds  to  pay  the

Remaining  Balance  in  full.   If  the  Digi-Data  Sale  is  a  sale  or  sales  of  the  stock  of

Digi-Data  and  there  are  insufficient  proceeds  at  closing  to  pay  the  Remaining

Balance   in   full,   iGambit   shall   continue   to   receive   the   Subsequent   Monthly

Payment until the full Remaining Balance is paid.

On  May  12,  2014,  Digi-Data paid  the  full  balance  due on  the  judgment  plus  all

accrued interest upon the sale of Digi-Data.

ITEM 4.(REMOVED AND RESERVED)

PART II

ITEM 5.MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED

STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY

SECURITIES

MARKET INFORMATION

Effective  March  19,  2011  the  Company’s  common  stock  is  quoted  on  the  Over

the  Counter  Bulletin  Board,  a  service  maintained  by  the  Financial  Industry  Regulatory

Authority, under the ticker symbol “IGMB”.

HOLDERS

As   of   April   14,   2016,   there   are   39,683,990   shares   of   our   common   stock

outstanding,  held  of  record  by  approximately  181  persons.   We  have  275,000  common

stock warrants outstanding and 1,718,900 common stock options outstanding.

11



As  of  April  14,  2016,  approximately  26,583,990  shares  of  our  common  stock  are

eligible to be sold under Rule 144.

DIVIDENDS

We  have   never   declared   or   paid   any  dividends   on   our   common   stock.   Any

determination  to  pay  dividends  in  the  future  will  be  at  the  discretion  of  our  Board  of

Directors  and  will  be  dependent  upon  our  results  of  operations,  financial  condition,

capital  requirements,  contractual  restrictions  and  other  factors  deemed  relevant  by  the

Board  of  Directors.  The  Board  of  Directors  is  not  expected  to  declare  dividends  or  make

any  other  distributions  in  the  foreseeable  future,  but  instead  intends  to  retain  earnings,  if

any, for use in business operations.

EQUITY COMPENSATION PLAN INFORMATION

We  currently do  not  have  an  equity compensation  plan.    In  2006, we  adopted  the

2006  Long-Term  Incentive  Plan  (the  "2006  Plan").    The  Plan  expired  on  December  31,

2009.   The  2006  Plan  provided  for  the  granting  of  options  to  purchase  up  to  10,000,000

shares  of  common  stock.  8,146,900  options  have  been  issued  under  the  plan  to  date  of

which  7,157,038  have  been  exercised  and  692,962  have  expired  to  date.  There  were

296,900  options  outstanding  under  the  2006  Plan  on  its  expiration  date  of  December  31,

2009.   All options issued subsequent to this date were not issued pursuant to any plan.

In   addition   to   the   2006   Long   Term   Incentive   Plan,   we   have   issued   and

outstanding compensatory  warrants  to  two  consultants  entitling the  holders  to  purchase  a

total  of  275,000  shares  of  our  common  stock  at  an  average  exercise  price  of  $0.94  per

share.  Warrants  to  purchase  25,000 shares of common stock vest  upon  6  months after the

Company  engages  in  an  IPO,  have  an  exercise  price  of  $3.00  per  share,  and  expire  2

years  after  the  Company  engages  in  an  IPO.  Warrants  to  purchase  250,000  shares  of

common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each

of  the  following  three  anniversaries  of  the  date  of  issuance,  have  exercise  prices  ranging

from  $0.50  per  share  to  $1.15  per  share,  and  expire  on  June 1,  2019.  The  issuance  of  the

compensatory warrants was not submitted to our shareholders for their approval.

RECENT SALES OF UNREGISTERED SECURITIES

During  2015Business Combinations, we did not sell  securitieshold an annual meeting in transactions2022.

Item 11. Executive Compensation and Other Information

Compensation Committee Report

The material in this report is not registereddeemed soliciting material or filed with the SEC and is not to be incorporated by reference in any filing by us under the

Securities Act of 1933, as amended (the “Securities Act”)., or the  Exchange Act, whether made before or after the date of this Amendment No. 1 and irrespective of any general incorporation language in those filings.

ITEM 6.SELECTED FINANCIAL DATA


The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of SEC Regulation S-K with management. Based on such review and discussions, the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in this Form 10-K/A.

Not Required

Respectfully
submitted by:

Mitchell Creem, MHA,
Cheryl Grenas, R.N., M.S.N.
Michael Reed, MPH

ITEM 7.Executive CompensationMANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

12This section discusses the material components of the executive compensation for Nutex executive officers who are named in the “Summary Compensation Table.” As of December 31, 2022, the “named executive officers” (“NEOs”) and their positions with Nutex Health Inc. were as follows:



Thomas T. Vo,‎ M.D. MBA, Chief Executive Officer;
Warren Hosseinion, M.D., President;
Jon C. Bates, Chief Financial Officer;
Michael Bowen (Chief Financial Officer until June 30, 2022);
Pamela Montgomery, Chief Legal Officer – Healthcare; and
Elisa Luqman, Chief Legal Officer – SEC.

Compensation Philosophy and Objectives

CRITICAL ACCOUNTING ESTIMATES

Our management’s  discussioncompensation philosophy is to attract, motivate, and analysisretain talented executives responsible for Nutex’s success, which operates in an extremely competitive and rapidly evolving industry. With this in mind, we strive to set our compensation programs within the appropriate competitive framework and based on the achievement of its overall financial results, individual contributions, performance by our employees, and each executive’s potential to enhance long-term stockholder value. Within this overall philosophy, Nutex’s objectives are to:

motivate executives to achieve quantitative financial objectives and create a meaningful link between achievement of these objectives and individual executive compensation;
align our executives’ financial interests with our stockholders’ financial interests by providing significant long term equity based incentives; and
offer a competitive total compensation package that enables us to attract and retain top talent in a competitive external job market.

The compensation committee uses Nutex’s compensation philosophy and objectives as a guide in establishing the compensation programs, practices, and packages offered to our executives. The compensation committee also uses these objectives in assessing the proper allocation between long-term and short-term incentive compensation, and cash and non-cash compensation although Nutex has no formal policies requiring any specific allocation.

The compensation for the NEOs generally consists of three primary components: base salary, annual incentive bonus, and equity awards. Other compensation components include severance and change of control provisions, and generally available benefits such as health insurance, 401(k) retirement benefits, and participation in our 2022 Plan (as defined below).

The compensation committee considers the proper allocation between fixed and variable compensation and long-term and short-term incentives by considering the balance that is required to attract and retain executives and reward them for the short-term success of Nutex’s business, while appropriately motivating the executives to strive to achieve Nutex’s long-term goals. The compensation committee also considers the need to offer compensation packages that are comparable to those offered by companies competing with Nutex for executive talent. In allocating between cash and non-cash compensation, Nutex generally seeks to be in the middle of its peer group for cash compensation, and above average for equity-based compensation so as to align the interests of Nutex stockholders and its NEOs. Nutex also believes that generally available benefits should be competitive with the external job market, in order to allow it to attract and retain talent. The compensation committee, however, does not have a pre-established policy or target a specific percentile among our peers for the allocation between long-term and short-term incentive compensation and cash and non-cash compensation.


Role and Authority of the Board and Compensation Committee

Our Compensation Committee is responsible for the executive compensation programs for our executive officers and reports to our Board on its discussions, decisions and other actions. Our Chief Executive Officer makes recommendations for the respective executive officers that report to him to our Compensation Committee and typically attends compensation committee meetings. Our Chief Executive Officer makes such recommendations (other than with respect to himself) regarding base salary, and short-term and long-term compensation, including equity incentives, for our executive officers based on our results, an executive officer’s individual contribution toward these results, the executive officer’s role and performance of his or her duties and his or her achievement of individual goals. Our Compensation Committee then reviews the recommendations and other data, including various compensation survey data and publicly-available data of our financial  conditionpeers, and resultsmakes decisions as to the target total direct compensation for each executive officer, as well as each individual compensation element. While our Chief Executive Officer typically attends meetings of the Compensation Committee, the Compensation Committee meets outside the presence of our Chief Executive Officer when discussing and approving his compensation and when discussing certain other matters, as well.

Our Compensation Committee is authorized to retain the services of operationsone or more executive compensation advisors, as it sees fit, in connection with the establishment of our executive compensation programs and related policies. In fiscal year 2022, the Board and the Compensation Committee retained Mercer, a national compensation consulting firm, to provide it with market information, analysis and other advice relating to executive compensation on an ongoing basis. The Board and the Compensation Committee engaged Mercer to, among other things, assist in developing an appropriate group of peer companies to help us determine the appropriate level of overall compensation for our executive officers, as well as to assess each separate element of compensation, with a goal of ensuring that the compensation we offer to our executive officers, individually as well as in the aggregate, is competitive and fair. We do not believe the retention of, and the work performed by Mercer creates any conflict of interest.

This discussion may contain forward-looking statements that are based on our financial   statements,   which   have   been   prepared   in

accordance   with   accounting   principles   generally   acceptedcurrent plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt in the United   States   offuture could vary significantly from our historical practices and currently planned programs summarized in this discussion.

America.  


The preparation  of  financial  statements  may  require  us  to  make  estimates  and

assumptions  that  may  affectfollowing table sets forth information concerning the reported  amounts  of  assets  and  liabilities  and  the  related

disclosures at the datecompensation of the financial statements. We do not currently have any estimates

or  assumptions  where  the  nature  of  the  estimates  or  assumptions  is  material  due  to  the

levels  of  subjectivity  and  judgment  necessary  to  accountNEOs for  highly  uncertain  matters  or

the   susceptibility   of   such   matters   to   change   or   the   impact   of   the   estimates   and

assumptions   on   financial   condition   or   operating   performance   is   material,   except   as

described below.

Principles of Consolidation

The  consolidated  financial  statements  include  the  accounts  of  the  Company  and

its   wholly-owned   subsidiaries,   Wala,   Inc.   and   Gotham   Innovation   Lab,   Inc.  All

intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

The  preparation  of  financial  statements  in  conformity  with  generally  accepted

accounting principles requires management to make estimates and assumptions that affect

the  reported  amounts  of  assets  and  liabilities  and  disclosure  of  contingent  assets  and

liabilities  at  the  date of  the  consolidated  financial  statements  and  the  reported  amounts  of

revenues and expenses during the period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

For  certain  of  our  financial  instruments,  including  cash,  accounts   receivable,

prepaid  expenses,  accounts  payable,  accrued  interest,  deferred  revenue,  and  amounts  due

to   related   parties,   the   carrying   amounts   approximate   fair   value   due   to   their   short

maturities.     Additionally,   there   are   no   assets   or   liabilities   for   which   fair   value   is

remeasured on a recurring basis.

Long-Lived Assets

We  assess  the  valuation  of  components  of  its  property  and  equipment  and  other

long-lived  assets  whenever  events  or  circumstances  dictate  that  the  carrying  value  might

not  be  recoverable.  We  base  our  evaluation  on  indicators  such  as  the  nature  of the  assets,

the   future   economic   benefit   of   the   assets,   any   historical   or   future   profitability

measurements and other external market conditions or factors that may be present. If such

factors   indicate   that   the   carrying   amount   of   an   asset   or   asset   group   may   not   be

recoverable,  we  determine  whether  an  impairment  has  occurred  by analyzing an  estimate

of  undiscounted  future  cash  flows  at  the  lowest  level  for  which  identifiable  cash  flows

exist.  If  the  estimate  of  undiscounted  cash  flows  during  the  estimated  useful  life  of  the

asset  is  less  than  the  carrying  value  of  the  asset,  we  recognize  a  loss  for  the  difference

13



between  the  carrying  value  of  the  asset  and  its  estimated  fair  value,  generally  measured

by the present value of the estimated cash flows.

Revenue Recognition

We   recognize   revenue   from   product   sales   when   the   following   four   revenue

recognition  criteria  are  met:  persuasive  evidence  of  an  arrangement  exists,  an  equipment

order  has  been  placed  with  the  vendor,  the  selling  price  is  fixed  or  determinable,  and

collectability  is  reasonably  assured.    Revenues  from  maintenance  contracts  covering

multiple  future  periods  are  recognized  during  the  current  periods  and  deferred  revenue  is

recorded  for  future  periods  and  classified  as  current  or  noncurrent,  depending  on  the

terms of the contracts.

Deferred Revenue

Deposits  from  customers  are  not  recognized  as  revenues,  but  as  liabilities,  until

the  following  conditions  are  met:  revenues  are  realized  when  cash  or  claims  to  cash

(receivable)  are  received  in  exchange  for  goods  or  services  or  when  assets  received  in

such   exchange   are   readily   convertible   to   cash   or   claim   to   cash   or   when   such

goods/services  are  transferred.  When  such  income  item  is  earned,  the  related  revenue

item  is  recognized,  and  the  deferred  revenue  is  reduced.  To  the  extent  revenues  are

generated  from  our  support  and  maintenance  services,  we  recognize  such  revenues  when

services are completed and billed. We have received deposits from various customers that

have  been  recorded  as  deferred  revenue  in  the  amount  of  $1,190,279  and  $0  as  of  the

years ended December 31, 2015 and 2014, respectively.

Deferred  revenue  at  December  31,  2015  will  be  realized  in  the  following  years

ended December 31,

2016

$

811,227

2017

78,307

2018

298,446

2019

1,200

2020

1,099

$     1,190,279

Gotham’s  revenues  were  derived  primarily from  the  sale  of  products  and  services

rendered  to  real  estate  brokers.    Gotham  recognized  revenues  when  the  services  or

products  have  been  provided  or  delivered,  the  fees  charged  are  fixed  or  determinable,

Gotham  and  its  customers  understood  the  specific  nature  and  terms  of  the  agreed  upon

transactions, and collectability was reasonably assured.

14



Cash and Cash Equivalents

For  purposes  of  reporting  cash  flows,  cash  and  cash  equivalents  include  checking

and  money  market  accounts  and  any  highly  liquid  debt  instruments  purchased  with  a

maturity of three months or less.

Accounts Receivable

We  analyze  the  collectability  of  accounts  receivable  from  continuing  operations

each  accounting  period  and  adjust  our  allowance  for  doubtful  accounts  accordingly.  A

considerable  amount  of  judgment  is  required  in  assessing  the  realization  of  accounts

receivables,  including  the    creditworthiness  of  each  customer,  current  and  historical

collection  history  and  the  related  aging  of  past  due  balances.   We   evaluate  specific

accounts  when  we  become  aware  of  information  indicating  that  a  customer  may  not  be

able  to  meet  its  financial  obligations  due  to  deterioration  of  its  financial  condition,  lower

credit   ratings,   bankruptcy   or   other   factors   affecting   the   ability   to   render   payment.

Allowance  for  doubtful  accounts  was  $8,344  and  $0  at  December  31,  2015  and  2014,

respectively.   Bad  debt  expense  of  $5,971  and  $4,295  was  charged  to  operations  for  the

years ended December 31, 2015 and 2014, respectively.

Property and equipment and depreciation

Property and equipment are stated at cost.  Maintenance and repairs are charged to

expense  when  incurred.   When  property  and  equipment  are  retired  or  otherwise  disposed

of,   the   related   cost   and   accumulated   depreciation   are   removed   from   the   respective

accounts  and  any  gain  or  loss  is  credited  or  charged  to  income.   Depreciation  for  both

financial  reporting  and  income  tax  purposes  is  computed  using  combinations  of  the

straight  line  and  accelerated  methods  over  the  estimated  lives  of  the  respective  assets  as

follows:

Office equipment and fixtures

5 - 7 years

Computer hardware

5 years

Computer software

3 years

Development equipment

5 years

Depreciation expense of $4,917 and $4,766 was charged to operations for the

years ended December 31, 2015 and 2014, respectively.

Goodwill

Goodwill  represents  the  excess  of  liabilities  assumed  over  assets  acquired  of

ArcMail  and  the  fair  market  value  of  the  common  shares  issued  by  the  Company  for  the

acquisition  of  ArcMail.   In  accordance  with  ASC  Topic No.  350  “Intangibles  –  Goodwill

and Other”),  the  goodwill  is  not  being amortized,  but  instead  will  be  subject  to an  annual

assessment  of  impairment  by applying  a  fair-value  based  test,  and  will  be  reviewed  more

frequently   if   current   events   and   circumstances   indicate   a   possible   impairment.   An

impairment loss is charged to expense in the period identified. If indicators of impairment

are  present  and  future  cash  flows  are  not  expected  to  be  sufficient  to  recover  the  asset’s

15



carrying  amount,  an  impairment  loss  is  charged  to  expense  in  the  period  identified.  A

lack   of   projected   future   operating   results   from   ArcMail’s   operations   may   cause

impairment.   As the acquisition of ArcMail  occurred on November 4, 2015, it is too early

for  management  to  evaluate  whether  goodwill  has  been  impaired.   No  impairment  was

recorded during the year ended December 31, 2015.2022, 2021, and 2020:

Stock-Based

Summary Compensation Table

Stock-based

Current Officers Name & Principal
Position
 Year  Salary  Bonus  Stock (1)  Option
Awards (2)
  Non-equity
Incentive Plan
Compensation
  Change in
pension value
and
Nonqualified
Deferred
Compensation
Earnings
  All Other
Compensation
  Total 
       ($)   ($)   ($)   ($)   ($)   ($)   ($)   ($) 
   2022   931,841   0   0   0   0   0   6,384(8)   938,225 
Thomas T. Vo, MD, MBA,  2021   251,310   0   0   0   0   0   6,354   257,664 
Chief Executive Officer (4)  2020   151,310   0   0   0   0   0   7,536   158,846 
   2022   686,350   0   0   1,960,228   0   0   25,500(8)   2,672,078 
Warren Hosseinion MD,  2021   342,805   150,000   0   964,602   0   0   375,263(3)   1,307,407 
President (5)  2020   0   0   0   338,638   0   0   0   338,638 
   2022   150,000   0   0   0   0   0   2,912(8)   152,912 
Jon Bates,  2021   0   0   0   0   0   0   0   0 
Chief Financial Officer (6)  2020   0   0   0   0   0   0   0   0 
   2022   230,100   0   0   455,984   0   0   0   686,084 
   2021   167,509   50,000   0   0   0   0   0   217,509 
Michael Bowen (7)  2020   0   0   0   0   0   0   0   0 
   2022   247,596   12,500   0   0   0   0   15,259(8)   275,355 
Pamela Montgomery,  2021   143,872   86,402   0   0   0   0   14,034   244,308 
Chief Legal Officer - Healthcare  2020   143,872   62,018   0   0   0   0   8,786   214,676 
   2022   251,334   0   0   341,988   0   0   0   593,322 
Elisa Luqman,  2021   157,600   125,000   2,415   643,068   0   0   0   928,083 
Chief Legal Officer - SEC  2020   133,225   0   0   217,328   0   0   0   350,553 

(1)Discretionary stock grants made in 2021 for 2020 performance. These amounts reflect the grant date fair values of performance awards. The amounts reported do not reflect compensation actually received.


(2)Discretionary stock option grants made in 2022 for completion of Nutex merger, 2021 for completion of AHA and AHP Mergers and discretionary stock option grants made in 2020 for performance. These amounts reflect the grant date fair values of performance awards. The amounts reported do not reflect compensation actually received.

(3)Tax gross-up payment to Dr. Hosseinion for effect of stock option grants pursuant to the AHA AHP Mergers in light of his contributions and this tax being applicable due to Dr. Hosseinion receiving reduced amounts of compensation for his service prior to entering into the AHA and AHP Merger Agreement.

(4)Dr. Vo was appointed Chief Executive Officer of Nutex Health Inc. on April 1, 2022 with an annual base salary of $1,000,000. Prior to April 1,2022, Dr. Vo was Chief Executive Officer of an affiliate of Nutex Health Holdco LLC. In such capacity, he received an annual salary of $‎251,310‎ and 151,310 for each of 2021 and 2020, respectively.

(5)Dr. Hosseinion was appointed President of the Company on April 1, 2022 with an annual base salary of $750,000. Prior to April 1, 2022, and starting February 26, 2021, Dr. Hosseinion was Chief Executive Officer of Clinigence Holdings, Inc. with a base salary of $475,000.

(6)Jon Bates was appointed Chief Financial Officer of the Company effective June 30, 2022, with an annual base salary of $300,000.

(7)Michael Bowen served as the Company’s Chief Financial Officer from February 26, 2021 until June 30, 2022 with an annual base salary of $225,000. Pursuant to his Employment and Transition Agreement dated June 8, 2022, Mr. Bowen was paid $225,000 during fiscal year 2022.

(8)Reflects health, dental, and life insurance premiums paid for the applicable year.

Narrative to Summary Compensation Table

2022 Salaries

Nutex provides base salary to the NEOs and other employees to compensate them for services rendered on a day-to-day basis during the fiscal year.

The compensation expense  for  all  stock-based  award  programs, including

grants  of  stock  options  and  warrants,  is  recordedcommittee reviews executive base salaries in accordanceconjunction with "Compensation—

StockCompensation",  Topic  718Nutex’s annual performance review process. During this process, Nutex’s Chief Executive Officer will review the performance of the FASB  ASC.  Stock-basedNEOs (other than himself) and will report those findings to the Compensation Committee. A NEO’s personal performance will be judged in part on whether Nutex’s business objectives are being met. In setting base salary, management and the Compensation Committee considers each NEO’s experience, skills, knowledge, responsibilities, and performance, Nutex’s performance as a whole, and the report and recommendations of Nutex’s Chief Executive Officer (other than for himself). An assessment of a NEO’s personal performance is qualitative, with much reliance on our Chief Executive Officer’s subjective evaluation of a NEO’s personal performance (other than his own personal performance) and the Compensation Committee’s experience and knowledge regarding compensation expense,

whichmatters. No specific weight is calculated  netattributed to any of estimated  forfeitures,  is  computed  using  the grant  date  fair-

valuefactors considered by the Compensation Committee in setting base salary changes. For newly hired NEOs, the Compensation Committee also considers the base salary of the individual at his or her prior employment and amortizedany unique personal circumstances that motivated the executive to leave that prior position and join Nutex. The compensation committee aims to keep salaries in line with the external job market. Increases over the requisite  service  period  for  all  stock   awards   that  are

expected  to  vest.  The  grant  date  fair  value  for  stock  options  and  warrants  is  calculated

using  the  Black-Scholes  option  pricing  model.  Determining  the  fair  value  of  options  at

the  grant  date  requires   judgment,  including  estimating  the  expected  term  that  stock

optionsprior year’s base salary will be outstanding  priorconsidered within the context of Nutex’s overall annual compensation adjustment budget to exercise,ensure that any increases are fiscally prudent and feasible for Nutex. The compensation committee does not apply specific formulas to determine increases. There is no process in setting these annual merit increase budgets other than the associated  volatilityannual business planning process.

In 2022, the NEOs received an annual base salary to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. The 2022 annual base salaries for our NEOs were $1,000,000 for Thomas T. Vo, M.D., MBA, $750,000 for Warren Hosseinion, M.D., $300,000 for Jon C. Bates, $225,000 for Michael Bowen, $250,000 for Pamela Montgomery and $250,000 for Elisa Luqman. The actual base salaries earned by our NEOs for services in 2022 are set forth above in the Summary Compensation Table in the column entitled “Salary”.


2022 Bonuses

Previously, Nutex has utilized incentive bonuses to reward performance achievements and has annual target incentive bonuses for certain of our executives, payable either in whole or in part, depending on the extent to which the financial performance goals set by the Compensation Committee are achieved. Our NEOs were eligible to earn cash bonuses for work performed in calendar year 2022, as determined by our Board and Compensation Committee (or a subcommittee thereof). In connection with the Closing of the Company’sMerger, our Chief Legal Officer- Healthcare was awarded a bonus of $12,500. ‎As of the Closing of the Merger, ‎the board/Compensation Committee elected not to award any cash bonus payments to any of the executive officers for fiscal 2022.

common    stock,    expected    dividends,    and    a    risk-free    interest    rate.    Stock-based

compensation  expense  is   reported   under   general  and  administrative   expensesEquity Compensation Plan Information

Internal Revenue Code Section 409A

Internal Revenue Code Section 409A (“Section 409A”) imposes additional significant taxes in the event that an executive officer, director or service provider receives “deferred compensation” that does not satisfy the requirements of Section 409A. Although Nutex does not maintain a traditional nonqualified deferred compensation plan, Section 409A does apply to certain severance and bonus arrangements and equity awards. Further, Nutex intends to structure its equity awards in a manner to either avoid the application of Section 409A or, to the extent doing so is not possible, comply with the applicable Section 409A requirements.

accompanying consolidated statements of operations.

Options2019 Omnibus Equity Incentive Plan

In 2006,2019, we adopted the 2006  Long-Term2019 Omnibus Equity Incentive Plan (the "2006  Plan"“2019 Plan”).

Awards granted under the 2006  Plan2019 ‎Plan have a ten-year term and may be incentive stock

options, non-qualifiednon-statutory stock options, restricted stock, ‎restricted stock units (“RSUs”), stock appreciation rights, performance units or warrants.performance shares. The awards arewere granted at an‎an exercise

price equal to the fair market value on the date of grant and generally vest over a three  or

four  yearfour-year period. The 2019 Plan expiredhas since been replaced by the 2022 Plan (as defined below).‎

2022 Equity Incentive Plan

On March 16, 2022, the shareholders of the Company approved the Amended and Restated Nutex Health Inc. ‎‎2022 Equity Incentive Plan (the “2022 Plan”) which amended and ‎replaced, in its entirety, the 2019 Plan upon the closing of the ‎merger by and among the Company, Nutex Acquisition LLC (“Merger Sub”), Micro Hospital Holding LLC (solely ‎for the purposes of certain sections), Nutex Health LLC (solely for the purposes of certain sections) and Thomas T. ‎Vo, solely in his capacity as the representative of the equityholders of the Company (the “Merger Agreement”), ‎pursuant to which Merger Sub merged with and into the Company, with the Company surviving as a wholly owned ‎subsidiary of the Company (the “Merger”). Awards granted under the 2022 Plan have a ten-‎year term and may be ‎incentive stock options, non-statutory stock options, restricted stock, RSUs, ‎stock appreciation rights, ‎performance units or performance shares. The awards are granted at an exercise price ‎equal to the fair market ‎value on the date of grant and generally vest over a four-year period. ‎ The Compensation Committee believes that unvested equity awards are a key factor in motivating and retaining executive personnel, as well as incentivizing executive personnel to preserve the current value and grow the future value of Nutex common stock, thereby furthering the interests of Nutex’s other stockholders.

The 2022 Plan can be found in its entirety as Exhibit 5.4 to the Company’s Annual Report on Form 10-K filed with ‎the SEC on March 3, 2023, and available at www.sec.gov.‎

In March of 2022, the Compensation Committee made grants of 3,624,000 Nonqualified Stock ‎Options to the executive ‎officers, consultants, and directors under the 2022 Plan.‎ In December 31,  2009,  thereforeof 2022, 1,040,221 stock option grants were surrendered and cancelled.


Number of Awards Granted to Employees, Directors and Consultants in 2022

Plan category Number of
securities to be
issued upon
exercise of
outstanding
options,
warrants and
rights
 Weighted-average exercise price of
outstanding options, warrants and rights
 Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in column (a))
 Notes 
   (a)   (b)   (c)     
Equity compensation plans approved by security holders  5,147,770   $2.32   1,352.240   

6,500,010 Original reserve when plan approved by security holders

 
Equity compensation plans not approved by security holders                
                 
Total  5,147,770   $2.32   1,352,240      

Stock Options. Both Incentive Stock Options (“ISOs”) (which are entitled to potentially favorable tax treatment) and nonqualified stock options (“NQSOs”) may be granted under the 2022 Plan. The committee will determine the vesting schedule and number of shares covered by each stock option granted to a participant. The stock option exercise price is determined at grant by the committee and must be at least 100% of the fair market value of a share of common stock on the date of grant (110% for ISOs granted to stockholders who own more than 10% of the total outstanding shares of the company, its parent or any of its subsidiaries). The term of a stock option shall not exceed 10 years from the date of grant (or 5 years for ISOs granted to stockholders who own more than 10% of the total outstanding shares of the company, its parent or any of its subsidiaries).

Other Shares or Share-Based Awards. The committee may grant other forms of equity-based or equity-related awards other than stock options, restricted stock, or RSUs. Such awards may be based upon attainment of performance goals established by the administrator and may involve the transfer of actual shares to participants, or payment in cash or otherwise of amounts based on the value of shares.

Clawback Rights. Awards granted under the 2022 Plan will be subject to recoupment or clawback under the Company’s clawback policy or applicable law, both as in effect from time to time.

Change of Control of Company. Awards granted under the 2022 Plan do not automatically accelerate and vest, become exercisable (with respect to stock options), or have performance targets deemed earned at target level if there is a sale of the Company. The 2022 Plan provides flexibility to the committee to determine how to adjust awards at the time of a sale of the Company.

No Repricing. The 2022 Plan prohibits the amendment of the terms of any outstanding award, and any other action taken in a manner to achieve (i) the reduction of the exercise price of NQSOs, ISOs or stock appreciation rights (collectively, “Stock Rights”); (ii) the cancellation of outstanding Stock Rights in exchange for cash or other awards with an exercise price that is less than the exercise price or base price of the original award; (iii) the cancellation of outstanding Stock Rights with an exercise price or base price that is less than the then current fair market value of a share of common stock in exchange for other awards, cash or other property or (iv) otherwise effect a transaction that would be considered a “repricing” for the purposes of the stockholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the common stock is listed or quoted without stockholder approval.


Transferability of Awards. Awards under the 2022 Plan generally are not transferable by the recipient other than by will or the laws of descent and distribution. Any amounts payable or shares issuable pursuant to an award generally will be paid only to the recipient or the recipient’s beneficiary or representative.

Adjustments. As is customary in incentive plans of this nature, each share limit and the number and kind of shares available under the 2022 Plan and any outstanding awards, as well as the exercise price or base price of awards, and performance targets under certain types of performance-based awards, are subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, stock splits, reverse stock splits, stock dividends, or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the stockholders.

Amendment and Termination. The Board may amend, modify or terminate the 2022 Plan without stockholder approval, except that stockholder approval must be obtained for any amendment that, in the reasonable opinion of the board or the committee, constitutes a material change requiring stockholder approval under applicable laws, policies or regulations or the applicable listing or other requirements of a stock exchange on which shares of common stock are then listed. The 2022 Plan will terminate at the earliest of (i) termination of the 2022 Plan by the Board or (ii) the tenth anniversary of the board adoption of the 2022 Plan. Awards outstanding upon expiration of the 2022 Plan shall remain in effect until they have been exercised or terminated or have expired.

Benefits and Perquisites

Pension Benefits

None of the NEOs participates in or has account balances in qualified or non-qualified defined benefit plans sponsored by Nutex.

Nonqualified Deferred Compensation

None of the NEOs participates in or has account balances in non-qualified defined contribution plans or other deferred compensation plans maintained by Nutex.

Health and Welfare Plans

In 2022, we reimbursed our President for medical benefits pursuant to his employment agreement as set forth in the ‎executive compensation table above, and the remaining‎ NEOs participated in a 401(k) retirement savings plan maintained by Nutex. The Internal Revenue Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) plan. In 2022, the Company made matching contributions up to 3% under the 401(k) plan.

In 2022, the NEOs participated in standard health and welfare plans maintained by Nutex Health Inc. We believe the benefits described above are necessary and appropriate to provide a competitive compensation package to our NEOs.


Tax Gross-Ups

There were no gross up payments in 2022. Each employment agreement provides that if the compensation and benefits ‎payable under such agreement would constitute a “parachute payment” under Section 280G of the Internal Revenue Code, then the ‎employment agreement or award agreements, as the case may be, (would provide either the full amount or a lesser ‎amount such that no portion is subject to Section 280G, whichever provides the higher after-tax amount, including ‎the potential taxes under Section 4999.) ‎

Outstanding Equity Awards at Fiscal Year-End

The following table presents certain information concerning the outstanding option and RSU awards held as of December 31,

2015,  there  was  no  unrecognized  compensation  cost  related  to  non-vested  share-based

compensation arrangements granted under the 2006 plan.

2022 by each NEO. The 2006  Plan  provided  for  the  granting  of  options  to  purchase  up  to  10,000,000

shares  of  common  stock.  8,146,900  options  have  been  issued  under  the  plan  to  date  of

which  7,157,038  have  been  exercised  and  692,962  have  expired  to  date.  There  were

296,900  options  outstanding  under  the  2006  Plan  on  its  expiration  date  of  December  31,

2009. All options issued subsequent to this date were not issued pursuant to any plan.

Stock option activity during the  years ended December 31, 2015 and 2014 follows:

16



Weighted

Average

Weighted

Remaining

Weighted

Average

Average

Contractual

Options

Grant-Date

Life

Outstanding

Exercise Price

Fair Value

(Years)

Options outstanding at

December 31, 2013

668,900

$

0.06

$

0.10

4.69

Options granted

850,000

0.04

0.10

Options outstanding at

December 31, 2014

1,518,900

0.03

0.10

4.76

Options granted

200,000

0.01

0.10

Options outstanding at

December 31, 2015

1,718,900

$

0.03

$

0.13

3.82

Options outstanding at December 31, 2015 consist of:

Date

Number

Number

Exercise

Expiration

Issued

Outstanding

Exercisable

Price

Date

May 1, 2006

100,000

100,000

$0.01

May 1, 2016

May 1, 2006

100,000

100,000

$0.01

May 1, 2016

May 1, 2006

50,000

50,000

$0.01

May 1, 2016

May 1, 2006

46.900

46,900

$0.01

May 1, 2016

June 9, 2014

213,000

213,000

$0.03

June 9, 2024

June 9, 2014

159,000

159,000

$0.03

June 9, 2024

June 9, 2014

600,000

600,000

$0.03

June 9, 2024

June 6, 2014

250,000

250,000

$0.05

June 6, 2019

March 24, 2015

200,000

200,000

$0.01

March 24, 2020

Total

1,718,900

1,718,900

Warrants

In  addition  to  our  2006  Long  Term  Incentive  Plan,  we  have  issued  and  outstanding

compensatory  warrants  to  two  consultants  entitling  the  holders  to  purchase  a  total  of

275,000  shares  of  our  common  stock  at  an  average  exercise  price  of  $0.94  per  share.

Warrants  to  purchase  25,000  shares  of  common  stock  vest  upon  6  months  after  the

Company  engages  in  an  IPO,  have  an  exercise  price  of  $3.00  per  share,  and  expire  2

years  after  the  Company  engages  in  an  IPO.  Warrants  to  purchase  250,000  shares  of

common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each

of  the  following  three  anniversaries  of  the  date  of  issuance,  have  exercise  prices  ranging

from  $0.50  per  share  to  $1.15  per  share,  and  expire  on  June 1,  2019.  The  issuance  of  the

compensatory warrants was not submitted to our shareholders for their approval.

Warrant activity during the years ended December 31, 2015 and 2014 follows:

17



Weighted

(1)Weighted

Weighted

Average Grant-

Average

Date

Remaining

Warrants

Average

Contractual

Outstanding

Exercise Price

Fair Value

Life (Years)

Warrants outstanding

at December 31, 2013

275,000

$

0.94

$

0.10

5.42

No warrant activity

--

--

--

Warrants outstanding

at December 31, 2014

275,000

$

0.94

$

0.10

4.42

No warrant activity

--

--

--

Warrants outstanding

at December 31, 2015

275,000

$

0.94

$

0.10

3.42

(1)  Exclusive of 25,000 warrants expiring 2 years after initial IPO.

Warrants outstanding at December 31, 2015 consist of:

Date

Number

Number

Exercise

Expiration

Issued

Outstanding

Exercisable

Price

Date

April 1, 2000

25,000

25,000

$3.00

2 years after IPO

June 1, 2009

100,000

100,000

$0.50

June 1, 2019

June 1, 2009

50,000

50,000

$0.65

June 1, 2019

June 1, 2009

50,000

50,000

$0.85

June 1, 2019

June 1, 2009

50,000

50,000

$1.15

June 1, 2019

Total

275,000

275,000

Convertible Note

On  September  16,  2013,  we  issued  an  8%  convertible  note  in  the  aggregate

principal  amount  of  $103,500,  convertible  into  shares  of  tour  common  stock.   The  Note,

including accrued  interest  was  due  June  18,  2014  and  was  convertible  any  time  after  180

days  at  the  option  of  the  holder  into  shares  of  the  our  common  stock  at  55%  of  the

average  stock  price  of  the  lowest  3  closing  bid  prices  during  the  10  trading  day  period

endingmarket values below are based on the latest  complete  trading  day  prior  to  the  conversion  date.    Interest  expense

on the convertible note of $3,242 was recorded for the year ended December 31, 2014.

Initially  we  anticipated  repaying  the  obligation  prior  to  the  effective  date  of  the

holder  electing  to  convert.   Since  the  effective  date  of  the  election  to  convert  has  passed

we   recorded   a   debt   discount   related   to   identified   embedded   derivatives   relating   to

conversion  features  and  a  reset  provisions  (see  Note  7)  based  fair  values  as  of  the

inception  date of the  Note.   The  calculated debt  discount  equaled  the  face  of the  note and

was  amortized  over  the  term  of  the  note.   During  the  year  ended  December  31,  2014,  the

note  holder  converted  $49,000  of  the  principal  balance  to  1,539,934  shares  of  common

stock,  and  we  repaid  the  remaining  note  balance  of  $54,500  and  accrued  interest  of

$5,646 on June 18, 2014.

18



Derivative Liability

Convertible Note

During the year ended December 31, 2013, we issued a convertible note.

The note is convertible into common stock, at the  holders’ option, at  a discount to

thereported closing market price of our common stock.   stock on Nasdaq as of December 30, 2022 ($1.90 per share).

  Option Awards  Stock Awards 
Name Number of
Securities
Underlying
Unexercised
Options(#):
Exercisable
  Number of
Securities
Underlying
Unexercised
Options (#):
Unexerciseable
  Option
Exercise
Price
  Option
Expiration
Date
  Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
  Market
Value of
Shares or
Units of
Stock That
Have Not
Vested ($)
  Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other Rights
That Have
Not Vested
($)
  Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested ($)
 
Thomas T. Vo  0   0   0   0   0   0   0   0 
Warren Hosseinion  1,659,779   1,659,779   (1)  (1)  0   0   0   0 
Jon C. Bates  0   0   0   0   0   0   0   0 
Michael Bowen  200,000   200,000  $2.75   9/9/2031   0   0   0   0 
Elisa Luqman  667,106   667,106   (2)  (2)  0   0   0   0 
Pamela Montgomery  0   0   0   0   0   0   0   0 

(1)Includes options to purchase 100,000 shares of common stock at $1.50 per share with an expiration date of 1/27/2030, options to purchase 100,000 shares of the common stock at $1.50 per share with an expiration date of 1/28/2031, options to purchase 600,000 shares of the common stock at $1.61 per share with an expiration date of 5/11/2027, and options to purchase 859,779 shares of the common stock at $2.75 per share with an expiration date of 9/9/2031.

(2)Includes options to purchase 67,106 shares of the commons stock at $1.50 per share with an expiration date of 1/27/2030, options to purchase 50,000 shares of the commons stock at $1.50 per share with an expiration date of 5/22/2027, options to purchase 400,000 shares of the common stock at $1.61 and per share with an expiration date of 1/28/2031 and options to purchase 150,000 shares of common stock at $2.75 per share with an expiration date of 9/9//2031.


Executive Compensation Arrangements

We have identified   embedded   derivativesentered into offers of employment letters or employment agreements with each of Drs. Vo and Hosseinion, as well as Jon Bates. The material terms of these agreements are described below.

included  in  these  notes

Thomas T. Vo, M.D., MBA entered into an employment agreement with the Company (the “Vo Employment Agreement”) to serve as a  result  of  certain  anti-dilutive  (reset)  provisions,  related  to

certain  conversion  features.  The  accounting  treatment  of  derivative  financial  instruments

requires  that  we  record  the  fair  valueChief Executive Officer of the derivatives  asCompany for a five-year term following completion of the inception  dateMerger. The Vo Employment Agreement provides for an annual base salary of the

convertible  note$1,000,000, subject to a three percent minimum increase annually and debt  discount  amortizationreview on at least an annual basis. Dr. Vo is eligible to fair  value  asreceive an annual cash bonus, the decision to provide, amount and terms of each  subsequent

reporting date.   This resultedwhich are in a fair value of derivative liability of $152,076 in which to

the extentsole and absolute discretion of the face  value  of  convertible  note  was  treated  as  debt  discount  with  the

remainder treated as interest expense.

The  fair  valueCompensation Committee of the embedded  derivatives  at  December  31,  2013,Board. In addition, Dr. Vo is entitled to participate in the amount

2022 Plan. Dr. Vo’s employment may be terminated at any time by Dr. Vo or the Company, subject to certain notice requirements. Upon termination of $152,076,  was  determined  usingDr. Vo’s employment by the Binomial  Option  Pricing  Model  based  on  the

following  assumptions:  (1)  dividend  yieldCompany without cause or Dr. Vo’s resignation for good reason and completion of 0%;  (2)  expected  volatilitya general release of 243.00%,  (3)

weighted average  risk-free interest rateclaims, Dr. Vo will be entitled to receive (i) an amount equal to three times Dr. Vo’s most recent base salary, plus (ii) a proportional payment of 0.09%, (4) expected lives of 0.72any annual bonus amount Dr. Vo would have earned with respect to 0.75 years,

and  (5)  estimated  fair  value  of  the  Company’s  common  stock  of  $0.51  per  share.  The

Company  recorded  interest  expense  from  the  excess  of  the  derivative  liability  over  the

convertible  note  of  $48,576days employed during the year ended  December  31,  2013.  A  gain   on

derivative  liability  of $152,076  was  recorded  duringtermination, and (iii) treatment of any outstanding equity awards as determined in accordance with the year  ended  December  31,  2014

for the satisfactionterms of the convertible note.

Based  upon  ASC  840-15-25  (EITF  Issue  00-19,  paragraph  11)applicable award agreements. In the event that Dr. Vo’s employment is terminated by the Company hasfor cause, Dr. Vo will be entitled to receive any earned but unpaid base salary and annual bonus for services rendered through the date of termination and compensation or benefits vested subject to the terms of the applicable compensation or benefits program or arrangement. The Vo Employment Agreement also includes provisions regarding confidentiality, the assignment of intellectual property of the Company, participation in the Company’s employee benefit plans and reimbursement of expenses.

adopted

Warren Hosseinion, M.D. entered into an employment agreement with the Company (the “Hosseinion Employment Agreement”) to serve as President of the Company for a sequencing   approach   regardingfive-year term following completion of the applicationMerger. The Hosseinion Employment Agreement provides for an annual base salary of ASC   815-40$750,000, subject to a minimum three percent increase annually and review on at least an annual basis. Dr. Hosseinion is eligible to receive an annual cash bonus, the decision to provide, amount and terms of which are in the sole and absolute discretion of the Board. In addition, Dr. Hosseinion is eligible to participate in any long-term incentive plan the Company makes available to its

outstanding   convertible   note.   Pursuant executives. Dr. Hosseinion’s employment may be terminated at any time by Dr. Hosseinion or the Company, subject to certain notice requirements. Upon termination of Dr. Hosseinion’s employment by the Company without cause or Dr. Hosseinion’s resignation for good reason and completion of a general release of claims, Dr. Hosseinion will be entitled to receive a cash payment equal to (i) two times Dr. Hosseinion’s most recent base salary, plus (ii) an amount equal to the sequencing   approach,premium amounts paid for group medical, dental and vision coverage of Dr. Hosseinion for a period of twelve months. In the Company

evaluates its contracts based upon earliest issuance date.

Stock Transactions

On  September  25,  2014,  the  Board  unanimously  approved  an  amendment  to  the

Company’s  Articles  of  Incorporation  to  increase  the  number  of  shares  of  Common  Stock

whichevent that Dr. Hosseinion’s employment is terminated by the Company is  authorizedfor cause, Dr. Hosseinion will be entitled to issue  from  seventy  five  million  (75,000,000)receive any earned but unpaid base salary and annual bonus for services rendered through the date of termination and compensation or benefits vested subject to

Three  Hundred  Million  (300,000,000)  shares  of  Common  Stock,  $0.001  par  value  per

share,   and   to   create   a   new   class   of   stock   entitled   “preferred   stock”   (together, the

“Capitalization  Amendments”).  The  Capitalization  Amendments  create  provisions  in  the

Company’s  Articles  of  Incorporation,  which  allows  the  voting  powers,  designations,

preferences  and  other  special  rights,  and  qualifications,  limitations  and  restrictions  of

each  series  of  preferred  stock  to  be  established  from  time  to  time  by  the  Board  without

approval terms of the stockholders. No dividend, voting, conversion, liquidationapplicable compensation or redemptions

rights as well  as redemptionbenefits program or sinking fundarrangement. The Hosseinion Employment Agreement also includes provisions are  yet established  with respect to

regarding confidentiality, the assignment of intellectual property of the Company, participation in the Company’s preferred  stock.   On October 3, 2014, the Majority Stockholders executedmedical and similar insurance plans and reimbursement of expenses.

and   delivered   to   the    Company   a   written   consent    approving   the   Capitalization

Amendments.

19



Common Stock Issued

In connection with Jon Bates’ appointment as the acquisitionCompany’s Chief Financial Officer, on June 8, 2022, the Company entered into a two (2) year employment agreement with Mr. Bates (the “Bates Agreement”) pursuant to which Mr. Bates is entitled to receive a base annual salary of Wala,  Inc.  we  issued  11,500,000  common

shares  valued$300,000, subject to annual review by the Company’s Chief Executive Officer and Board. The employment agreement contains automatic one-year extensions at $.10  per  share  to  the president  and  CEOend of Wala,  Inc.  on  November  4,

2015.

We  issued  1,000,000  and  600,000  common  shares  for services, valued  at  $.20 per

share on August 3, 2015 and May 18, 2015, respectively.

In connection with the convertible note payable the note holder converted $49,000

each term unless 60-day advance notice of the  principal  balance  to  1,539,934  shares  of  common  stock  during  the  year  ended

December   31,   2014.     The   stock   issued   was   determined   based   on   the  terms   of  the

convertible note.

Income Taxes

We  account  for  income  taxes  using  the  asset  and  liability  method  in  accordance

with  ASC  Topic  No.  740,IncomeTaxes.  Under  this  method,  deferred  tax  assets  and

liabilities  are  determined  based  on  differences  between  financial  reporting  and  tax  bases

of  assets  and  liabilities,  and  are  measured  using  the  enacted  tax  rates  and  laws  that  are

expected to be in effect when the differences are expected to reverse.

We  apply  the  provisions   of  ASC  Topic  No.  740  for  the  financial  statement

recognition,  measurement  and  disclosure  of  uncertain  tax  positions  recognized  in  the

Company’s  financial  statements.  In  accordance  with  this  provision,  tax  positions  must

meet  a  more-likely-than-not  recognition  threshold  and  measurement  attribute  for  the

financial statement recognition and measurement of a tax position.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

Introduction

iGambitnon-extension is a  company  focused  on  the  technology  markets.  Our  sole  operating

subsidiary,  of  Wala,  Inc.  doing  business  as  ArcMail  Technology  (ArcMail)  is  in  the

business  of  providing simple,  secure  and  cost-effective  We  are  focused  on  expanding the

operations of ArcMaildelivered by marketing the company to existing and potential new clients.

Year Ended December 31, 2015 as Compared to Year Ended December 31, 2014

Assets. At December 31, 2015, we had $890,686 in current assets and $7,637,996

in  total  assets,  compared  to  $276,398  in  current  assets  and  $280,786  in  total  assets  as  of

December 31,  2014.    The  increase  in  total  assets  was  primarily  due  to  an  increase  in

goodwill, inventories,  accounts  receivable and  prepaid  expenses  from the  purchase  of the

ArcMail  business,  and  an  increase  in  assets  from  discontinued  operations  as  a  result  of

the sale of Gotham in 2015.

20



Liabilities.   At   December 31,   2015,   we   had   total   liabilities   of   $6,076,680

compared  to  $285,277  at  December 31,  2014.  Our  total  liabilities  at  December 31,  2015

consisted   of   current   liabilities   including   accounts   payable   and   accrued   expenses   of

$636,633,  accrued  interest  on  notes  payable  of  $302,278,  Notes  payable  of  $779,750,

Notes  Payable  to  a  related  party  of  $156,566,  liabilities  from  discontinued  operations  of

$127,353  and  deferred  revenue  of  $811,227,  and  long-term  liabilities  including  notes

payable of $2,339,251,  notes payable to a  related  party of $469,699  and deferred revenue

of  $379,052,  whereas  our  total  liabilities  at  December  31,  2014  consisted  of  current

liabilities   including     accounts   payable   of   $91,177   and   liabilities   from   discontinued

operations  of  $194,100.  We  had  no  long term  liabilities  for  the  year  ended  December  31,

2014.      The  increase  in  liabilities  was  primarily  due  to  the  liabilities  assumed  in  the

purchase of the ArcMail business.

Stockholders’   Equity   (Deficiency).   Our   Stockholders’   Equity   was   $1,561,316   at

December  31,  2015  compared  to  Stockholders’  Deficiency   of  $(4,491)  at  December 31,

2014. This  increase  was  due  to  the  common  shares  issued  in  the  purchase  of the  ArcMail

business  and   a  decrease  in  accumulated  deficit  from  $(2,882,199)  at  December  31,  2014

to  $(2,798,390)  at  December 31, 2015  resulting from net  income   of $83,809 for  the  year

ended December 31, 2015 compared to net loss of $684,342 for the  year ended December

31, 2014

Revenue  and  Net  Income.  We  had  revenue  of  $474,679  for  the  year  ended

December 31, 2015, compared to revenue of $1,068,617 for the year ended December 31,

2014.   The  decrease  in  revenue  was  due  primarily to  the  sale of the  Gotham  business  and

purchase  of  the  ArcMail  business  in  November  2015.   We  had  no  other  income  for  the

year  ended  December  31,  2015  compared  to  other  income  of  $84,701  for  the  year  ended

December  31,  2014  primarily  due  to  the  gain  on  derivative  liability  of  $152,076.  In

addition   to   ArcMail’s   operations,   we   had   income   from   discontinued   operations   of

$627,384  and  $17,531  for  the  year  ended  December  31,  2015  and  December  31,  2014,

respectively.

General  and  Administrative  Expenses.  General  and  Administrative  Expenses

decreased  to  $965,609  for  the  year  ended  December 31,  2015  from  $1,383,646  for  the

year  ended  December 31,  2014.  For  the  year  ended  December 31,  2015  our  General  and

Administrative Expenses consisted of corporate administrative expenses of $73,308, legal

and  accounting  fees  of  $165,041,  payroll  expenses  of  $330,671,  Directors  and  Officers

Insurance   of   $42,206,   employee   benefits   expenses   of   $22,385   (medical,   dental,

retirement  plan,  and  life  insurance)  and   $331,998  in  stock  based  compensation  expense.

For   the   year   ended   December 31,   2014   our   General   and   Administrative   Expenses

consisted  of  corporate  administrative  expenses  of  $292,096,  legal  and  accounting  fees  of

$111,477,  payroll  expenses  of  $731,606,  Directors  and  Officers  Insurance  of  $43,754,

employee   benefits   expenses   of   $74,975   (medical,   dental,   retirement   plan,   and   life

insurance),  $74,664  in  stock  based  compensation  expense,    and  a  bad  debt  write  off  of

$55,074.  Therefore  the  decreases  from  the  year  ended  December 31,  2014  to  the  year

ended December 31, 2015 relate  primarily to  a  decrease in payroll  and employee  benefits

expenses.either party. In the event the company  effectuates  an  acquisition  in  2016  we  anticipate

additional professional fees associated withCompany (or its successor) terminates Mr. Bates employment without cause or Mr. Bates resigns for good reason, severance benefits would be twelve months of base salary and a cash subsidy for group medical, dental and vision programs for twelve months. No severance is payable under the acquisition.

21



LIQUIDITY AND CAPITAL RESOURCES

General

As  reflectedBates Agreements if Mr. Bates employment is terminated by the Company for cause (as defined in the accompanying  consolidated  financial  statements,  at  December

31, 2015, we had $131,987 of cash and stockholders’ equity of $1,561,316.  At December

31, 2014, we had $126,833 of cash and stockholders’ deficit of $(4,491).

Our primary capital requirements in 2016 are likely to arise from the expansion of

our  ArcMail  operations,  and,Bates Agreement), Mr. Bates resigns without good reason (as defined in the event  we  effectuateBates Agreement) or is unable to perform due to death or disability. Mr. Bates is entitled to receive payment of all salary and benefits accrued up to the termination date of his employment upon any termination of employment, unpaid expense reimbursements, and accrued but unused paid time off within thirty (30) days. Mr. Bates will also be eligible to receive an acquisition,  from:  (i) the

annual cash bonus (the “Annual Bonus”) in an amount of up to forty percent (40%) of his Base Salary. The amount of the purchase  price  payable  in  cash  at  closing,  if  any;  (ii) professional  fees

associated  with  the  negotiation,  structuring,  and  closing  of  the  transaction;  and  (iii) post

closing  costs.  It  is  not  possible  to  quantify  those  costs  at  this  point  in  time,  in  that  they

depend on ArcMail’s business opportunities, the state of the overall economy, the relative

size  of  any  target  company  we  identify  and  the  complexity  of  the  related  acquisition

transaction(s).  We  anticipate  raising  capital  in  the  private  markets  to  cover  any  such

costs,  though  there  can  be  no  guaranty  weAnnual Bonus will be able  to  do  so  on  terms  we  deem  to  be

acceptable.  We  do  not  have  any  plans  at  this  point  in  time  to  obtain  a  line  of  credit  or

other loan facility from a commercial bank.

While  we  believe  inrecommended by the  viability  of  our  strategy  to  improve  ArcMail’s  sales

volume  and  to  acquire  companies,  and  in  our  ability  to  raise  additional  funds,  there  can

be no assurances that we will be able to fully effectuate our business plan.

We  believe  we  will  continue  to  increase  our  cash  position  and  liquidity  for  the

foreseeable future. We believe we have enough capital to fund our present operations.

Cash Flow Activity

Net   cash   provided   by   operating   activities   was   $44,907   for   the   year   ended

December  31,  2015,  compared  to  $159,202  for  the  year  ended  December  31,  2014.   Net

cash  used  by  continuing  operating  activities  was  $451,023  for  the  year  ended  December

31,  2015,  compared  to  $491,127  for  the  year  ended  December  31,  2014.  Our  primary

source  of  operating  cash  flows  from  continuing  operating  activities  for  the  year  ended

December 31, 2015 was from our ArcMail subsidiary’s revenues of $466,628 and  for the

year   ended   December   31,   2014   our   primary   source   of   operating   cash   flows   from

continuing   operating   activities   was   from   revenues   of   $1,068,617   from   our   Gotham

subsidiary  that  was  sold  in  November  2015.    Additional  contributing  factors  to  the

change  were  from  a  decrease  in  accounts  receivable  of  $56,697,  an  increase  in  prepaid

expenses  of  $199,207,  a  decrease  in  accounts  payable  and  accrued  expenses  of  $90,944,

an  increase  in accrued interest  of $47,559  and  a  decrease  in  deferred  revenue  of $64,586,

Net  cash  provided  by  discontinued  operating  activities  was  $495,930  for  the  year  ended

December 31, 2015 and   $650,329 for the  year ended December 31, 2014.  Cash provided

by  discontinued  operations  for  the  year  ended  December  31,  2015  consisted  of  $495,930

in cash payments received from VHT Inc. pursuant to the VHT  Purchase Agreement.

22



Cash  provided  by investing activities  was  $11,524  for  the  year  ended  December  31,

2015  and  cash  used  by  investing  activities  was  $4,739  for  the  year  ended  December  31,

2014.  For  the  year  ended  December  31,  2015  the  primary  source  of  cash  from  investing

activities  was  cash  from  the  subsidiary  acquisitions  and  a  decrease  in  deposits.   For  the

year  ended  December  31,  2014  the  primary  source  of  cash  used  by  investing  activities

was  from  purchases  of  property  and  equipment  of  $2,026  and  an  increase  in  deposits  of

$2,713.

Cash  used  by  financing  activities  was  $(51,277)  for  the  year  ended  December  31,

2015  compared  to  cash  used  by  financing  activities  of  $(54,500)  for  the  year  ended

December  31,  2014.  The  cash  flows  used  by  financing  activities  for  the  year  ended

December  31,  2015  was  primarily  from  repayment  of  stockholders  loans  and  a  note

payable.  The  cash  flows  used  by  financing  activities  for  the  year  ended  December  31,

2014 was primarily from repayment of the convertible note payable.

Supplemental Cash Flow Activity

In   the   year   ended   December   31,   2015   the  company  paid   interest   of   $3,146

compared to interest of $10,033 in the year ended December 31, 2014.

OFF BALANCE SHEET ARRANGEMENTS

We have no off balance-sheet arrangements.

ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT

MARKET RISK

Not Required.

ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Financial Statements required by this Item 8 are included in this Report beginning

on page F-1, as follows:

Report of Independent Registered Public Accounting Firm

F-1

Consolidated Balance Sheet as of December 31, 2014 and 2013

F-3

Consolidated Statement of Income for the years ended December 31, 2014 and

F-4

2013

Consolidated Statement of Changes in Stockholder’s Equity for the years ended

F-5

December 31, 2014 and 2013

Consolidated Statement of Cash Flows for the years ended December 31, 2014

F-6

and 2013

Notes to Financial Statements

F-7

ITEM 9.CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON

23



ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We  carried  out  an  evaluation,  as  required  by  paragraph  (b) of  Rule 13a-15  and

15d-15  of  the  Exchange  Act  under  the  supervision  and  with  the  participation  of  our

management,  including  our Chief Executive Officer at his discretion and approved by the Company Board. Mr. Bates shall be eligible to participate in the Company’s long-term incentive plan that may be available to similarly positioned executives.


Mr. Bowen, who resigned as the Company’s Chief Financial Officer effective June 30, 2022, was entitled to a base salary of the$225,000 pursuant to his original employment agreement and $250,000 pursuant to his Employment and Transition Agreement, dated June 8, 2022.

effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and

15d-15(e)  under the  Exchange Act as  of December 31, 2015.  Based upon  that  evaluation,Director Compensation

our  Chief  Executive  Officer  and  Chief  Financial  Officer  concluded  that  our  disclosure

controls and procedures were effective as of December 31, 2015.

Management’s Annual Report on Internal Control over Financial Reporting.

We  are  responsible  for  establishing  and  maintaining  adequate  internal  control

over  financial  reporting.  Internal  control  over  financial  reporting  is  defined  in  Rule 13a-

15(f)  and  Rule  15d-15(f)  promulgated  under  the  Exchange  Act  as  a  process  designed  by,

or  under  the  supervision  of,  our  Chief  Executive  Officer  (our  principal  executive  officer)

and  Chief  Financial  Officer  (our  principal  accounting and  financial  officer),  and  effected

by  our   board   of   directors,   management   and   other   personnel,   to   provide   reasonable

assurance  regarding  the  reliability  of  financial  reporting  and  the  preparation  of  financial

statements   for   external   purposes   in   accordance   with   generally   accepted   accounting

principles.   Our   internal   control   over   financial   reporting   includes   those   policies   and

procedures that:

§     Pertaintothemaintenanceofrecordsthat,inreasonabledetail,accurately

and fairly reflect the transactions and dispositions of our assets;

§     Providereasonableassurancethattransactionsarerecordedasnecessary

to  permit  preparation  of  financial  statements  in  accordance  with  generally

accepted  accounting  principles,  and  that  our  receipts  and  expenditures  are

being  made  only  in  accordance  with  authorizations  of  our  management

and our directors; and

§     Providereasonableassuranceregardingpreventionortimelydetectionof

unauthorized  acquisition,  use  or disposition  of  our assets  that  could  have  a

material effect on the financial statements.

Our  internal  control  system  was  designed  to  provide  reasonable  assurance  to  our

management  and  board  of  directors  regarding  the  preparation  and  fair  presentation  of

published  financial  statements.  Because  of  its  inherent  limitations,  internal  control  over

financial  reporting  may  not  prevent  or  detect  misstatements.  Also,  projections  of  any

evaluation  of  effectiveness  to  future  periods  are  subject  to  the  risk  that  controls  may

become  inadequate  because  of  changes  in  conditions,  or  that  the  degree  of  compliance

with the policies or procedures may deteriorate.

24



Our  management  assessed  the  effectiveness  of  the  Company’s  internal  control

over   financial   reporting   as   of   December 31,    2015.   In   making   this   assessment,

management  used  the  criteria  set  forth  in  the  Internal  Control  —  Integrated  Framework

issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission

(COSO).  Based  on  management’s  assessment,  we  concluded  that,  as  of  December 31,

2015, our internal control over financial reporting was effective.

Change in Internal Controls

During the quarter ended December 31, 2015, there were no changes in our

internal control over financial reporting that materially affected, or are reasonably likely

to materially affect, our internal control over financial reporting.

ITEM 9B.OTHER INFORMATION

None.

PART III

ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE

GOVERNANCE

DIRECTORS AND EXECUTIVE OFFICERS

Our board of directors manages our business and affairs. Under our Articles of

Incorporation and Bylaws, the Board will consist of not less than one, nor more than

seven directors. Currently, our Board consists of five directors.

The names,  ages,  positions  and  dates  appointed  of  our  current  directors  and

executive officers are set forth below.

Name

Age

Position

Appointed

John Salerno

77     Chief Executive Officer, President,    March 2009

Chairmannon-executive members of the Board and

(appointed Chairman

Director

are eligible to receive both cash and Director in

April 2000)

Elisa Luqman

51     Chief Financial Officer, Executive     March 2009

Vice President, General Counsel,

(appointed Director

and Director

in August 2009)

James J. Charles

73     Director

March 2006

George G. Dempster

76     Director

January 2001

John Keefe

73     Director

July 2013

JohnSalerno,ChiefExecutiveOfficer,President,ChairmanoftheBoard,

and  Director.  Mr.  Salerno  is  a  seasoned  hands-on  executive  with  over  40 years  of

experience    with    public    and    private    computer    software    andequity compensation for their service companies.

25



Mr. Salerno  built  a  multi-million  dollar  business  from  a  start  up,  servicing  the  real  estate

industry.  The  business  was  sold  in  1984  and  Mr. Salerno  provided  consulting services  to

a  wide  rangeas board members. Members of clients  through  1995.  In  1996, along with  his  daughter and  a  small  group

of  private  accredited  investors,  he  co-founded  the  Company.  Mr. Salerno  was  President

and  CEO  of  the  Company  from  April 1,  2000  until  February 28,  2006.  After  signing

contracts with Verizon and Cablevision, the Company sold its assets in 2006 to Digi-Data

Corporation.  From  March 1,  2006  thru  February 2009  Mr. Salerno  served  as  President  of

the  Vault  Services  Division  of  Digi-Data  Corporation.  Upon  the  expiration  of  his  3 year

contract the Vault Services Division was at a revenue run rate of $12 million annually. As

of March 1, 2009,  Mr. Salerno returned to his full  time management roll  at  the Company.

Mr. Salerno is an ex — US Marine Corps, Crypto/ Communications Officer and has a BS

in Mathematics from Fordham University. Mr. Salerno is Elisa Luqman’s father.

Mr. Salerno was nominated as a Director because  if his intimate  knowledge of the

Company  and  its  history  as  a  founder.    Additionally,  Mr.  Salerno’s  mathematical  and

technical background as a data center manager early in his professional career and later as

a  software  developer  offers  the  board  hand’s  on  technical  experience  in  both  operations

and  software  analysis.     Mr.  Salerno  utilized  his  experience  and  contacts  to  secure  the

major  customers  driving  the  sales  that  generate  the  Company’s  payment  stream  from

DDC.   Moreover,  Mr.  Salerno  adds  value  to  Gotham  through  his  40  plus  years  serving

the  New  York  Real  Estate  industry.   He  is  thoroughly  familiar  with  the  unique  workings

of  the  New  York  real  estate  industry  and  has  many  contacts  within  that  community  that

who are a benefit to Gotham.

ElisaLuqman,  Chief  FinancialOfficer,Executive  Vice  President,General

Counsel,andDirector.  Ms. Luqman  is  a  computer  literate  attorney  with  over  18 years

experience  with  intellectual  property  and  computer  software.  Prior  to  co-founding  the

Company,   Ms. Luqman   was   president   of   University   Software   Corp.,   a   software

development  company  focused  on  a  wide  range  of  student  educational  and  intellectual

applications.  Ms. Luqman  was  Chief  Operating  Officer  of  the  Company,  from  April 1,

2000   until   February 28,   2006.   From   March 1,   2006   through    February 28,   2009

Ms. Luqman  was  employed  as  Chief  Operating  Officer  of  the  Vault  Services  Division  of

Digi-Data  Corporation,  the  company  that  acquired  the  Company’s  assets  in  2006,  and

subsequently  during  her  tenure  with  Digi-Data  Corporation  she  became  the  in-house

general  counsel  for  the  entire  corporation.  In   that  capacity  she  was   responsible  for

acquisitions,  mergers,  patents,  and  employee  contracts,  and  worked  very  closely  with

Digi-Data’s outside counsel firms, DLA-Piper, the  Law Offices of Sandra T. Carr and the

patent  firm  of  Jordan  and  Hamburg.  As  of  March 1,  2009,  Ms.  Luqman  rejoined  the

Company in her current  capacities. Ms  Luqman  received  a BA degree in  Marketing, a JD

in  Law,  and  a  MBA  Degree  in  Finance  from  Hofstra  University.  Ms. Luqman  is  a

member   of   the   bar   in   New   York   and   New   Jersey.   Ms. Luqman   is   John   Salerno’s

daughter.

Ms.  Luqman  was  nominated  as  a  Director  because  of  her  intimate  knowledge  of

the  Company  and  its  history  as  a  founder.   Additionally,  as  an  attorney,  Ms.  Luqman’s

legal  background  enables  her  to  provide  counsel  to  the  Company.  Her  experience  as

general  counsel  to  the  Company  provides  her  with  a  unique  insight  into  the  Company’s

26



contracts  with  customers  and  vendors,  intellectual  property  assets  and  issues,  financing

transactions  and  shareholder  transactions.    Moreover,  having  been  through  the  merger

and  acquisition  process  on  both  sides  of  the  table,  Ms.  Luqman  offers  the  Company  in-

house  guidance  throughout  the  acquisition  process.  That  combined  with  Ms.  Luqman’s

MBA  in  Finance  aids  in  providing  the  Board  with  more  efficient  analysis  of  input  from

outside auditors and legal advisors.

JamesJ.Charles,Director.  Mr. Charles  is  a  high  profile  financial  executive

with  a  broad  base  of  experience  with  firms  ranging  in  size  from  $24MM  to  $180MM  in

annual revenue. He  worked closely with  management  and Boards of Directors on  matters

ranging  from  mergers  and  acquisitions  to  stock  restructurings  and  spin-offs.  Mr. Charles

has  been  a  self  employed  Certified  Public  Accountant  from  1999  to  present.  From  1994

to   1999   Mr. Charles   was   the   chief   financial   officer   of   Interpharm   Holdings,   Inc.

Interpharm   Holdings,   Inc.,   through   its   subsidiary,   Interpharm,   Inc.,   engaged   in   the

development,  manufacture,  and  marketing  of  generic  prescription  strength  and  over-the-

counter  pharmaceuticals  in  the  United  States.  It  also  focused  on  the  development  of

products  in  the  areas  of  female  hormone,  scheduled  narcotic,  soft  gelatin  capsule,  oral

liquid,  products  coming  off  patent,  and  other  products.  From1966to1994Mr. Charles

was  a  Senior  Managing  Partner  with  Ernst  &  Young.  Mr. Charles’  education  includes

studies   and   management   programs   at   Harvard   University   and   Williams   College.

Mr. Charles received his BBA in Accounting at Manhattan College.

Mr.  Charles  was  nominated  as  a  Director  because  of  his  financial  expertise.  He

has  been  involved  in  the  practice  of  public  accounting  for  over  forty  years.   During  his

tenure  as  a  Senior  Managing  Partner  at  Ernst  &  Young  he  spent  considerable  years

analyzing  potential  acquisition  targets  for  corporate  clients  and  has  particular  experience

and  skills  on  matter  such  as  mergers  and  acquisitions,  stock  restructuring  and  spin-offs.

He has also been a Chief Financial Officer of a public company.

GeorgeG.Dempster,Director.  Mr. Dempster  was  Commissioner  of  Commerce

for  the  State  of  New  York  from  1979  to  1983.  He  served  as  the  Chairman  of  the  Finance

Committee  for  Hofstra  University  for  25 years  from  1976  through  2001,  and  is  currently

Chairman  Emeritus  of  the  Board  of  Trustees.  Mr. Dempster  has  been  the  Chairman  of

Tran-Leisure  Corp.  since  1983,  and  was  its CEO from 1983-2002.   Tran -Leisure  Corp  is

a   diversified   holding   company   with   interests   ranging   from   helicopter   services   to

manufacturing.  From  1969  to  1973  Mr. Dempster  served  as  the  CEO  of  Cybernetics,  a

major  computer  software  developer.  Mr. Dempster  served  as  a  marketing  manager  for

IBM from 1961 to 1968. Mr. Dempster has a BA in business administration from Hofstra

University.

Mr.  Dempster  was  nominated  as  a  Director  because  of  his  strong  administrative,

financial  and  economic  background.   Having  served  as  Commissioner  of  Commerce  for

the  State  of  New  York  for  4  years  and on the Board of  Hofstra  Universityare not eligible for over  25

years,  Mr.  Dempster  provides  the  Company  with  extensive  experience  in  commerce  and

administration  in  both  the  private  and  public  sectors.     Moreover,  during  his  tenure  at

Hofstra   University   Mr.    Dempster   was   intimately   involved   in   several   financing

transactions  to  maintain  the  University in  a  solvent  and  profitable  manner.   Additionally,

27



having been  CEO of a  diversified holding company, Mr. Dempster is thoroughly familiar

with   the   merger   and   acquisition   process.   He   offers   years   of   experience   analyzing

business, their models and economics, and identifying the appropriate financing vehicles.

JohnKeefe,Director.  Mr.  Keefe  is  an  investment  banker,  venture  capitalist,  founder

of  three  businesses,  and  a  turnaround  consultant  to  businesses  in  trouble.   Since  2011  to

Present,  Mr.  Keefe  is  the  Founder  and  Chief  Development  Officer  of  Security  Capital

Advisors  LLC,  located  in  Jersey  City,  NJ.    Security  Capital  Advisors  LLC  is  a  firm

providing  indirect  financing  to  local  governments  in  the  US.     From  2007  to  2011  Mr.

Keefe  was  Managing  Director  of  Nachman  Hays  Brownstein,  located  in  New  York,  NY.

Nachman   Hays   Brownstein   is   a   national   turnaround   management   firm,   assisting

underperforming   and   troubled   companies,   maximizing   valueadditional compensation for owners,   investors,

creditors  and  employees.  Mr.  Keefe  was  also  a  founding  General  Partner  of  a  venture

capital   firm,   a   founder   and   CFO   of   a   computer   software   company,   a   Senior   Vice

President  of  an  investment  banking  firm,  and  emergency  CFO  and  Chief  Restructuring

Officer of several distressed businesses. He is a  graduate of Harvard College and Harvard

Business School.

Mr.   Keefe’   was   nominatedservice as a   Director   because   of   his   financial   expertise

combined  with  his  strong  technical  background.  He  started  his  career  as  a  computer

software  engineer  and  designer  for  IBM,  General  Electric,  and  Litton  Industries.  He

evolved  into  the  financial  arena  serving  many  years  a  corporate  Chief  Financial  Officer.

He   is  now  involved  in  the  practice  of  venture  capital  and  investment  banking   He  has

particular   skills   acting   as   a   turnaround   consultant   to   businesses   in   trouble   being   a

‘Certified  Turnaround  Professional’  by  the  Turnaround  Management  Association.  He

offers  years  of  experience  analyzing  business,  their  revenue  models,  and  identifying

appropriate financing vehicles.

COMMITTEES OF THE BOARD

The  Board  has  established  an  Audit  Committee  and  a  Compensation  Committee.

The   Board   does   not   currently   have   a   Nominating   Committee.   The   work   typically

conducted by a Nominating Committee is conducted by the full Board.

Audit Committee

The    Audit    Committee    presently   consists    of    Messrs. Charles,    Keefe    and

Dempster,   with   Mr.   Charles   serving   as   chairman.   Our   Board   has   determined   that

Mr. Charles  qualifies  as   an  “audit  committee  financial  expert”  as  defined  under  the

federal securities laws. The Audit Committee is responsible for monitoring and reviewing

our  financial  statements  and  internal  controls  over  financial  reporting.  In  addition,  they

recommend  the  selection  of  the  independent  auditors  and  consult  with  management  and

our  independent  auditors  prior  to  the  presentation  of  financial  statements  to  stockholders

and  the  filing  of  our  forms  10-Q  and  10-K.  The  Audit  Committee  has  adopted  a  charter

and it is posted on our web site at www.igambit.com.

28



Compensation Committee

board members. The Compensation Committee presently  consists  of  Messrs.  Charles,  Keefeperiodically reviews the Nutex compensation program and

Dempster,   with   Mr. Keefe   serving   as   chairman.   The   Compensation   Committee   is

responsible for reviewing and  recommending may, from time-to-time, recommend to the Board, changes to the compensation  and  over-all

benefits  of  our  executive  officers,  including  administering  the  Company’s  2006  Long

Term  Incentive  Plan.program. The Compensation Committee may butseek the advice of an independent compensation consultant to the extent it deems necessary or appropriate in the discharge of its duties.

Cash Retainers

We provide our non-executive directors with cash retainers, paid monthly. The annual cash retainer for each non-executive director is $150,000. Additionally, we provided the following annual cash retainers in fiscal 2022, which are prorated for partial years of service:

Additional Annual Retainer for Committee Membership   
Audit Committee Chairman $20,000 
Compensation Committee Chairman $15,000 
Nominating and Governance Committee Chairman $15,000 

In 2022, commencing April 1, 2022, we provided the following cash retainers to our non-executive directors:

John Waters, Audit Committee Chair $148,748 
Mitchell Creem, Compensation Committee Chair $144,375 
Michael Reed, Nominating and Governance Audit Committee Chair $144,375 
Cheryl Grenas, Director $131,250 


The following table presents compensation received by our non-executive directors during fiscal 2022. Drs. Vo and Hosseinion did not required  to,  consult

with  outsidereceive compensation consultants.  The  Compensation  Committee  has  adopted  a

charterfor their service on the Board and the charter is posted on our web site at www.igambit.com.

COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.

Based  solely  upon  a  reviewcompensation paid to Drs. Vo and Hosseinion as employees of Forms  3  and  4  and  amendments  thereto  furnished

to the Company under Rule 16a-3(e)Nutex are set forth under the Exchange Act during its most recent fiscal

year  and  Forms  5  and  amendments  thereto  furnished  to  the  Company  with  respect  to  its

most recent fiscal  year, and any written representation to the Company from the reporting

person  that  no  Form  5  is  required,  no  person  who,  at  any time  during the  fiscal  year, was

a  director, officer,  beneficial  owner of  more  than  ten  percent  of  the  Company’s  Common

Stock,  or  any  other  person  known  to  the  Company  to  be  subject  to  section  16  of  the

Exchange  Act  with  respect  to  the  Company,  failed  to  file  on  a  timely  basis,  as  disclosed

in  the  above  Forms,  reports  required  by  section  16(a)  of  the  Exchange  Act  during  the

most recent fiscal year or prior fiscal years, except as described below:

Name

No. of Late Reports

No. of transactions

Failure to file a

that were not

required Form

reported on a timely

basis

Rory T Welch

1

1

0

CODE OF ETHICS

The  Company has  adopted  a  Code  of  Ethics  that  applies  to  its  principal  executive

officer,  principal  financial  officer,  principal  accounting  officer  or  controller,  or  persons

performing  similar  functions.    A  copy  of  the  Code  of  Ethics  is  attached  as  an  exhibit  to

this  report.    A  copy  of  the  Code  of  Ethics  is  available  on  the  Company’s  website  at

www.igambit.com.    Any  amendments  to,  or  waivers  from,  the  Code  of  Ethics  will  be

disclosed on the Company’s website at www.igambit.com.

ITEM 11.EXECUTIVE COMPENSATION

2022 Summary Compensation Table:

Name Fees Earned or
Paid
in Cash ($)
  Stock
Awards ($) (1)
  Total ($) 
John Waters  148,748   0   148,748 
Mitchell Creem  144,375   0   144,375 
Michael Reed  144,375   0   144,375 
Cheryl Grenas  131,250   0   131,250 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth the compensation received by our executive

officers, for their service, during the year ended December 31, 2015.

29



Current

Nonqualified

Officers

Non-equity

Deferred

Name &

Option      Incentive Plan      Compensation

All Other

Principal

Salary

Bonus     Stock     Awards      Compensation

Earnings

Compensation

Total

Position

Year

($)

($)

($)

($)

($)

($)

($)

($)

John

Salerno

2015

46,635

0

0

0

0

0

20,790 (1)

67,425

CEO,

President      2014      131,250

0

0

0

0

0

13,206(2)

144,456

Chairman

&

2013      200,000

0

0

0

0

0

10,237(3)

210,237

Director

Elisa

Luqman

2015

60,577

0

0

0

0

0

0

60,577

Acting

CFO,

2014      143,746

0

0

0

0

0

36,514(4)

180,260

EVP,  GC

and

2013      200,000

0

0

0

0

0

30,125(5)

230,125

Director

Rory T

Welch

2015     37,500(6)

0

0

0

0

0

1831(7)

39,331

(1)    Includes $5,220 in health insurance premiums and $15,670 in life insurance

premiums.

(2)    Includes $6,264 in health insurance premiums and $6,942 in life insurance

premiums.

(3)    Includes $6,168 in health insurance premiums and $4,069 in life insurance

premiums.

(4)    Includes $36,514 in health and dental insurance premiums.

(5)    Includes $30,125 in health and dental insurance premiums.

(7)    Includes $1,831  in health, dental and life insurance premiums.

Employment Arrangements with Named Executive Officers

Effective   November   4,   2015,   along   with   the   acquisition   ArcMail,   we   entered   into   an

employment  agreement  with  Rory  T.  Welch  (the  Welch  Employment  Agreement).  Under  the

five-year agreement, Mr. Welch is entitled to (a) a base salary of $180,000 per year, (b) an annual

bonus  of  $45,000,  and  (c)  participation  in  all  benefit  programs  generally  made  available  to

ArcMail  employees.  The  Welch  Employment  Agreement  also  contains  provisions  designed  to

protect  the  confidentiality  of  the  Company’s  confidentialcertain information  and  restricting  Mr.  Welch

from  engaging  in  certain ��competitive  activities  for  the  greater  of  60  months  from  the  date  of  the

agreement or two years following the termination of his employment.

Mr.  Welch  has  diverse  management  experience  in  growing  international  businesses

across multiple industries, Rory Welch is ushering ArcMail into the next phase  of the Company’s

lifecycle with emphasis on expanding global sales, marketing and distribution strategies. A senior

executive  with  more  than  20  years  of  experience  in  strategy,  supply chain,  sourcing,  distribution,

logistics,  marketing  and  sales  management,  he  has  success  in  expanding  profits  through  both

revenue growth and cost savings.

30



Prior  to  joining  ArcMail,  he  managed  his  own  consulting  firm,  and  then  before  that  held

leadership  positions  at  Movado  Group,  Inc.,  including  COO  for  the  boutique  division  and  Senior

Vice  President  of  wholesale  operations.  Earlier  in  his  career,  Welch  served  as  VP  of  strategic

planning  and  analysis  at  Arrow  Electronics,  where  he  was  responsible  for  building  performance

models across all aspects of the organization. While at Arrow, Welch also held positions as VP of

product  management  for  Asia-Pacific,  with  responsibility  for  overseeing  all  aspects  of  product

management for the $1 billion division; as well as general manager of aerospace/military program

accounts; product manager; and asset and logistics manager.

A  graduate  of  Indiana  University’s  Kelley  School  of  Business  with  a  master’s  degree  in

business administration, Welch holds a bachelor’s degree in economics from Furman University.

We do not currently have any other employment agreements with our executive officers.

Compensation of the Board of Directors

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

OPTION AWARDS

STOCK AWARDS

Name (a)

Number of Securities Underlying Unexercised Options
(#)
Exercisable
(b)

Number of Securities Underlying Unexercised Options
(#)
Unexercisable
(c)

Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options
(#)
(d)

Option Exercise Price
($)
(e)

Option Expiration Date
(f)

Number of Shares or Units of Stock That Have Not Vested
(#)
(g)

Market Value of Shares or Units of Stock That Have Not Vested
($)
(h)

Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested
(#)
(i)

Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested
(#)
(j)

James Charles

59,000

0

0

$0.03

06/09/2024

0

0

0

0

James Charles

100,000

0

0

$0.03

06/09/2024

0

0

0

0

George Dempster

113,000

0

0

$0.03

06/09/2024

0

0

0

0

George Dempster

100,000

0

0

$0.03

06/09/2024

0

0

0

0

John Keefe

600,000

0

0

$0.03

06/09/2024

0

0

0

0

The  following  table  sets  forth  the  compensation  received  by  our  directors,  for  their

service as directors, during the year ended December 31, 2014.

31



Nonqualified

Fees

Non-equity

deferred

earned or

Stock

Option

incentive plan

compensation

All other

paid in

awards

awards

compensation

earnings

compensation

Total

Name

cash ($)

($)

($)

($)

($)

($)

($)

John Salerno (1)

-

-

-

-

-

-

0

Elisa Luqman (1)

-

-

-

-

-

-

0

James J. Charles

$4,000

-

-

-

-

$4,000

George G. Dempster

$4,000

-

-

-

-

$4,000

John Keefe

$4,000

-

-

-

-

$4,000

(1)  These  individuals  serve  as  executive  officers  of  the  Company,  and  do  not

receive   any   compensation   for   the   services   they   provide   as   directors   of   the

Company.

Members of our Board receive $1,000 per quarter for their service to the Company.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The  following  table  sets  forth  information  known  to  us, as of April 14,  2016,4, 2023, with respect to holdings of our common stock:

relating to the beneficial ownership

stockholders who beneficially owned more than 5% of the outstanding shares of our common stock;

each of our NEOs and directors; and

all directors and executive officers as a group.

The number of shares of common stock by:  (i)beneficially owned by each stockholder is determined under rules issued by the SEC and includes voting or investment power with respect to securities. These rules generally provide that a person who is

known  by  us  to  be the beneficial owner of more  than  5%securities if such person has or shares the power to vote or direct the voting thereof, or to dispose or direct the disposition thereof or has the right to acquire such powers within 60 days.

Unless otherwise indicated, we believe, based on information provided to us, that each of the Company’s  outstanding

common   stock;   (ii) each   director;   (iii) each   executive   officer;   and   (iv) all   executive

officers  and  directors  as  a  group.  Under  securities  laws,  a  person  is  considered  to  be  the

beneficial  owner  of  securities  owned  by  him  (or  certain  persons  whose  ownership  is

attributed  to  him)  or  securities  that  can  be  acquired  by  him  within  60 days,  including

upon the exercise of options, warrants or convertible securities. The Company determines

a   beneficial   owner’s   percentage   ownership   by   assuming   that   options,   warrants   and

convertible  securities  that  are  held  by  the  beneficial  owner  and  which  are  exercisable

within 60 days, have been exercised or converted.  The Company believes that  all persons

named  in  the  table  havestockholders listed below has sole voting and investment power with respect to allthe shares ofbeneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.

Name of Beneficial Owner Amount and Nature of Beneficial
Ownership
 Percent of Class 
Micro Hospital Holding LLC (1)267,322,77641.07%
Premier Macy Management Holdings, LLC(2)41,964,8326.45%
Michael L. Chang, Chief Medical Officer12,008,5231.84%
Warren Hosseinion, President and Director (3)1,930,047*
Mitchell Creem, Director (4)343,866*
Cheryl Y. Grenas, Director*
Michael L. Reed, Director*
John J. Waters, Director (5)508,320*
Jon C. Bates, CFO*
Elisa Luqman, Chief Legal Officer (SEC) and Secretary (6)679,976*
Pamela W. Montgomery, Chief Legal Officer (Healthcare)*
Executive Officers and Directors as a Group324,758,34049.89%

*Less than 1%.

(1)Micro Hospital Holding LLC (“MHH”) is the direct beneficial owner of 267,322,776 shares of common stock. Dr. Vo, the Chairman and Chief Executive Officer of the Company, as the 100% owner and sole manager of MHH, is deemed to be the indirect beneficial owner of such shares.


(2)Premier Macy Management Holdings, LLC is the direct beneficial owner of 41,964,832 shares of common stock. Each of Dr. Young and Cynthia J. Young, as co-trustees of the First Amended & Restated Matthew Stephen Young & Cynthia Jane Young Joint Living Trust, the 99% owner of Macy GP LLC, the 100% owner of Premier Macy Management Holdings, LLC, can be deemed to be the indirect beneficial owners of the shares reported herein.

(3)Includes options to purchase 200,000 shares of the common stock at $1.50 per share, and options to purchase 600,000 shares of the common stock at $1.61 per share, options to purchase 859,779 shares of the common stock at $2.75 per share and a warrant to purchase 21,590 shares of the common stock at $6.67 per share.

(4)Includes options to purchase 10,120 shares of the common stock at $5.56 per share, options to purchase 75,000 shares of common stock at $1.50 per share, options to purchase 45,000 shares at $1.61 and options to acquire 182,000 shares of common stock at $2.75 per share.

(5)Includes options to purchase 102,800 shares of common stock at $1.50, 45,000 common shares at $1.61, per share, warrants to purchase 32,258 common shares at $1.55 per share and options to acquire 182,000 shares of common stock at $2.75 per share.

(6)Includes 1,370 shares of common stock held by Muhammad Luqman, Ms. Luqman’s husband, options to purchase 117,106 shares of the commons stock at $1.50 per share, options to purchase 400,000 shares of the common stock at $1.61 per share and options to purchase 150,000 shares of common stock at $2.75 per share.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our officers and directors, and persons who beneficially own more than 10% of our common stock shownto file with the SEC reports of their ownership and changes in their ownership of our common stock. To our knowledge, based solely on review of the copies of such reports and amendments to such reports with respect to the year ended December 31, 2022 filed with the SEC and on written representations by our directors and executive officers, all required Section 16 reports under the Exchange Act for our directors, officers and beneficial owners of greater than 10% of our common stock were filed on a timely basis during the year ended December 31, 2022 other than 11 Form 4s filed by John Waters, Warren Hosseinion, Lawrence Schimmel, Mitchell Creem, Michael Bowen, Elisa Luqman, Andrew Barnett, and Fredrick Sternberg, which were filed late.

Item 13. Certain Relationships and Related Persons Transactions

Our Chief Executive Officer Thomas T. Vo., M.D., MBA has interests in the Physician LLCs (as defined ‎below) and Micro Hospital Holding LLC, an affiliate of the Company, which has been consolidated by the Company as being‎a variable interest entity (“VIE,” together with the other Physician LLCs, “VIEs”).‎

Most of our hospital division facilities, including the Physician LLC controlled by or affiliated with Dr. Vo, are leased from real estate ‎entities which are owned by them.  Unless  otherwise  indicated,‎related parties (“Physician LLCs”). These leases are typically on a triple net basis where ‎our hospital division is ‎responsible for all operating costs, repairs and taxes on the addressfacilities. During the years ended ‎December 31, 2022, 2021 and 2020, we ‎made cash payments for these lease obligations totaling $13,016,727, ‎‎$10,736,652 and ‎‎$5,492,007, respectively.‎ Currently, we consolidate real estate entities as VIEs when they do not ‎have sufficient equity at risk and ‎our hospital entities are guarantors or co-borrowers under their outstanding ‎mortgage loans. The ‎consolidated real estate entities have mortgage loans payable to third parties which are ‎‎collateralized by the land and buildings.‎

While we have no direct ownership interest, we have historically provided support to the Physician LLCs in the ‎event of cash shortages and received the benefit of their cash ‎surpluses, the amounts due from Physician LLCs ‎totaled $0 at December 31, 2022 and $1,891,147 at ‎December 31, 2021. In 2022, we forgave certain amounts due ‎from Physician ‎LLCs for past advances made by us in support of their operations. We recognized a net expense of ‎‎‎$1,506,650 in the three months ended March 31, 2022 as general and administrative expense in ‎the consolidated ‎statements of operations. No such expense was recognized subsequently.‎


Policies and Procedures for Approval of Related Person Transactions

Our Board has adopted a written Related Person Transaction Policy, setting forth the policies and procedures for the review and approval or ratification of related person transactions. Under the policy, our legal team is primarily responsible for developing and implementing processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. If our legal team determines that a transaction or relationship is a related person transaction requiring compliance with the policy, our Chief Legal Officer (SEC) is required to present to the Audit Committee all relevant facts and circumstances relating to the related person transaction. Our Audit Committee must review the relevant facts and circumstances of each beneficial  ownerrelated person transaction, including if the transaction is on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third party and the extent of the related person’s interest in the table  set  forth  belowtransaction, take into account the conflicts of interest and corporate opportunity provisions of our Code of Business Conduct and Ethics, and either approve or disapprove the related person transaction. If advance Audit Committee approval of a related person transaction requiring the Audit Committee’s approval is carenot feasible, then the transaction may be preliminarily entered into by management upon prior approval of iGambitthe transaction by the chairman of the Audit Committee subject to ratification of the transaction by the Audit Committee at the Audit Committee’s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person, then upon such recognition the transaction will be presented to the Audit Committee for ratification at the Audit Committee’s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. Our management will update the Audit Committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then current related person transactions. No director may participate in approval of a related person transaction for which he or she is a related person.

Director Independence

For the information required by this item relating to the independence of our directors please see “Directors, Executive Officers and Corporate Governance ” in Item 10 of this Amendment No. 1.


Relationships and Transactions with Directors, Executive Officers and Significant Stockholders

Transactions in connection with the Business Combinations

Subscription Agreements

In November 2019, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued convertible promissory notes. Each noteholder received warrants to purchase common stock of 50% of the principal at an exercise price of $5.56 per share with an expiration date of October 31, 2025.

Common Stock Warrants.

Clinigence Holdings, Inc.,  1050  W.

Jericho  Turnpike,  New  York,  11787.  The  percentages  in  the  following  table  are  based

upon 25,044,056 shares had 12,401,240 common stock warrants outstanding as of the merger date. Warrant activity follows:

 ​Warrants
Outstanding
  ​Weighted Average
Exercise Price
  ​Weighted Average
Remaining Contractual
Life (years)
 
Warrants outstanding at April 1, 2022 merger date  12,401,240  $2.04   4.65 
Warrants exercised  (2,187,225)  2.27    
Warrants cancellation of exercised  819,000   1.55    
Warrants outstanding at December 31, 2022  11,033,015  $1.96   3.80 

Warrants outstanding at December 31, 2022 consist of:

Expiration  Number  Number  Exercise 
Date  Outstanding  Exercisable  Price 
February 5, 2023   1,500   1,500  $25.00 
April 27, 2023   1,500   1,500   25.00 
December 31, 2024   554,873   554,873   6.67 
October 31, 2025   16,250   16,250   1.25 
October 31, 2025   1,566,451   1,566,451   1.55 
February 26, 2026   288,235   288,235   4.00 
July 31, 2026   2,532,900   2,532,900   1.55 
February 1, 2027   1,456,453   1,456,453   1.55 
May 31, 2027   4,614,853   4,614,853   1.75 
Total   11,033,015   11,033,015    

Private Placement

On April 14, 2016.

Amount and Nature

of Beneficial

Name of Beneficial Owner

Ownership

Percent of Class

John Salerno, C.E.O., President, Chairman

of12, 2022, the Board, and Director

5,146,900(1)

%

Elisa Luqman, C.F.O., Executive Vice

President, General Counsel and Director

5,685,000,(2)

%

James J. Charles, Director

600,000(3)

%

George G. Dempster, Director

605,000(4)

%

Rory T. Welch, CEO & President ArcMail

10,000,000

Executive Officers and Directors as Group:

20,036,900 (4)

%

32



1.    Includes: options to purchase 46,900Company issued 500,000 shares of common stock at $0.01to ApolloMed after the exercise for $3.50 per share held by John L.

Salerno, Mr. Salerno’s son; and optionson April 12, 2022 of the warrants issued on October 1, 2021 in a private placement in connection with an investment in the Company. On September 23, 2021, Clinigence Holdings, Inc. (n/k/a Nutex Health Inc.) had entered into an investment agreement with ApolloMed, pursuant to purchase 100,000which the Company received a direct private investment of $3 million on October 1, 2021. In connection with the investment, the Company issued, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, 1,000,000 shares of common stock to ApolloMed at $0.01$3.00 per

share held by Dean T. Salerno, Mr. Salerno’s son.

2.    Includes 685,000 shares of common stock held by Muhammad Luqman, Ms. Luqman’s husband.

3.    Includes optionswith and warrants to purchase 159,000an additional 500,000 shares of the common stock at $0.03$3.50 per share.

4.    Includes options to purchase 213,000 shares of the common stock at $0.03 per share.

5.    Includes the disclosures in footnotes 1 through 4 above.


ITEM 13.CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS ANDItem 14. Principal Accountant Fees and Services

DIRECTOR INDEPENDENCE

RELATED PARTY TRANSACTIONS

None.

BOARD INDEPENDENCE

The Company has elected to use  the independence standards of the  NYSE AMEX

Equities   Exchange   in   its   determination   of   whether   the   members   of   its   Board   are

independent.  Based  on  the  foregoing,  the  Company  has  concluded  that  Mr. Charles  and

Mr. Dempster  are  independent.  The  Board  has  established  an  Audit  Committee  and  a

Compensation  Committee.  The  Board  does  not  currently  have  a  Nominating  Committee.

The  work  typically  conducted  by  a  Nominating  Committee  is  conducted  by  the  full

Board.

ITEM 14.PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table shows what Michael  F.  Albanese,  CPA  billedMarcum LLP fees were for the audit

and other services for the year ended December 31, 20152022 and December 31,   20142021, respectively.

respectively.

  2022  2021 
Audit Fees  1,424,460   646,325 
Audit-Related Fees  29,355   25,750 
Tax Fees  0   0 
Other Fees  0   0 
Total  1,453,815   672,075 

Year Ended  Year Ended

12/31/ 2015    12/31/2014

Audit Fees

$

38,500  $

39,725

Audit-Related Fees

15,000-

---

All Tax Fees

---

Other Fees

---

Total

$

53,500  $

39,725

Audit Fees — - This category includes the audit of the Company’s annual financial

statements, review of financial statements included in the Company’s Form 10-Q

Quarterly Reports and services that are normally provided by the independent auditors in

connection with engagements for those years.

33



Audit-RelatedFees  — - This category includes assurance and related services by

the independent auditor that are reasonably related to the performance of the audit or

review of the Company’s financial statements and that are not reported under the caption

“Audit “Audit Fees.”

TaxFees - This category includes services rendered by the independent auditor

for tax compliance, tax advice, and tax planning.

AllOtherFees - This category includes products and services provided by the

independent auditor other than the services reported under the captions “Audit Fees,”

“Audit-Related “Audit-Related Fees,” and “Tax Fees.”

Overview- The Company’s Audit Committee, reviews, and in its sole

discretion pre-approves, our independent auditors’ annual engagement letter including

proposed fees and all audit and non-audit services provided by the independent auditors.

Accordingly, all services described under “Audit Fees,” “Audit-Related Fees,” “Tax

Fees,” and “All Other Fees” were pre-approved by our Company’s Audit Committee. The

Audit Committee may not engage the independent auditors to perform the non-audit

services proscribed by law or regulation. The Company’s Audit Committee may delegate

pre-approval authority to a member of the BoardBoard.


Item 15. Exhibits and Financial Statement Schedules

(a)  The following documents are filed as part of Directors,  and  authority delegated  inthis Report:

such manner must be reported at the next scheduled meeting of the Board of Directors.

Management Report on Internal Control Over Financial Reporting
Reports of Independent Registered Public Accounting Firm (PCAOB ID Number 688)
Consolidated Balance Sheets as of December 31, 2022 and 2021
Consolidated Statements of Operations for the Years Ended December 31, 2022, 2021 and 2020
Consolidated Statements of Equity (Deficit) for the Years Ended December 31, 2022, 2021 and 2020
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021 and 2020
Notes to Consolidated Financial Statements


(b)  Exhibits:

PART IV

    Incorporated by Reference (File
No. 000-53862)
Exhibit
No.
 Description Form Exhibit File Date
2.1 Agreement and Plan of Merger, dated as of February 25, 2021 by and among the Registrant, AHP, Merger Sub, and the Signing Stockholder 8- K 2.1 Mar. 2, 2021
2.2 Agreement and Plan of Merger, dated as of February 25, 2021 by and among the Registrant, AHA, and Merger Sub 8-K 2.3 Mar. 2, 2021
2.3 Agreement and Plan of Merger dated as of November 23, 2021 among Clinigence Holdings, Inc., Nutex Acquisition LLC, Nutex Health Holdco LLC, Micro Hospital Holding LLC (solely for the purposes of certain Sections ), Nutex Health LLC (solely for the purposes of certain Sections) and Thomas T. Vo in his capacity as the Nutex Representative 8-K 99.1 Nov. 24, 2021
2.4 Agreement and Plan of Merger dated effective as of October 21, 2021, by and between Clinigence Holdings, Inc., Clinigence Procare Health, Inc., Procare Health, Inc. Anh Nguyen and Tram Nguyen 8-K 2.1 Oct. 21, 2021
2.5 Form of Contribution Agreement (Under Construction Hospitals) as of November 23, 2021 by and among Nutex Health Holdco LLC and the owners listed on the signature pages thereto 10-Q 2.5 Aug. 22, 2022
2.6 Form of Contribution Agreement (Ramping Hospitals) as of November 23, 2021 by and among ‎Nutex Health Holdco LLC and the owners listed on the signature pages thereto 10-Q 2.6 Aug. 22, 2022
2.7 Form of Contribution Agreement (Mature Hospitals) as of November 23, 2021 by and among Nutex Health Holdco LLC and the owners listed on the signature pages thereto 10-Q 2.7 Aug. 22, 2022
3.1 Amended and Restated Certificate of Incorporation of Clinigence Holdings, Inc. filed April 1, 2022 10-Q 3.1 Aug. 22, 2022
3.2 Second Amended and Restated Bylaws 8-K 3.2 Apr. 4, 2022
4.1 Note Purchase Agreement dated May 15, 2019. 10-K 4.1 May 14, 2020
4.2 Form of Convertible Promissory Note November 18, 2019 8-K 10.2 Nov. 22. 2019
4.3 Form of Warrant November 18, 2019 8-K 10.3 Nov. 22. 2019
4.4 2019 Omnibus Equity Incentive Plan S-8 (333-267710) 10.2 Sep. 30, 2022
4.5 Amended and Restated Nutex Health Inc. 2022 Equity Incentive Plan S-8 (333-267710) 10.1 Sep. 30, 2022
4.6 Description of common stock 10-Q 4.6 Aug. 22, 2022
4.7 Registration Rights Agreement dated as of September 21, 2021 by and among Clinigence Holdings, Inc. and Apollo Medical Holdings, Inc. 10-Q 4.7 Aug. 22, 2022


4.8 Registration Rights Agreement dated as of April 1, 2022 by and among Nutex Health Inc. and the stockholders of Nutex Health Holdco LLC set forth on Schedule A thereto S-3 (333-267686) 4.4 Apr. 11, 2022
4.9 Amendment No. 1 dated as of July 1, 2022 to Registration Rights Agreement dated as of April 1, 2022 10-Q 4.9 Aug. 22, 2022
4.10 Registration Rights Agreement dated as of November 14, 2022 between Nutex Health Inc. and Lincoln Park Capital Fund, LLC 8-K 10.2 Nov. 18, 2022
10.1 Master Services Agreement dated as of February 25, 2021 by and between AHA Management, Inc. and AHPIPA 8-K 2.2 Mar. 2, 2021
10.2 Intellectual Property Asset Purchase Agreement, dated as of May 27, 2020 by and among the Registrant, Clinigence Health, AHA, and AHA Analytics 8-K 2.1 Jun. 3, 2020
10.3 Intellectual Property License Agreement, dated as of May 27, 2020 by and between Clinigence Health and AHA Analytics 8-K 2.2 Jun. 3, 2020
10.4 Managed Services Agreement, dated as of May 27, 2020 by and between Clinigence Health and AHA Analytics 8-K 2.3 Jun. 3, 2020
10.5 Securities Purchase Agreement between Clinigence Holdings, Inc. and Apollo Medical Holdings, Inc. dated as of September 21, 2021 8-K 3.02 Oct. 1, 2021
10.6 Form of Board Agreement 8-K 10.1 Apr. 26, 2022
10.7 Employment Agreement between Thomas T. Vo and Clinigence Holdings, Inc. (to be renamed Nutex Health Inc.) dated as of April 1, 2022 8-K 10.1 Apr. 4, 2022
10.8 Employment Agreement between Warren Hosseinion and Clinigence Health Holdings, Inc. (to be renamed Nutex Health Inc.) dated April 1, 2022 8-K 10.2 Apr. 4, 2022
10.9 Employment Agreement, dated as of June 8, 2022, between the Company and Jon Bates. 8-K 10.2 Jun. 10, 2022
10.10 Employment and Transition Agreement, dated as of June 8, 2022, between the Company and Michael Bowen 8-K 10.1 Jun. 10, 2022
10.11 Form of Commercial Lease Agreement (Hospital Entities) including Parent Guarantee (Nutex Health Inc.) 10-Q 10.11 Aug. 22, 2022
10.12 Form of Construction Loan Agreement (Hospital Entities) including Personal Guarantee (Related Parties) 10-Q 10.12 Aug. 22, 2022
10.13 Purchase Agreement dated as of November 14, 2022 between Nutex Health Inc. and Lincoln Park Capital Fund, LLC 8-K 10.1 Nov. 18, 2022
10.14 Form of Restricted Stock Award Rescission Agreement 10-K 10.14 March 3, 2023
10.15 Partial Option Cancellation Agreement 8-K 10.1 Jan. 4, 2023
21.1 List of Subsidiaries 10-K 21.1 March 3, 2023
23.1 Consent of Marcum LLP 10-K 23.1 March 3, 2023
31.1* Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.      
31.2* Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.      
32.1 Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 10-K 32.1 March 3, 2023
32.2 Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 10-K 32.2 March 3, 2023
101.INS** XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.      
101.SCH XBRL Taxonomy Extension Schema Document.      
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.      
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.      
101.LAB XBRL Taxonomy Extension Label Linkbase Document.      
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.      
104** Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.      

ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES* Filed herewith

(a) Financial Statements

Report of Independent Registered Public Accounting Firm

F-1

Consolidated Balance Sheet as of December 31, 2015 and 2014

F-2

Consolidated Statement of Income for the years ended December 31, 2015 and

F-4

2014

Consolidated Statement of Changes in Stockholder’s Equity for the years

F-5

ended December 31, 2015 and 2014

Consolidated Statement of Cash Flows for the years ended December 31, 2015

F-6

and 2014

Notes to Financial Statements

F-8

(b) Exhibits

Exhibit No.Description

3.1(i)    Certificate of Incorporation, filed with the Delaware Secretary of State on

April 13, 2000 (1)

3.1(ii)

Certificate of Merger, filed with the Delaware Secretary of State on

April 18, 2000 (1)

3.1(iii)

Certificate of Amendment Changing Name, filed with the Delaware

Secretary of State on December 19, 2000 (1)

34



3.1(iv)

Certificate of Merger filed with the Delaware Secretary of State on

February 17, 2006 (1)

3.1(v)

Certificate of Amendment Changing Name filed with the Delaware

Secretary of State on April 5, 2006 (1)

3.1(vi)

Certificate of Amendment Increasing Authorized Common Stock to 75

Million Shares, filed with the Delaware Secretary of State on

December 2, 2009 (1)

3.1(vii)

Certificate of Amendment Increasing Authorized Common Stock to300

Million shares of Common Stock and to create a new class of stock

entitled “Preferred Stock, filed with the Delaware Secretary of State on

November 24, 2014.

3.2

Bylaws (1)

4.1

Form of Stock Certificate (2)

4.2

Common Stock Purchase Warrant issued to Roetzel & Andress (3)

10.1

iGambit Inc. 2006 Long Term Incentive Plan, Amended 12/31/2006 (1)

10.2

Employment Agreement between Digi-Data Corporation and Mr. Salerno

(2)

10.3

Employment Agreement between Digi-Data Corporation and

Mrs. Luqman (2)

14

Code of Ethics (5)

21

Subsidiaries (1)

31.1

Certification of the Chief Executive Officer Pursuant to Section 302 of

the Sarbanes-Oxley Act of 2002

31.2

Certification of the Chief Financial Officer Pursuant to Section 302 of the

Sarbanes-Oxley Act of 2002

32.1

Certification of the Chief Executive Officer Pursuant to Section 906 of

the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed

“filed” for the purposes of Section 18 of the Securities Exchange Act of

1934, as amended or otherwise subject to the liability of that section.

Further, this exhibit shall not be deemed incorporated by reference into

any other filing under the Security Act of 1933, as amended, or by the

Security Exchange Act of 1934, as amended.)

32.2

Certification of the Chief Financial Officer Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed”

**Furnished herewith. This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as

amended or otherwise subjectthe registrant has duly caused this report to the liability of that section. Further, this

exhibit shall not be deemed incorporated by reference into any other

filing under the Security Act of 1933, as amended, orsigned on its behalf by the Securityundersigned thereunto duly authorized.

Exchange Act of 1934, as amended.)

April  6, 2023/s/ Thomas T. Vo
Thomas T. Vo, M.D.

Chief Executive Officer and Chairman of the Board

(principal executive officer)

(1)  Incorporated by reference to Form 10 filed on December 31, 2009.

(2)  Incorporated by reference to Amendment No. 1 to Form 10 filed on June 11, 2010.

(3)  Filed with initial Form 10-K on June 15, 2010.

(4)  We hereby agree to furnish the SEC with any omitted schedule or exhibit upon

request.

(5)  Filed with Form 10-K/A (Amendment No. 1) on September 13, 2010.

35



36



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the

registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by

the undersigned, thereunto duly authorized, in the City of Hauppauge, New York, on

April 14, 2016.

iGambit Inc.

April 14, 2016

By:   /s/ John Salerno

John Salerno, Chief Executive

Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this

Annual Report on Form 10-Kreport has been signed below by the following persons on behalf of the registrant and in the capacities

indicated:

Signature

Title

Date

/s/ John Salerno

Chief Executive Officer and

Director

April 14, 2016

John Salerno

/s/ Elisa Luqman

Chief Financial Officer, Executive

April 14, 2016

Vice President, General Counsel,

Elisa Luqman

Principal Accounting Officer and

Director

/s/ James J. Charles

Director

April 14, 2016

James J. Charles

/s/ George G. Dempster

Director

April 14, 2016

George G. Dempster

/s/ John Keefe

Director

April 14, 2016

John Keefe

37



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of iGambit Inc.

We  have  audited  the  accompanying  consolidated  balance  sheet  of  iGambit  Inc.  as  of

December  31,  2015  and  December  31,  2014,  and  the  related  consolidated  statement  of

operations,  consolidated  statement  of  changes  in  stockholders’  equity  (deficiency),  and

consolidated  statement  of  cash  flows  for  the  two  year  period  ended  December  31,  2015.

iGambit    Inc.’s    management    is    responsible    for    these    financial    statements.    Our

responsibility is to express an opinion on these financial statements based on our audits.

We  conducted   our  audits   in  accordance  with  the  standards   of  the   Public  Company

Accounting  Oversight  Board  (United  States).  Those  standards  require  that  we  plan  and

perform  the  audit  to  obtain  reasonable  assurance  about  whether  the  financial  statements

are  free  of  material  misstatement.  The  company  is  not  required  to  have,  nor  were  we

engaged  to  perform,  an  audit  of  its  internal  control  over  financial  reporting.  Our  audit

included consideration of internal control over financial  reporting as a basis for designing

audit  procedures  that  are  appropriate  in  the  circumstances,  but  not  for  the  purpose  of

expressing   an   opinion on the effectiveness   of   the   company’s   internal   control   overdates indicated.

financial  reporting.  Accordingly,  we  express  no  such  opinion.  An  audit  also  includes

April 6, 2023/s/ Thomas T. Vo
Thomas T. Vo, M.D.

Chief Executive Officer and Chairman of the Board

(principal executive officer)

April 6, 2023/s/ Jon C. Bates
Jon C. Bates

Chief Financial Officer

(principal financial officer and principal accounting officer)

April 6, 2023/s/ Warren Hosseinion
Warren Hosseinion, M.D.
President and Director
April 6, 2023/s/ Daniell Stites
Danniell Stites, M.D.
Director
April 6, 2023/s/ John Waters
John Waters, CPA
Director
April 6, 2023/s/ Cheryl Grenas
Cheryl Grenas, R.N., M.S.N.
Director
April 6, 2023/s/ Michael L. Reed
Michael L. Reed, MPH
Director
April 6, 2023/s/ Mitchell Creem
Mitchell Creem, MHA
Director

examining,  on   a  test  basis,  evidence  supporting  the  amounts  and  disclosures  in  the

financial  statements,  assessing  the  accounting  principles  used  and  significant  estimates

made  by  management,  as  well  as  evaluating  the  overall  financial  statement  presentation.

We believe that our audits provide a reasonable basis for our opinion.

In  our  opinion,  the  financial  statements  referred  to  above  present  fairly,  in  all  material

respects, the financial position of iGambit Inc. as of December 31, 2015 and 2014 and the

results  of  its  operations  and  its  cash  flows  for  the  year  in  the  period  ended  December  31,

2015, in conformity with accounting principles  generally accepted in the United States of

America.

/s/ Michael F. Albanese

Michael F. Albanese, CPA

Parsippany, New Jersey

April 14, 2016

F-1



IGAMBITINC.

CONSOLIDATED BALANCE SHEETS

DECEMBER31,

2015

2014

ASSETS

Current assets

Cash

$

131,987

$

126,833

Accounts receivable, net

230,182

--

Inventories

21,160

--

Prepaid expenses

244,592

34,529

Assets from discontinued operations, net

262,765

115,036

Total current assets

890,686

276,398

Property and equipment, net

40,433

2,318

Other assets

Goodwill

6,705,157

--

Deposits

1,720

2,070

Total other assets

6,706,877

2,070

$

7,637,996

$

280,786

LIABILITIES AND STOCKHOLDERS'EQUITY (DEFICIENCY)

Current liabilities

Accounts payable and accrued expenses

$

636,633

$

91,177

Accrued interest on notes payable

291,107

--

Accrued interest on notes payable  - related party

11,171

--

Amounts due to related parties

74,871

--

Deferred revenue, current portion

811,227

--

Notes payable, current portion

779,750

--

Note payable - related party, current portion

156,566

--

Liabilities from discontinued operations

127,353

194,100

Total current liabilities

2,888,678

285,277

Long-term liabilities

F-2



Deferred revenue, net of current portion

379,052

--

Notes payable

2,339,251

--

Note payable - related party

469,699

--

Total long-term liabilities

3,188,002

--

Total liabilities

6,076,680

285,277

Stockholders' equity (deficiency)

Preferred stock, $.001 par value; authorized - 100,000,000 shares;

issued and outstanding - 0 shares in 2015 and 2014, respectively

--

--

Common stock, $.001 par value; authorized - 200,000,000 shares;

issued and outstanding - 39,683,990 shares in 2015 and

26,583,990 shares in 2014

39,684

26,584

Additional paid-in capital

4,320,022

2,851,124

Accumulated deficit

(2,798,390)

(2,882,199)

Total stockholders' equity (deficiency)

1,561,316

(4,491)

$

7,637,996

$

280,786

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-3



IGAMBIT INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

YEARS ENDED DECEMBER 31,

2015

2014

Sales:

Hardware and software

$

140,942

$

--

Support and maintenance

333,737

--

Total sales

474,679

--

Cost of sales

8,051

--

Gross profit

466,628

--

Operating expenses

General and administrative expenses

965,609

723,432

Loss from operations

(498,981)

(723,432)

Other income (expenses)

Gain on derivative liability

--

152,076

Interest expense

(44,598)

(4,719)

Amortization of debt discount

--

(63,250)

Interest income

4

--

Total other income (expenses)

(44,594)

84,107

Loss from continuing operations

(543,575)

(639,325)

Income (loss) from discontinued operations

627,384

(45,017)

Net income (loss)

$

83,809

$

(684,342)

Basic and fully diluted earnings (loss) per common share:

Continuing operations

$

(.02)

$

(.03)

Discontinued operations

$

.02

$

.00

Net earnings per common share

$

.00

$

(.03)

Weighted average common shares outstanding - basic

29,168,374

25,947,791

Weighted average common shares outstanding - fully

diluted

30,962,274

27,373,471

The   accompanying   notes   are   an   integral   part   of   these   condensed   consolidated   financial

statements.

F-4



IGAMBIT INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

YEARS ENDED DECEMBER 31, 2015 AND 2014

Common stock

Paid-in

Accumulated

Shares

Amount

Capital

Deficit

Totals

Balances, December 31, 2013

25,044,056

$

25,044

$     2,729,000

$

(2,197,857)

$

556,187

Note payable converted to

common stock

1,539,934

1,540

47,460

--

49,000

Compensation for vested stock

options

--

--

74,664

--

74,664

Net loss

(684,342)

(684,342)

Balances, December 31, 2014

26,583,990

26,584

2,851,124

(2,882,199)

(4,491)

Compensation for vested stock

options

--

--

11,998

--

11,998

Common stock issued for

services

1,600,000

1,600

318,400

--

320,000

Common stock issued in

business acquisition

11,500,000

11,500

1,138,500

--

1,150,000

Net income

83,809

83,809

Balances, December 31, 2015

39,683,990

$

39,684

$     4,320,022

$

(2,798,390)

$     1,561,316

The  accompanying  notes  are  an  integral  part  of  these  condensed  consolidated  financial

statements.

F-5



IGAMBIT INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED DECEMBER 31,

2015

2014

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income (loss)

$

83,809

$    (684,342)

Adjustments to reconcile net income (loss) to net

cash provided by operating activities

Income from discontinued operations

(627,384)

45,017

Sale of discontinued property and equipment

6,118

--

Depreciation

4,917

4,766

Debt discount amortization

--

63,250

Stock-based compensation expense

331,998

74,664

Gain on derivative liability

--

(152,076)

Increase (Decrease) in cash flows as a result of

changes in asset and liability account balances:

Accounts receivable

56,697

--

Prepaid expenses

(199,207)

(26,021)

Due from rescission agreement

--

239,779

Accounts payable and accrued expenses

(90,944)

(56,164)

Accrued interest on notes payable

47,559

--

Deferred revenue

(64,586)

--

Net cash used by continuing operating activities

(451,023)

(491,127)

Net cash provided by discontinued operating activities

495,930

650,329

NET CASH PROVIDED BY OPERATING ACTIVITIES

44,907

159,202

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment

(1,797)

--

Cash received from acquisition

10,198

--

(Increase) decrease in deposits

10,413

--

Net cash provided (used) by continuing investing activities

18,814

--

Net cash used by discontinued investing activities

(7,290)

(4,739)

NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES

(4,739)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from stockholders' loans

3,516

3,600

Repayments of stockholders' loans

(38,671)

(3,600)

F-6



Repayments of note payable

(26,058)

--

Repayments of convertible note payable

--

(54,500)

Net cash used by continuing financing activities

(61,213)

(54,500)

Net cash provided by discontinued financing activities

9,936

--

NET CASH USED BY FINANCING ACTIVITIES

(51,277)

(54,500)

NET INCREASE (DECREASE) IN CASH

5,154

99,963

CASH - BEGINNING OF YEAR

126,833

26,870

CASH - END OF YEAR

$

131,987

$

126,833

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid during the year for:

Interest

$

3,146

$

10,333

Non-cash investing and financing activities:

Note payable converted to common stock

$

--

$      (49,000)

Common stock issued in business acquisition

1,150,000

--

The   accompanying   notes   are   an   integral   part   of   these   condensed   consolidated   financial

statements.

F-7



IGAMBIT INC.

Notes to Consolidated Financial Statements

Years Ended December 31, 2015 and 2014

Note 1 - Organization and Basis of Presentation

The   consolidated   financial   statements   presented   are   those   of   iGambit   Inc.,   (the

“Company”)  and  its  wholly-owned  subsidiaries,  Wala,  Inc.  doing  business  as  Arcmail

Technology  (“ArcMail”)  and  Gotham  Innovation  Lab  Inc.  (“Gotham”).  The  Company

was  incorporated  under  the  laws  of  the  State  of  Delaware  on  April  13,  2000.  The

Company was originally incorporated as Compusations Inc. under the laws of the State of

New  York  on  October  2,  1996.   The  Company  changed  its  name  to  BigVault.com  Inc.

upon  changing  its  state  of  domicile  on  April  13,  2000.   The  Company  changed  its  name

again  to  bigVault  Storage  Technologies  Inc.  on  December  21,  2000  before  changing  to

iGambit  Inc.  on  April  5,  2006.   Gotham  was  incorporated  under  the  laws  of  the  state  of

New York on  September  23, 2009.   The  Company is  a holding company which seeks out

acquisitions  of  operating  companies  in  technology  markets.    ArcMail  provides  email

archive solutions to domestic and international businesses through hardware and software

sales,   support,   and   maintenance.     Gotham   is   in   the   business   of   providing   media

technology services to real estate agents and brokers in the New York metropolitan area.

Business Acquisition

On  November  4,  2015,  the  Company  acquired  Wala,  Inc.  doing  business  as  ArcMail

Technology  in  accordance  with  a  stock  purchase  agreement.    Pursuant  to  the  stock

purchase agreement, the total consideration paid for the outstanding capital stock of  Wala

was  11,500,000  shares  of  iGambit  common  stock,  valued  at  $.10  per  share.

The

following  table  presents  the  allocation  of  the  value  of  the  common  shares  issued  for

ArcMail to the acquired identifiable assets, liabilities assumed and goodwill:

Common shares issued, valued at $.10 per share

$     1,150,000

Cash

$

10,198

Accounts receivable, net

205,208

Inventories

21,160

Prepaid expenses

276

Fixed assets

41,235

Total identifiable assets

278,077

Accounts payable and accrued expenses

(442,300)

Accrued interest

(254,718)

Deferred revenue

(1,254,865)

Note payable

(3,881,351)

Total liabilities assumed

(5,833,234)

Excess of liabilities assumed over identifiable assets

5,555,157

Total goodwill

$     6,705,157

F-8



The results of operations of ArcMail have been included in the consolidated statements of

operations  from  the  acquisition  date.  The  following  table  presents  pro  forma  results  of

operations  of  the  Company  and  ArcMail  as  if  the  companies  had  been  combined  as  of

January  1,  2014.  The  pro  forma  condensed  combined  financial  information  is  presented

for  informational  purposes  only.  The  unaudited  pro  forma  results  of  operations  are  not

necessarily indicative  of  results  that  would  have  occurred  had  the  acquisition  taken  place

at the beginning of the earliest period presented, or of future results.

December 31,

December 31,

2015

2014

Pro forma revenue

$

1,876,313

$

3,423,954

Pro forma gross profit

$

1,791,518

$

2,579,661

Pro forma loss from operations

$

(703,699)

$

(1,381,581)

Pro forma net loss

$

(496,347)

$

(1,828,332)

Note 2 – Discontinued Operations

Sale of Business

On  November  5,  2015,  pursuant  to  an  asset  purchase  agreement  Gotham  sold  assets

consisting  of  fixed  assets,  client  and  supplier  lists,  trade  names,  software,  social  media

accounts  and  websites,  and  domain  names  to  VHT,  Inc.,  a  Delaware  corporation  for  a

purchase  price of  $600,000.   Gotham received $400,000 and  commencing on January 29,

2016,  VHT,  Inc.  shall  pay  twelve  equal  monthly  installments  of  $16,667  on  the  last

business   day  of   each   month  (the   “Installment   Payments”  and   each,   an   “Installment

Payment”),  each  Installment  Payment  to  consist  of  (1)  an  earn-out  payment  of  $10,000

(the  “Earn-Out  Payments”  and  each,  an  “Earn-Out  Payment”),  and  (2)  an  additional

payment  of  $6,667  (the  “Additional  Payments”  and  each,  an  “Additional  Payment”);

provided  that  VHT,  Inc.  shall  only  be  required  to  make  the  Earn-Out  Payments  for  as

long  as  it  maintains  its  relationship  with  Gotham’s  major  client,  unless  it  is  dissatisfied

with VHT, Inc.

The  assets  and  liabilities  of  the  discontinued  operations  are  presented  in  the  consolidated

balance  sheets  under  the  captions  “Assets  from  discontinued  operations”  and  “Liabilities

from  discontinued  operations”,  respectively.   The  underlying  assets  and  liabilities  of  the

discontinued  operations  for  the  years  ended  December  31,  2015  and  2014  are  presented

as follows:

2015

2014

Assets:

Cash

$

13,893

$

6,603

Accounts receivable, net

247,372

81,671

Prepaid expenses

1,500

10,581

Deposits

--

10,063

F-9



Property and equipment

--

6,118

Total assets

$

262,765

$

115,036

Liabilities:

Accounts payable and accrued expenses

117,417

194,100

Note payable - related party

9,936

--

$

127,353

$

194,100

Note 3 – Summary of Significant Accounting Policies

Principles of Consolidation

The  consolidated   financial  statements  include  the  accounts   of  the  Company  and   its

wholly-owned    subsidiaries,    Wala,    Inc.    and    Gotham    Innovation    Lab,    Inc.  All

intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted accounting

principles   requires   management   to   make   estimates   and   assumptions   that   affect   the

reported   amounts   of   assets   and   liabilities   and   disclosure   of   contingent   assets   and

liabilities  at  the  date of  the  consolidated  financial  statements  and  the  reported  amounts  of

revenues and expenses during the period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

For  certain  of  the  Company’s  financial  instruments,  including  cash,  accounts  receivable,

prepaid  expenses,  accounts  payable,  accrued  interest,  deferred  revenue,  and  amounts  due

to   related   parties,   the   carrying   amounts   approximate   fair   value   due   to   their   short

maturities.     Additionally,   there   are   no   assets   or   liabilities   for   which   fair   value   is

remeasured on a recurring basis.

Revenue Recognition

The  Company  recognizes  revenue  from  product  sales  when  the  following  four  revenue

recognition  criteria  are  met:  persuasive  evidence  of  an  arrangement  exists,  an  equipment

order  has  been  placed  with  the  vendor,  the  selling  price  is  fixed  or  determinable,  and

collectability  is  reasonably  assured.    Revenues  from  maintenance  contracts  covering

multiple  future  periods  are  recognized  during  the  current  periods  and  deferred  revenue  is

recorded  for  future  periods  and  classified  as  current  or  noncurrent,  depending  on  the

terms of the contracts.

Gotham’s   revenues   were   derived   primarily   from   the   sale   of   products   and   services

rendered  to  real  estate  brokers.    Gotham  recognized  revenues  when  the  services  or

products  have  been  provided  or  delivered,  the  fees  charged  are  fixed  or  determinable,

F-10



Gotham  and  its  customers  understood  the  specific  nature  and  terms  of  the  agreed  upon

transactions, and collectability was reasonably assured.

Advertising Costs

The  Company  expenses  advertising  costs  as  incurred.   There  were  no  advertising  costs

for the years ended December 31, 2015 and 2014, respectively.

Cash and Cash Equivalents

For  purposes  of  reporting  cash  flows,  cash  and  cash  equivalents  include  checking  and

money market accounts and any highly liquid debt instruments purchased with a maturity

of three months or less.

Accounts Receivable

The   Company   analyzes   the   collectability   of   accounts   receivable   from   continuing

operations   each   accounting   period   and   adjusts   its   allowance   for   doubtful   accounts

accordingly.   A  considerable  amount  of  judgment  is  required  in  assessing  the  realization

of  accounts  receivables,  including  the  creditworthiness  of  each  customer,  current  and

historical  collection  history  and  the  related  aging  of  past  due  balances.   The  Company

evaluates  specific  accounts  when  it  becomes  aware  of  information  indicating  that  a

customer  may  not  be  able  to  meet  its  financial  obligations  due  to  deterioration  of  its

financial  condition,  lower  credit  ratings,  bankruptcy  or  other  factors  affecting  the  ability

to render payment.  Allowance  for doubtful  accounts  was  $8,345 and $0 at  December 31,

2015  and  2014,  respectively.    Bad  debt  expense  of  $5,971  and  $0  was  charged  to

operations for the  years ended December 31, 2015 and 2014, respectively.

Inventories

Inventories  consisting  of  finished  products  are  state  at  the  lower  of  cost  or  market.   Cost

is determined on an average cost basis.

Property and equipment and depreciation

Property  and  equipment  are  stated  at  cost.    Maintenance  and  repairs  are  charged  to

expense  when  incurred.   When  property  and  equipment  are  retired  or  otherwise  disposed

of,   the   related   cost   and   accumulated   depreciation   are   removed   from   the   respective

accounts  and  any  gain  or  loss  is  credited  or  charged  to  income.   Depreciation  for  both

financial  reporting  and  income  tax  purposes  is  computed  using  combinations  of  the

straight  line  and  accelerated  methods  over  the  estimated  lives  of  the  respective  assets  as

follows:

Office equipment and fixtures

5 - 7 years

Computer hardware

5 years

Computer software

3 years

Development equipment

5 years

F-11



Goodwill

Goodwill represents the excess of liabilities assumed over assets acquired of ArcMail and

the  fair  market  value  of the  common  shares  issued  by the  Company for  the  acquisition  of

ArcMail.   In  accordance  with  ASC  Topic  No.  350  “Intangibles  –  Goodwill  and  Other”),

the  goodwill  is  not  being  amortized,  but  instead  will  be  subject  to  an  annual  assessment

of  impairment  by  applying  a  fair-value  based  test,  and  will  be  reviewed  more  frequently

if current events and circumstances indicate a possible impairment. An impairment loss is

charged  to  expense  in  the  period  identified.  If  indicators  of  impairment  are  present  and

future cash flows  are not  expected to be  sufficient  to recover the asset’s carrying amount,

an  impairment  loss  is  charged  to  expense  in  the  period  identified.  A  lack  of  projected

future  operating   results   from   ArcMail’s   operations   may  cause   impairment.     As   the

acquisition  of  ArcMail  occurred  on  November  4,  2015,  it  is  too  early for  management  to

evaluate  whether  goodwill  has  been  impaired.   No  impairment  was  recorded  during  the

year ended December 31, 2015.

Long-Lived Assets

The  Company  assesses  the  valuation  of  components  of  its  property  and  equipment  and

other  long-lived  assets  whenever  events  or  circumstances  dictate  that  the  carrying  value

might  not  be  recoverable.  The  Company  bases  its  evaluation  on  indicators  such  as  the

nature  of  the  assets,  the  future  economic  benefit  of  the  assets,  any  historical  or  future

profitability  measurements  and  other  external  market  conditions  or  factors  that  may  be

present.  If  such  factors  indicate  that  the  carrying  amount  of  an  asset  or  asset  group  may

not  be  recoverable,  the  Company  determines  whether  an  impairment  has  occurred  by

analyzing  an  estimate  of  undiscounted  future  cash  flows  at  the  lowest  level  for  which

identifiable  cash  flows  exist.  If  the  estimate  of  undiscounted  cash  flows  during  the

estimated  useful  life  of  the  asset  is  less  than  the  carrying value  of the  asset, the  Company

recognizes  a  loss  for  the  difference  between  the  carrying  value  of  the  asset  and  its

estimated fair value, generally measured by the present value of the estimated cash flows.

Deferred Revenue

Deposits  from  customers  are  not  recognized  as  revenues,  but  as  liabilities,  until  the

following   conditions   are   met:   revenues   are   realized   when   cash   or   claims   to   cash

(receivable)  are  received  in  exchange  for  goods  or  services  or  when  assets  received  in

such   exchange   are   readily   convertible   to   cash   or   claim   to   cash   or   when   such

goods/services  are  transferred.  When  such  income  item  is  earned,  the  related  revenue

item  is  recognized,  and  the  deferred  revenue  is  reduced.  To  the  extent  revenues  are

generated   from   the   Company’s   support   and   maintenance   services,   the   Company

recognizes  such  revenues  when  services  are  completed  and  billed.  The  Company  has

received  deposits  from its  various  customers  that  have  been  recorded  as  deferred revenue

in  the  amount  of  $1,190,279  and  $0  as  of  the  years  ended  December  31,  2015  and  2014,

respectively.

Stock-Based Compensation

The   Company   accounts   for   its   stock-based   awards   granted   under   its   employee

compensation  plan  in  accordance  with  ASC  Topic  No.  718-20,  AwardsClassifiedas

F-12



Equity,  which  requires  the  measurement  of  compensation  expense  for  all  share-based

compensation  granted  to  employees  and  non-employee  directors  at  fair  value  on  the  date

of  grant  and  recognition  of  compensation  expense  over  the  related  service  period  for

awards  expected  to  vest.  The  Company  uses  the  Black-Scholes  option  pricing  model  to

estimate  the  fair  value  of  its  stock  options  and  warrants.  The  Black-Scholes  option

pricing  model  requires  the  input  of  highly subjective  assumptions  including  the  expected

stock  price  volatility  of  the  Company’s  common  stock,  the  risk  free  interest  rate  at  the

date   of   grant,   the   expected   vesting   term   of   the   grant,   expected   dividends,   and   an

assumption   related   to   forfeitures   of   such   grants.  Changes   in   these   subjective   input

assumptions  can  materially affect  the  fair  value  estimate  of  the  Company’s  stock  options

and warrants.

Income Taxes

The   Company   accounts   for   income   taxes   using   the   asset   and   liability   method   in

accordance  with  ASC  Topic  No.  740,IncomeTaxes.  Under  this  method,  deferred  tax

assets  and  liabilities  are  determined  based  on  differences  between  financial  reporting  and

tax  bases  of  assets  and  liabilities,  and  are  measured  using  the  enacted  tax  rates  and  laws

that are expected to be in effect when the differences are expected to reverse.

The  Company  applies  the  provisions  of  ASC  Topic  No.  740  for  the  financial  statement

recognition,  measurement  and  disclosure  of  uncertain  tax  positions  recognized  in  the

Company’s  financial  statements.  In  accordance  with  this  provision,  tax  positions  must

meet  a  more-likely-than-not  recognition  threshold  and  measurement  attribute  for  the

financial statement recognition and measurement of a tax position.

Recent Accounting Pronouncements

FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers:

In May 2014, the FASB issued amended guidance  on contracts with customers to transfer

goods   or   services   or   contracts   for   the   transfer   of   nonfinancial   assets,   unless   those

contracts   are  within  the  scope  of  other  standards  (e.g.,  insurance  contracts  or  lease

contracts).   The   guidance   requires   an   entity  to   recognize   revenue   on   contracts   with

customers  to  depict  the  transfer  of  promised  goods  or  services  to  customers  in  an  amount

that  reflects  the  consideration  to  which  the  entity  expects  to  be  entitled  in  exchange  for

those  goods  or  services.  The  guidance  requires  that  an  entity  depict  the  consideration  by

applying the following steps:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

The  amendments  in  this  ASU  are  effective  for  annual  reporting  periods  beginning  after

December   15,   2016,   including   interim   periods   within   that   reporting   period.   Early

F-13



application  is  not  permitted.  This  amendment  is  to  be  either  retrospectively  adopted  to

each  prior  reporting  period  presented  or  retrospectively  with  the  cumulative  effect  of

initially  applying  this  ASU  recognized  at  the  date  of  initial  application.  Adoption  of  this

guidance  is  not  expected  to  have  a  material  impact  on  the  Company's  consolidated

financial statements.

FASB ASC 718 ASU 2014-12 – Compensation – Stock Compensation:

In June 2014, the  FASB  issued ASU No. 2014-12, "Compensation - Stock Compensation

(Topic   718):  Accounting   for   Share-Based   Payments   When   the  Terms   of  an   Award

Provide   that   a   Performance   Target   Could   be   Achieved   after   the   Requisite   Service

Period,"   ("ASU      2014-12").      The   amendments   in   ASU   2014-12   require   that   a

performance  target  that  affects  vesting  and  that  could  be  achieved  after  the  requisite

service  period  be  treated  as  a  performance  condition.   A  reporting  entity   should  apply

existing   guidance in ASC Topic No. 718,   "Compensation   - Stock   Compensation"   as  it

relates  to  awards  with   performance   conditions  that  affect   vesting  to  account  for  such

awards.   The  amendments  in  ASU  2014-12  are  effective  for  annual  periods  and  interim

periods  within  those  annual  periods  beginning  after  December  15,  2015.   Early  adoption

is   permitted.      Entities   may   apply   the   amendments   in   ASU   2014-12   either:   (a)

prospectively   to   all   awards   granted   or   modified   after   the   effective   date;   or   (b)

retrospectively  to  all  awards  with  performance  targets  that  are  outstanding  as  of  the

beginning  of  the  earliest  annual ��period  presented  in  the  financial  statements  and  to  all

new or modified awards thereafter. The Company does not anticipate that the adoption of

ASU 2014-12 will have a material impact on its consolidated financial statements.

FASB ASC 740 ASU 2015-17 - Balance Sheet Classification of Deferred Taxes:

In  November  2015,  the  FASB  issued  ASU  No.  2015-17,  “Income  Taxes  (Topic  740):

Balance  Sheet  Classification  of  Deferred  Taxes”  (“ASU  2015-17”).  The  FASB  issued

this  ASU  as  part  of  its  ongoing  Simplification  Initiative,  with  the  objective  of  reducing

complexity  in  accounting  standards.  The  amendments  in  ASU  2015-17  require  entities

that  present  a  classified  balance  sheet  to  classify all  deferred  tax  liabilities  and  assets  as  a

noncurrent   amount.   This   guidance   does   not   change   the   offsetting   requirements   for

deferred  tax  liabilities  and  assets,  which  results  in  the  presentation  of  one  amount  on  the

balance  sheet.  Additionally,  the  amendments  in  this  ASU  align  the  deferred  income  tax

presentation   with   the   requirements   in   International   Accounting   Standards   (IAS)   1,

Presentation of  Financial  Statements.  The  amendments  in  ASU 2015-17  are effective for

financial  statements  issued  for  annual  periods  beginning  after  December  15,  2016,  and

interim  periods  within  those  annual  periods.  The  Company  does  not  anticipate  that  the

adoption   of   this   standard   will   have   a   material   impact   on   its   consolidated   financial

statements.

FASB ASC 842 ASU 2016-02 – Leases:

In  February  2016,  the  FASB  issued  ASU  No.  2016-02, “Leases  (Topic  842)”  (“ASU

2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from

a lease for both financing and operating leases. The ASU will also require new qualitative

F-14



and  quantitative  disclosures  to  help  investors  and  other  financial  statement  users  better

understand  the  amount,  timing,  and  uncertainty  of  cash  flows  arising  from  leases. ASU

2016-02  is  effective  for  fiscal  years  beginning  after  December  15,  2018,  with  early

adoption permitted. The  Company is currently evaluating ASU 2016-02 and its impact on

its consolidated financial statements.

Note 4 – Property and Equipment

Property  and  equipment  are  carried  at  cost  and  consist  of  the  following  at  December  31,

2015 and 2014:

2015

2014

Office equipment and fixtures

$

139,006

$

7,164

Computer hardware

90,943

--

Computer software

77,700

--

Development equipment

35,318

--

342,967

7,164

Less: Accumulated depreciation

302,534

4,846

$

40,433

$

2,318

Depreciation expense of $4,917 and $4,766 was charged to operations for the years ended

December 31, 2015 and 2014, respectively.

Note 5 - Earnings (Loss) Per Common Share

The  Company  calculates  net  earnings  (loss)  per  common  share  in  accordance  with  ASC

260   “EarningsPerShare”  (“ASC   260”).   Basic  and   diluted   net   earnings   (loss)  per

common  share  was  determined  by  dividing  net  earnings  (loss)  applicable  to  common

stockholders  by  the  weighted  average  number  of  common  shares  outstanding  during  the

period.  The  Company’s  potentially  dilutive  shares,  which  include  outstanding  common

stock  options  and  common  stock  warrants,  have  not  been  included  in  the  computation  of

diluted net earnings (loss) per share for all periods as the result would be anti-dilutive.

Years Ended

December 31,

2015

2014

Stock options

1,718,900

1,518,900

Stock warrants

275,000

275,000

Total shares excluded from calculation

1,993,900

1,793,900

F-15



Note 6 – Stock Based Compensation

Stock-based  compensation  expense  for  all  stock-based  award  programs,  including  grants

of  stock  options  and  warrants,  is  recorded  in  accordance  with  "Compensation—Stock

Compensation", Topic 718 of the  FASB ASC. Stock-based compensation expense, which

is  calculated  net  of  estimated  forfeitures,  is  computed  using  the  grant  date  fair-value  and

amortized  over  the  requisite  service  period  for  all  stock  awards  that  are  expected  to  vest.

The  grant  date  fair  value  for  stock  options  and  warrants  is  calculated  using  the  Black-

Scholes  option  pricing  model.  Determining  the  fair  value  of  options  at  the  grant  date

requires  judgment,  including  estimating  the  expected  term  that  stock  options  will  be

outstanding  prior  to  exercise,  the  associated  volatility  of  the  Company’s  common  stock,

expected  dividends,  and  a  risk-free  interest  rate.  Stock-based  compensation  expense  is

reported  under  general  and  administrative  expenses  in  the  accompanying  consolidated

statements of operations.

Options

In  2006,  the  Company  adopted  the  2006  Long-Term  Incentive  Plan  (the  "2006  Plan").

Awards  granted  under  the  2006  Plan  have  a  ten-year  term  and  may  be  incentive  stock

options,  non-qualified  stock  options  or  warrants.  The  awards  are  granted  at  an  exercise

price  equal to the  fair market value  on the date of  grant  and  generally vest  over a  three  or

four  year  period.  The  Plan  expired  on  December  31,  2009,  therefore  as  of  December  31,

2015,  there  was  no  unrecognized  compensation  cost  related  to  non-vested  share-based

compensation arrangements granted under the 2006 plan.

The  2006  Plan  provided  for  the  granting  of  options  to  purchase  up  to  10,000,000  shares

of  common  stock.  8,146,900  options  have  been  issued  under  the  plan  to  date  of  which

7,157,038  have  been  exercised  and  692,962  have  expired  to  date.  There  were  296,900

options outstanding under the  2006 Plan on its expiration date of December 31, 2009. All

options issued subsequent to this date were not issued pursuant to any plan.

F-16



Stock option activity during the  years ended December 31, 2015 and 2014 follows:

Weighted

Average

Weighted

Remaining

Weighted

Average

Average

Contractual

Options

Grant-Date

Life

Outstanding

Exercise Price

Fair Value

(Years)

Options outstanding at

December 31, 2013

668,900

$

0.06

$

0.10

4.69

Options granted

850,000

0.04

0.10

Options outstanding at

December 31, 2014

1,518,900

0.03

0.10

4.76

Options granted

200,000

0.01

0.10

Options outstanding at

December 31, 2015

1,718,900

$

0.03

$

0.13

3.82

Options outstanding at December 31, 2015 consist of:

Date

Number

Number

Exercise

Expiration

Issued

Outstanding

Exercisable

Price

Date

May 1, 2006

100,000

100,000

$0.01

May 1, 2016

May 1, 2006

100,000

100,000

$0.01

May 1, 2016

May 1, 2006

50,000

50,000

$0.01

May 1, 2016

May 1, 2006

46.900

46,900

$0.01

May 1, 2016

June 9, 2014

213,000

213,000

$0.03

June 9, 2024

June 9, 2014

159,000

159,000

$0.03

June 9, 2024

June 9, 2014

600,000

600,000

$0.03

June 9, 2024

June 6, 2014

250,000

250,000

$0.05

June 6, 2019

March 24, 2015

200,000

200,000

$0.01

March 24, 2020

Total

1,718,900

1,718,900

Warrants

In  addition  to  our  2006  Long  Term  Incentive  Plan,  we  have  issued  and  outstanding

compensatory  warrants  to  two  consultants  entitling  the  holders  to  purchase  a  total  of

275,000  shares  of  our  common  stock  at  an  average  exercise  price  of  $0.94  per  share.

Warrants  to  purchase  25,000  shares  of  common  stock  vest  upon  6  months  after  the

Company  engages  in  an  IPO,  have  an  exercise  price  of  $3.00  per  share,  and  expire  2

years  after  the  Company  engages  in  an  IPO.  Warrants  to  purchase  250,000  shares  of

common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each

of  the  following  three  anniversaries  of  the  date  of  issuance,  have  exercise  prices  ranging

from  $0.50  per  share  to  $1.15  per  share,  and  expire  on  June 1,  2019.  The  issuance  of  the

compensatory warrants was not submitted to our shareholders for their approval.

F-17



Warrant activity during the years ended December 31, 2015 and 2014 follows:

Weighted

(1)Weighted

Weighted

Average Grant-

Average

Date

Remaining

Warrants

Average

Contractual

Outstanding

Exercise Price

Fair Value

Life (Years)

Warrants outstanding

at December 31, 2013

275,000

$

0.94

$

0.10

5.42

No warrant activity

--

--

--

Warrants outstanding

at December 31, 2014

275,000

$

0.94

$

0.10

4.42

No warrant activity

--

--

--

Warrants outstanding

at December 31, 2015

275,000

$

0.94

$

0.10

3.42

(1)  Exclusive of 25,000 warrants expiring 2 years after initial IPO.

Warrants outstanding at December 31, 2015 consist of:

Date

Number

Number

Exercise

Expiration

Issued

Outstanding

Exercisable

Price

Date

April 1, 2000

25,000

25,000

$3.00

2  years after IPO

June 1, 2009

100,000

100,000

$0.50

June 1, 2019

June 1, 2009

50,000

50,000

$0.65

June 1, 2019

June 1, 2009

50,000

50,000

$0.85

June 1, 2019

June 1, 2009

50,000

50,000

$1.15

June 1, 2019

Total

275,000

275,000

Note 7 – Deferred Revenue

Deferred  revenue  represents  sales  of  maintenance  contracts  that  extend  to  and  will  be

realized in future periods.   Deferred revenue at December 31, 2015 will be realized in the

following years ended December 31,

2016

$

811,227

2017

78,307

2018

298,446

2019

1,200

2020

1,099

$     1,190,279

F-18



Note 8 – Convertible Note Payable

On  September  16,  2013,  the  Company  issued  an  8%  convertible  note  in  the  aggregate

principal  amount  of  $103,500,  convertible  into  shares  of  the  Company’s  common  stock.

The Note, including accrued interest was due June 18, 2014 and was convertible any time

after  180  days  at  the  option  of  the  holder  into  shares  of  the  Company’s  common  stock  at

55%  of  the  average  stock  price  of  the  lowest  3  closing  bid  prices  during  the  10  trading

day period ending on the latest complete trading day prior to the conversion date.  Interest

expense on the  convertible note of $3,242  was  recorded for the  year ended  December 31,

2014.

Initially  the  Company  had  anticipated  repaying  the  obligation  prior  to  the  effective  date

of  the  holder  electing  to  convert.   Since  the  effective  date  of  the  election  to  convert  has

passed  the  Company  recorded  a  debt  discount  related  to  identified  embedded  derivatives

relating  to  conversion  features  and  a  reset  provisions  (see  Note  9)  based  fair  values  as  of

the  inception  date  of  the  Note.   The  calculated  debt  discount  equaled  the  face  of  the  note

and was  amortized  over  the term of the  note.   During the  year ended December 31, 2014,

the  Company  amortized  $63,250  of  debt  discount.   During  the  year  ended  December  31,

2014,  the  noteholder  converted  $49,000  of  the  principal  balance  to  1,539,934  shares  of

common  stock,  and  the  Company  repaid  the  remaining  note  balance  of  $54,500  and

accrued interest of $5,646 on June 18, 2014.

Note 9 - Derivative Liability

Convertible Note

During  the  year  ended  December  31,  2013,  the  Company  issued  a  convertible  note  (see

Note 8 above).

The  note  is  convertible  into  common  stock,  at  the  holders’  option,  at  a  discount  to  the

market  price  of  the  Company’s  common  stock.  The  Company  has  identified  embedded

derivatives  included  in  these  notes  as  a  result  of  certain  anti-dilutive  (reset)  provisions,

related  to  certain  conversion  features.  The  accounting  treatment  of  derivative  financial

instruments  requires  that  the  Company  record  the  fair  value  of  the  derivatives  as  of  the

inception  date  of  the  convertible  note  and  debt  discount  amortization  to  fair  value  as  of

each  subsequent  reporting  date.    This  resulted  in  a  fair  value  of  derivative  liability  of

$152,076  in  which  to  the  extent  of  the  face  value  of  convertible  note  was  treated  as  debt

discount with the remainder treated as interest expense.

The  fair  value  of  the  embedded  derivatives  at  December  31,  2013,  in  the  amount  of

$152,076,   was   determined   using   the   Binomial   Option   Pricing   Model   based   on   the

following  assumptions:  (1)  dividend  yield  of  0%;  (2)  expected  volatility  of  243.00%,  (3)

weighted average  risk-free interest rate of 0.09%, (4) expected lives of 0.72 to 0.75 years,

and  (5)  estimated  fair  value  of  the  Company’s  common  stock  of  $0.51  per  share.  The

Company  recorded  interest  expense  from  the  excess  of  the  derivative  liability  over  the

convertible  note  of  $48,576  during  the  year  ended  December  31,  2013.    A  gain  on

F-19



derivative  liability  of  $152,076  was  recorded  during  the  year  ended  December  31,  2014

for the satisfaction of the convertible note.

Based  upon  ASC  840-15-25  (EITF  Issue  00-19,  paragraph  11)  the  Company has  adopted

a   sequencing   approach   regarding   the   application   of   ASC   815-40   to   its   outstanding

convertible   note.   Pursuant   to   the   sequencing   approach,   the   Company   evaluates   its

contracts based upon earliest issuance date.

Note 10 – Notes Payable

Notes   payable   at   December   31,   2015   consist   of   various   notes   payable   in   annual

installments totaling $779,750 through September 2019.  The notes include interest at 7%

and are secured by the assets of ArcMail.

Principal amounts due on notes payable for the years ended December 31, are as follows:

2016

$

779,750

2017

779,750

2018

779,750

2019

779,751

$

3,119,001

Note 11 – Stock Transactions

On   September   25,   2014,   the   Board   unanimously   approved   an   amendment   to   the

Company’s  Articles  of  Incorporation  to  increase  the  number  of  shares  of  Common  Stock

which  the  Company  is  authorized  to  issue  from  seventy  five  million  (75,000,000)  to

Three  Hundred  Million  (300,000,000)  shares  of  Common  Stock,  $0.001  par  value  per

share,   and   to   create   a   new   class   of   stock   entitled   “preferred   stock”   (together,   the

“Capitalization  Amendments”).  The  Capitalization  Amendments  create  provisions  in  the

Company’s  Articles  of  Incorporation,  which  allows  the  voting  powers,  designations,

preferences  and  other  special  rights,  and  qualifications,  limitations  and  restrictions  of

each  series  of  preferred  stock  to  be  established  from  time  to  time  by  the  Board  without

approval of the stockholders. No dividend, voting, conversion, liquidation or redemptions

rights as well  as redemption or sinking fund provisions are  yet established  with respect to

the Company’s preferred  stock.   On October 3, 2014, the Majority Stockholders executed

and delivered to the Company a written consent approving the Current Action.

Common Stock Issued

In  connection  with  the  acquisition  of  ArcMail  the  Company  issued  11,500,000  common

shares  valued  at  $.10  per  share  to  the  president  and  CEO  of  Wala,  Inc.  on  November  4,

2015.

The  Company  issued  1,000,000  and  600,000  common  shares  for  services,  valued  at  $.20

per share on August 3, 2015 and May 18, 2015, respectively.

F-20



In  connection  with  the  convertible  note  payable  (see  Note  8   above)  the  noteholder

converted  $49,000  of  the  principal  balance  to  1,539,934  shares  of  common  stock  during

the  year  ended  December 31, 2014.   The  stock issued was  determined based on the  terms

of the convertible note.

Note 12 - Income Taxes

The  Company  follows  Accounting  Standards  Codification  subtopic  740,IncomeTaxes

(“ASC  740”)  which  requires  the  recognition  of  deferred  tax  liabilities  and  assets  for  the

expected  future  tax  consequences  of  events  that  have  been  included  in  the  financial

statements  or  tax  returns.  Under  such  method,  deferred  tax  assets  and  liabilities  are

recognized   for   the   future   tax   consequences   attributable   to   differences   between   the

financial  statement  carrying amounts  of  existing assets  and  liabilities  and  their respective

tax  bases  using  enacted  tax  rates  in  effect  for  the  year  in  which  the  differences  are

expected  to  reverse.  Deferred  taxes  are  classified  as  current  or non-current,  depending on

the classification of the assets and liabilities to which they relate.

The  difference  between  income  tax  expense  computed  by  applying  the  federal  statutory

corporate tax rate and actual income tax expense is as follows:

Years Ended

December 31,

2015

2014

Statutory U.S. federal income tax rate

34.0%

34.0%

State income taxes, net of

federal income tax benefit

0.0%

0.1%

Tax effect of expenses that are not

deductible for income tax purposes

(11.2)%

(.8)%

Return to Provision Items

0.0%

0.0%

Other

0.0%

0.0%

Change in Valuation Allowance

(45.2)%

(33.3)%

Effective tax rate

(0.0)%

(0.0)%

At  December 31,  the  significant  components  of  the  deferred  tax  assets  (liabilities)  are

summarized below:

2015

2014

Deferred Tax Assets:

Net Operating Losses

$412,750

$874,716

Other

184,646

36,744

Total deferred tax assets

597,397

911,460

Deferred Tax Liabilities:

--

--

Total deferred tax liabilities

--

--

F-21



Valuation Allowance

(597,397)

(911,460)

Net deferred tax assets

$

--

$

--

As   of   December   31,   2015,   the   Company   had   federal   and   state   net   operating   loss

carryforwards  of approximately $1.8  million  and  $2.5  million, respectively,  which  expire

at  various  dates  from  2023  through  2034.  These  net  operating  loss  carryforwards  may be

used  to  offset  future  taxable  income  and  thereby  reduce  the  Company’s  U.S.  federal  and

state income taxes.

In  accordance  with  ASC  740,  a  valuation  allowance  must  be  established  if  it  is  more

likely  than  not  that  the  deferred  tax  assets  will  not  be  realized.  This  assessment  is  based

upon  consideration  of  available  positive  and  negative  evidence,  which  includes,  among

other   things,   the   Company’s   most   recent   results   of   operations   and   expected   future

profitability.  Based  on  the  Company’s  cumulative  losses  in  recent  years,  a  full  valuation

allowance  against  the  Company’s  deferred  tax  assets  as  of  December  31,  2015  and  2014

has  been  established  as  Management  believes  that  the  Company  will  not  realize  the

benefit of those deferred tax assets.  Therefore, no tax provision has been recorded for the

years ended December 31, 2015 and 2014.

The   Company   complies   with   the   provisions   of   ASC   740-10   in   accounting   for   its

uncertain  tax  positions.   ASC  740-10  addresses  the  determination  of  whether  tax  benefits

claimed  or  expected  to  be  claimed  on  a  tax  return  should  be  recorded  in  the  financial

statements.  Under  ASC  740-10,  the  Company  may  recognize  the  tax  benefit  from  an

uncertain  tax  position  only  if  it  is  more  likely  that  not  that  the  tax  position  will  be

sustained  on  examination  by  the  taxing  authorities,  based  on  the  technical  merits  of  the

position.  Management  has  determined  that  the  Company  has  no  significant  uncertain  tax

positions requiring recognition under ASC 740-10.

The  Company  is  subject  to  income  tax  in  the  U.S.,  and  certain  state  jurisdictions.  The

Company  has  not  been  audited  by  the  U.S.  Internal  Revenue  Service,  or  any  states  in

connection   with   income   taxes.   The  Company’s   tax   years   generally   remain   open   to

examination  for  all  federal  and  state  income  tax  matters  until  its  net  operating  loss

carryforwards  are  utilized  and  the  applicable  statutes  of  limitation  have  expired.  The

federal  and  state  tax  authorities  can  generally  reduce  a  net  operating  loss  (but  not  create

taxable  income)  for  a  period  outside  the  statute  of  limitations  in  order  to  determine  the

correct amount of net operating loss which may be allowed as a deduction against income

for a period within the statute of limitations.

The  Company  recognizes  interest  and  penalties  related  to  unrecognized  tax  benefits,  if

incurred, as a component of income tax expense.

Note 13 - Retirement Plan

ArcMail   has   a   defined   contribution   401(k)   plan,   which   covers   substantially   all

employees.   Under   the   terms   of   the   Plan,   Wala   is   currently   not   required   to   match

F-22



employee  contributions.   The  Company  did  not  make  any  employer  contributions  to  the

Plan in 2015.

Note 14 – Concentrations and Credit Risk

Sales and Accounts Receivable

No  customer  accounted  for  more  than  10%  of  sales  for  the  years  ended  December  31,

2015 and 2014, respectively.

Cash

Cash  is  maintained  at  a  major  financial  institution.  Accounts  held  at  U.S.  financial

institutions  are  insured  by the  FDIC  up  to  $250,000.  Cash  balances  could  exceed  insured

amounts  at  any  given  time,  however,  the  Company  has  not  experienced  any  such  losses.

The  Company  did  not  have  any  interest-bearing  accounts  at  December  31,  2015  and

2014, respectively.

Note 15 - Fair Value Measurement

The  Company  adopted  the  provisions  of  Accounting  Standards  Codification  subtopic

825-10,  Financial  Instruments  (“ASC  825-10”)  on  January  1,  2008.  ASC  825-10  defines

fair  value  as  the  price  that  would  be  received  from  selling  an  asset  or  paid  to  transfer  a

liability  in  an  orderly  transaction  between  market  participants  at  the  measurement  date.

When  determining  the  fair  value  measurements  for  assets  and  liabilities  required  or

permitted  to  be  recorded  at  fair  value,  the  Company  considers  the  principal  or  most

advantageous  market  in  which  it  would  transact  and  considers  assumptions  that  market

participants  would  use  when  pricing  the  asset  or  liability,  such  as  inherent  risk,  transfer

restrictions,  and  risk  of  nonperformance.  ASC  825-10  establishes  a  fair  value  hierarchy

that  requires  an  entity  to  maximize  the  use  of  observable  inputs  and  minimize  the  use  of

unobservable  inputs  when  measuring  fair  value.  ASC  825-10  establishes  three  levels  of

inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level  2  –  Observable  inputs  other  than  Level  1  prices  such  as  quoted  prices  for  similar

assets  or  liabilities;  quoted  prices  in  markets  with  insufficient  volume  or  infrequent

transactions  (less  active  markets);  or  model-derived  valuations  in  which  all  significant

inputs  are  observable  or  can  be  derived  principally  from  or  corroborated  by  observable

market data for substantially the full term of the assets or liabilities.

Level  3  –  Unobservable  inputs  to  the  valuation  methodology  that  are  significant  to  the

measurement of fair value of assets or liabilities.

All  items  required  to  be  recorded  or  measured  on  a  recurring  basis  consist  of  derivative

liabilities and are based upon level 3 inputs.

F-23



To  the  extent  that  valuation  is  based  on  models  or  inputs  that  are  less  observable  or

unobservable  in  the  market,  the  determination  of  fair  value  requires  more  judgment.  In

certain  cases,  the  inputs  used  to  measure  fair  value  may  fall  into  different  levels  of  the

fair  value  hierarchy.  In  such  cases,  for  disclosure  purposes,  the  level  is  the  fair  value

hierarchy  within  which  the  fair  value  measurement  is  disclosed  and  is  determined  based

on the lowest level input that is significant to the fair value measurement.

Upon  adoption  of  ASC  825-10,  there  was  no  cumulative  effect  adjustment  to  beginning

retained earnings and no impact on the financial statements.

As  of  December  31,  2015  and  2014,  the  Company  did  not  have  any  items  that  would  be

classified as level 1 or 2 disclosures.

The  Company  recognizes  its  derivative  liabilities  as  level  3  and  values  its  derivatives

using  the  methods  discussed  in  Note  8.  While  the  Company  believes  that  its  valuation

methods  are  appropriate  and  consistent  with  other  market  participants,  it  recognizes  that

the  use  of  different  methodologies  or  assumptions  to  determine  the  fair  value  of  certain

financial  instruments  could  result  in  a  different  estimate  of  fair  value  at  the  reporting

date.  The  primary  assumptions  that  would  significantly  affect  the  fair  values  using  the

methods  discussed  in  Note  8  are  that  of  volatility  and  market  price  of  the  underlying

common stock of the Company.

As   of   December   31,   2015   and   2014,   the   Company   did   not   have   any   derivative

instruments that were designated as hedges.

Fluctuations  in  the  Company’s  stock  price  are  a  primary  driver  for  the  changes  in  the

derivative  valuations  during  each  reporting  period.  As  the  stock  price  decreases  for  each

of  the  related  derivative  instruments,  the  value  to  the  holder  of  the  instrument  generally

decreases,    therefore    decreasing    the    liability    on    the    Company’s    balance    sheet.

Additionally,  stock  price  volatility  is  one  of  the  significant  unobservable  inputs  used  in

the   fair   value   measurement   of   each   of   the   Company’s   derivative   instruments.   The

simulated  fair  value  of these  liabilities  is  sensitive to  changes  in  the  Company’s  expected

volatility.  A  10%  change  in  pricing  inputs  and  changes  in  volatilities  and  correlation

factors  would  currently  not  result  in  a  material  change  in  value  for  the  level  3  financial

liability.

Note 16 - Related Party Transactions

Note Payable – Related Party

ArcMail issued  a promissory note to the president  of ArcMail  on June  30,  2015 for funds

advanced.  The  note  is  payable  in  annual  installments  of  $155,566  through  December

2019.   The  notes  include  interest  at  6%  and  are  subordinated  to  the  notes  payable  (see

Note 10).

Principal amounts due on notes payable for the years ended December 31, are as follows:

F-24



2016

$

155,566

2017

155,566

2018

155,566

2019

155,567

$

626,265

Note 17 – Commitments and Contingencies

Lease Commitment

The  Company  is  obligated  under  two  operating  leases  for  its  premises  that  expire  at

various times through October 31, 2018.

Total  future  minimum  annual  lease  payments  under  the  leases  for  the  years  ending

December 31 are as follows:

2016

$  61,286

2017

46,581

2018

36,533

$144,400

Rent  expense  of  $68,564  and  $74,988  was  charged  to  operations  for  the  years  ended

December 31, 2014 and 2013, respectively.

Contingencies

The  Company  provides  accruals  for  costs  associated  with  the  estimated  resolution  of

contingencies  at  the  earliest  date  at  which  it  is  deemed  probable  that  a  liability  has  been

incurred and the amount of such liability can be reasonably estimated.

F-25